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Sheep scab is a highly contagious ectoparasitic disease caused by the mite, Psoroptes ovis, 
which causes intensely pruritic lesions with severe dermatitis and is a major welfare and 
production issue in the UK national flock. In an attempt to improve disease control, sheep 
scab was recently made notifiable in Scotland indicating that early diagnostic tests will be 
crucial to the success of this legislation. A sensitive and specific antibody based assay has 
been developed which can diagnose early infestation, but which does not indicate current 
disease status post-treatment due to residual circulating antibody levels. However, studies 
into host biology and response to disease have illustrated the potential use of biomarkers 
(BMs) in diagnostics as indicators of disease progression and the effectiveness of treatment 
regimes, including a recent microarray analysis which identified over 600 host genes 
differentially expressed in circulating leukocytes following P. ovis infestation. As many of 
these genes encoded proteins known to be involved in inflammatory responses, this data 
was used in the search for potential BMs. 
Initially the genes were filtered and ranked, using bioinformatic analysis, to identify the 
most promising BM candidates and then evaluated using Western blot analysis against a 
range of sera from P. ovis infested and naïve sheep. Promising results were obtained for a 
complement binding protein, C4BPB, showing it was rapidly up-regulated following 
infestation and correlated with disease progression as determined by lesion size 
development. The ovine C4BPB gene was successfully sequenced for the first time and a 
recombinant form of this protein expressed in E. coli. Antibodies, raised in rabbits against 
ovine rC4BPB, were used to develop a sandwich ELISA, results from which suggested the 
potential of C4BPB as a BM for sheep scab as it indicated current disease status post-




The major ruminant acute phase proteins (APPs) serum amyloid A (SAA) and haptoglobin 
(Hp) were then investigated using commercially available assays, as previous studies 
indicated they were effective markers of inflammatory disease in ruminants. Results from 
these analyses indicated that both APPs responded positively to infestation with P. ovis but 
this was not statistically significant until 4 weeks post-infestation. After treatment, the 
APPs declined rapidly, as described by their short half life of less than 3 days following 
successful treatment, compared with 56 days for the estimated half life of the host antibody 
against the mite antigen Pso o 2. Further statistical analysis of the APP response suggested 
that SAA was the more discriminatory marker, with lower pre-infestation levels and higher 
sensitivity at the estimated optimum cut-off values. The possibility of using a signature of 
BMs, as an alternative to a single BM, was discussed as a method of increasing the 
sensitivity and specificity of the improved test, along with the potential of combining the 
BM diagnostic with the existing antibody assay. It was concluded that this would provide a 
highly sensitive and specific test for sheep scab which would diagnose early infestation as 
well as indicating current disease status post-treatment, providing a highly beneficial tool 











bp     base pairs 
⁰C     degrees centigrade 
cDNA     complementary deoxynucleic acid 
cm     centimetre 
DAB     3, 3’diaminobenzidine 
dH₂O     distilled water 
dNTP     2’- deoxynucleotide - 5’– triphosphate 
DNA     deoxynucleic acid 
EDTA     ethylenediaminetetraacetic acid 
ELISA    enzyme linked immunosorbent assay 
g     grams 
g     gravitational force 
hr     hour 
HRP     horse radish peroxidase 
Ig     immunoglobulin 
IL     interleukin 
IPTG     isopropyl-1-thio-β-D-galactosidase 
kDa     kilo Dalton 
kg     kilogram 
L     litre 
LB broth    Luria-Bertani broth 
M     molar 
MES     2- (n-morpholino) ethanesulfonic acid 
mg     milligram 
ml     millilitre 
mM     millimolar 
mm     millimetre 




MW  molecular weight 
ng     nanogram 
µg     microgram 
µl     microlitre 
µM     micromolar 
OD     optical density 
OP     organophosphate 
PAGE     polyacrylamide gel electrophoresis 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
pH     -log₁₀ (hydrogen ion concentration) 
p.i     post-infestation 
p.t     post-treatment 
qPCR  real time PCR 
RNA     ribonucleic acid 
RNase     ribonuclease 
rpm     revolutions per minute 
RT     reverse transcriptase 
SDS     sodium dodecyl sulphate 
spp.     species 
TAE     tris-acetate acid-EDTA buffer 
tris     tris (hydroxymethyl) amino methane 
Triton X-100    octylphenoxypolyethoxethanol 
UV     ultraviolet 
V     volt 
vs  versus 
W     watt 
X-gal     5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside 
 
 
Chapter 1: General introduction 
1 
Chapter 1: General introduction 
1.1 Disease  
Sheep scab, or Psoroptic mange, is an ectoparasitic disease and one of the most 
contagious diseases of sheep in the UK (Kirkwood, 1986). Although known as a 
disease which affected the health and welfare of sheep as far back as 180 BC, the 
mite responsible, Psoroptes ovis, was not identified until 1809 (Hering, 1838). Sheep 
scab seriously affects the welfare of sheep (Sargison et al., 1995) but also has 
economic implications for the livestock industry and, as such, costs the UK sheep 
industry in excess of £8 million per annum, mainly in treatment costs (VLA, 2010). 
The overall impact of sheep scab on a flock is wide ranging and if factors such as 
increased ewe and lamb mortality, increased time to finishing, loss in body condition, 
secondary infections and reduced fleece value are included along with treatment 
costs, sheep scab infestation has the potential to turn a profit of £5.27 per ewe into an 
overall loss of £13.57 per ewe on a typical lowland sheep farm (Stubbings, 2007). 
The disease has been widespread in the world’s sheep producing countries, with 
varying degrees of success at eradication and control. For example it was eradicated 
successfully from Norway in 1894, New Zealand in 1885, Canada in 1929 and 
Sweden in 1934 but in South American countries, such as Brazil and Argentina, the 
disease has continued to spread, partly because of an increase in the incidence of 
acaricide resistance problems (Kirkwood 1986). In the UK, during the first half of 
the 20
th
 Century, a stringent programme of compulsory dipping with the 
organochlorine lindane, along with movement restrictions resulted in the eradication 
of sheep scab in 1952 (Kirkwood, 1986). However, sheep scab was reintroduced in 
1973 through the importation of infested sheep from Ireland to a farm in Lancashire 
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and for the next 19 years unsuccessful attempts were made to eradicate it by 
compulsory dipping twice per annum until 1988 and annual dipping from 1988 until 
1992 (French et al., 1999). Over this 19 year period,  only 1480 outbreaks of scab in 
UK flocks were reported and, with growing concerns about the effect of acaricides 
on the environment and human health, deregulation of the control of sheep scab 
occurred in 1992 when compulsory national treatment and control programmes were 
removed  (French et al., 1999). Since then the incidence of the disease has increased 
to such a level that it is now considered endemic in the UK national flock (Van den 
Broek and Huntley, 2003a) with the national annual prevalence estimated at 7000 
outbreaks in 2004 (Bisdorff et al., 2006). This resulted in calls for a national scab 
eradication programme which was led by the National Sheep Association (NSA) and 
the steering group The Sustainable Control of Parasites in Sheep (SCOPS) (NSA, 
2010). These programmes aimed to progress from a nationwide awareness campaign 
through to targeted eradication programmes, aided by the Sheep Scab Order 1997 
[Ministry of Agriculture, Fisheries and Food (MAFF)], which stated that: 
 “It is an offence for any sheep owner to fail to treat sheep visibly affected with sheep 
scab along with all other sheep in the same flock, or to move sheep visibly affected 
with sheep scab” (MAFF, 1997).  
However, policing of this act was very difficult, particularly in upland areas where an 
association between high sheep scab prevalence and common grazing has been 
observed (O'Brien, 1999, Bisdorff et al., 2006). New legislation came into force on 
the 17
th
 December 2010 in Scotland which reinstated sheep scab as a notifiable 
disease through the Sheep Scab (Scotland) Order 2010. This current legislation 
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differs from previous orders by placing a legal obligation on any sheep owner to 
notify the Divisional Veterinary Manager if any sheep in their possession is 
suspected or confirmed as having sheep scab. Following positive diagnosis, all sheep 
on that holding must be treated and movement restrictions are applied to the farm for 
a minimum of 16 days following successful treatment. The order also gives provision 
for farmers to report a neighbour if they are suspected of having P. ovis infested, 
untreated, sheep on their premises. This is an important aspect of the legislation as it 
effectively brings farms where sheep have not been treated to account. It is too soon 
to analyse the effects of this order, but the scale of the problem is evident as during 
the first year of this order being in place, there were 144 notifications in total with a 
widespread distribution over much of Scotland (Blissitt et al., 2012).   
Eradication or control of sheep scab therefore continues to provide a challenge in 
many sheep producing countries. In Switzerland where the disease is also notifiable, 
compulsory prophylactic treatment of all sheep returning to common grazing in 
spring resulted in the incidence of scab being reduced by more than half  between 
1975 and 1999, showing that progress can be made to control and reduce the 
incidence of sheep scab through effective management and husbandry practices 
(Falconi et al., 2002). Subsequently, an immunodiagnostic assay was developed 
(Ochs et al., 2001) resulting in the treatment of only seropositive sheep. This ‘test 
and treat’ strategy, which was applied each spring prior to the sheep being moved 
onto the common grazings, led to a significant reduction in seropositive flocks from 
5.8% in 2001 to 2.2% in 2003, illustrating the potential of accurate diagnosis 
followed by treatment as an important element in control strategies (Jacober et al., 
2006). 
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1.2 The causative mite  
1.2.1 Life cycle 
Psoroptes ovis belongs to the order Astigmata, family Psoroptidae, which has four 
genera – Psoroptes, Chorioptes, Otodectes and Caparinia.  Psoroptes ovis is visible 
to the naked eye, appearing white on the sheep, with the adult females being 
approximately 0.75 mm long and slightly larger than the males. They are distinctive 
among the other genera of their family due to the primary genus-specific 
characteristic, the jointed pre-tarsus, along with the funnel shaped suckers on the end 
of their legs (see Figure 1.1) as opposed to the more usual bell shaped suckers (Bates, 
1999a).  
 
Figure 1.1: The sheep scab mite Psoroptes ovis showing characteristic funnel-shaped 
suckers and surface feeding mouthparts. Photographs reproduced with kind 
permission from Dr Gerry Brennan, University of Ulster and Prof. Richard Wall, 
University of Bristol. 
Psoroptes ovis is a non burrowing mite with a five stage life-cycle progressing from 
egg, to larva, two nymph stages and adult as shown in Figure 1.2. All developmental 
stages take place on the host and under optimal conditions the life cycle can be 
completed in 14 days (Kirkwood, 1986). Mature females can produce up to 90 eggs 
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during their lifetime (Downing, 1936) and a single ovigerous female is sufficient to 
establish a successful infestation (Babcock and Black, 1933). 
 
Figure 1.2: Life cycle of P. ovis showing the characteristic five stages all of which 
take place on the host.  
1.2.2 Transmission 
Transmission is mainly through direct contact between an infested and a susceptible 
animal, but can also occur indirectly as infested sheep scratch on any available object 
and dislodge mites (O'Brien et al., 1994). The mites, under normal conditions of 
temperature and humidity, can remain infective for 15-16 days off host which has 
implications for spreading the disease as gates, fences, bedding, transporters, 
handlers and shearing blades all become potential sources of infestation (O'Brien et 
al., 1994). Added to this is the fact that some sheep appear clinically normal but 
remain “carriers”, with mites living in cryptic sites such as around the eyes, in the ear 
canals and in the folds of skin between the hind legs, where they can survive for up 
to 2 years (Babcock and Black, 1933). These sub-clinical carrier animals are 
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Infestations occur throughout the year although an increase of disease incidence has 
been reported in the winter months (Kirkwood, 1986), possibly due to the fleece of 
the sheep being thicker and longer, increasing mite survival. Management factors are 
also thought to be important as dipping and handling of sheep are reduced in winter 
months so infestations may go unnoticed (French et al, 1999).   
1.2.3 Feeding 
 The mites live at the base of the fleece feeding on the outer layer of the skin, the 
stratum corneum, with mouthparts designed to abrade rather than pierce the skin 
(Figure 1.1) (Sinclair and Kirkwood, 1983, Van den Broek and Huntley, 2003a). 
Healthy sheep skin has a surface layer of lipid which provides a food source for the 
mites during early infestation (Sinclair and Filan, 1989). Within hours of an 
infestation the mites cause inflammation and serous exudation which forms an 
additional liquid food source (Bates, 1999b). As this occurs, the mites move out in a 
concentric manner onto naive skin, while the pustulated lesion (the main clinical sign 
of infestation) behind dries forming the crusty yellow scabs which, along with the 
thickening of the skin, are characteristic of sheep scab (Van den Broek et al., 2000). 
It has been suggested that mite proteinases may have an anticoagulant effect, 
enhancing serous exudation and thereby aiding mite feeding (Kenyon and Knox, 
2002) and, as with other mites, the faecal pellets of P. ovis may be responsible for the 
initial inflammatory response of the host which provides the mite with its main food 
source (Sinclair, 1990). Extracts from mites, including P. ovis, contain a range of 
proteinases including cysteine proteinase and metalloproteinases, which are able to 
degrade a variety of host proteins (Nisbet and Billingsley, 1999, Nisbet and 
Billingsley, 2000, Kenyon and Knox, 2002). The relative activities of these 
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proteinases may reflect the diet of the different mite species (Hamilton et al., 2003). 
For example, immunoglobulin G (IgG) has been isolated from within the gut of P. 
ovis, demonstrating that host immunoglobulin (Ig) is ingested by the mite and may 
also be at least partially digested, as degraded components of the antibody as well as 
intact IgG were identified (Pettit et al., 2000). Psoroptes cuniculi [which may 
actually represent a rabbit-adapted con-specific variant of  P. ovis (Pegler et al., 
2005)] ingest erythrocytes from their rabbit host and extracts of this mite contain 
haemoglobin-degrading aspartyl proteinases (Nisbet and Billingsley, 1999). A study 
on the scabies mite Sarcoptes scabiei has illustrated its ability to ingest filaggrin, a 
structural epidermal protein, suggesting this may be a food source  as well as 
contributing to the pathogenesis of the disease (Beckham et al., 2009).  
1.3 Clinical symptoms 
The clinical symptoms of sheep scab are illustrated in Figures 1.3, 1.4 and 1.5. In 
early infestation, they  are consistent with mild pruritis which, over the course of 
several weeks in experimental infestations or several months in the field, progresses 
to an intense pruritis (Bates, 1997). Initially head shaking, lip smacking, scratching 
and rubbing at the infested site are the obvious behavioural abnormalities, but as the 
lesion continues to develop, the animal becomes increasingly restless and irritated. 
Biting at the flanks and scratching the body with the hind feet increases, causing 
shorter but more frequent bouts of grazing (Corke and Broom, 1999). The result is 
that the animal loses condition leading to lower live-weight gains, reduced birth-
weight in lambs born to infected ewes, and reduced milk yield causing reduced 
weight gain in lambs (Kirkwood, 1980, Sargison et al., 1995).  Wool loss from 
intensive scratching occurs initially over a small area which may benefit the sheep by  
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Figure 1.3: Farm outbreak of sheep scab showing classic disease clinical 
symptoms and behaviour including scratching, rubbing and wool loss. Photograph 
reproduced with kind permission from Prof. N. Sargison, The Royal (Dick) 
School of Veterinary Studies [R(D)SVS], University of Edinburgh. 
 
 
Figure 1.4: Sheep scab lesion in early disease with characteristic crusty, yellow 
appearance. Photograph reproduced with kind permission from Dr J. Huntley, 
Moredun Research Institute (MRI). 
 
exposing the mites to a less favourable micro-environment, but as the infestation and 
lesions spread wool loss can become severe with the remaining wool stained and wet 
from the serous exudate (Corke and Broom, 1999). Clearly, in winter especially, this 
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has consequences for heat loss and can lead to further production losses and in some 
cases death, particularly in hill sheep.  
 
 
Figure 1.5: Severe case of sheep scab showing clinical signs of scabs, wet wool and 
wool loss as a result of pruritis. Photograph reproduced with kind permission from 
Prof. N. Sargison, R(D)SVS, University of Edinburgh. 
 
Apart from production losses, sheep scab is also a major welfare issue as the intense 
pruritus quickly becomes an obsessive preoccupation for infected animals, resulting 
in wool loss, self trauma and open wounds, with often secondary infections 
developing which can lead to a decline in production and occasionally fitting and 
death (Kirkwood, 1980). In the majority of animals the lesions eventually resolve as 
a protective immune response is initiated and the animal recovers. In these cases, 
new wool growth removes the scabs and the new skin appears normal underneath 
(Bates, 1997). 
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1.4 Treatment and Control 
The treatment options currently open to UK sheep farmers are listed in Table 1.1. 
The only licensed dipping products in the UK currently are organophosphates (OPs) 
which are effective if manufacturer’s instructions are followed (SAC, 2005) as the 
washing action of the dip, as well as killing the mites, leads to their dislodgement and 
allergen removal allowing more rapid healing. However, the problems of OP dip use 
include harmful residues in the environment and meat, handler health issues and 
reported incidences of parasite resistance (Sargison et al., 2006). In addition, sheep 
farmers in the UK require a licence to dip and as dip disposal is under the strict 
regulation of the Scottish Environmental Protection Agency (SEPA), these factors 
add to the costs and time associated with this procedure.  
Injectable endectocides, such as the macrocyclic lactones, ivermectin, doramectin 
and moxidectin, are a useful alternative to OP dips and many UK sheep farmers now 
rely on them as their sole means of treatment (Sargison et al., 2006). A study 
investigating the control and management of sheep scab and pediculosis in 2003-
2004, found that 44% of farmers who responded (966 farmers throughout UK) 
treated prophylactically to prevent sheep scab, 41% by using macrocyclic lactones 
and 36% using OP dips, the remainder using either a combination of the above or 
pyrethroids. For therapeutic treatment of sheep scab 58% used macrocyclic lactones, 
predominantly doramectin (Bisdorff and Wall, 2008). The study concluded that due 
to the continued high national prevalence of sheep scab, the current control methods 
were not successful and that although most farmers questioned appeared to 
differentiate correctly between the different treatments required for lice and scab, a 
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large proportion of insecticide applications were taking place at the wrong time of 
year for maximum efficacy, i.e. June and July (Bisdorff and Wall, 2008).  
Table 1.1: Treatment options and comparisons for sheep scab for UK farmers based 
on Scottish Agricultural College (SAC) guidelines. *Gold standard (= the optimum 
desired result from the treatment strategy used) and table obtained from SAC 
Veterinary Services (2011) 












Within 24 hrs 2-3 days Up to 7 days Up to 7 days Up to 7 
days 
Persistence>28days Yes No No Yes (60 
days) 
Non toxic Concentrate 
toxic 
Non toxic Non toxic Non toxic 















Ease of disposal Licence 
required 




Cost effective 70kg ewe 70p plus 
disposal 




Macrocyclic lactones are extremely effective in treating sheep scab (O'Brien, 1999) 
and recently a long-acting moxidectin with a persistence of 60 days became 
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commercially available, giving farmers the option of coordinating treatment across 
neighbouring grazings more easily, enabling effective regional control (N. Sargison, 
Pers. Comm.). However, a major problem with the use of injectable endectocides is 
that these compounds are also used to treat internal parasites and therefore their 
increasing usage may increase the selection pressure for resistant gastro-intestinal 
nematodes (Bisdorff and Wall, 2008, Sargison et al., 2007, NSA, 2007). It is 
generally believed that this approach is unsustainable; therefore it was deemed 
imperative that alternative strategies for treatment and control were designed and 
implemented before sheep scab threatened the tenability of the sheep industry in the 
UK (Sargison et al., 2006). Since December 2010, it has been anticipated that the 
Sheep Scab Order (Scotland) 2010 will provide a useful legislative tool to improve 
long term disease control in Scotland. In addition, with heightened publicity and 
interest in sheep scab control, additional potential has arisen for regional control 
strategies, an approach which has had successful results in geographically defined 
areas such as the Angus glens, Cheviot hills and the Pentland hills near Edinburgh 
(Sargison et al., 2006). The success of these programmes has depended on 
cooperative treatment and control regimes within the persistence time of the 
acaricides used, along with rigorous biosecurity, such as quarantining and 
preventative treatment of newly acquired animals and thorough cleaning with an 
acaricide of any equipment potentially exposed to mites. Despite the problems 
associated with cooperative treatment in regional areas, these collaborative 
approaches were considered to have the potential to further control sheep scab 
outbreaks (Sargison et al., 2006). Currently for the rest of the UK and other countries 
where sheep scab is not a notifiable disease, regional control programmes could be 
 
Chapter 1: General introduction 
13 
facilitated by using a modelling approach to identify “high risk” areas of endemic 
sheep scab using sheep density, height above sea level, temperature and rainfall as 
predictors of the probability of an outbreak (Rose et al., 2009). This approach would 
target high risk areas and aim to reduce scab incidence, thereby conserving the 
treatment compounds that remain available (Rose et al., 2009). For such enhanced 
control approaches to sheep scab, a resource which will be vital to any successful 
treatment and control campaign is the ability to accurately diagnose early, active 
infestation with the causative organism, P. ovis. Problems of misdiagnosis have been 
reported, in particular confusion between the symptoms produced by sheep scab 
mites and lice was seen as an issue (SCOPS, 2005) and as treatment for these two 
endoparasites is different, misdiagnosis was not only recognised as a problem for 
failed treatment but for selection for resistance to injectable endectocides (SCOPS, 
2005). An accurate diagnostic test specific for early sheep scab infestation is 













1.5.1 Developments in ectoparasitic immunodiagnostic tools 
In many cases, the diagnosis of ectoparasite infections is a more straightforward 
process than that for endoparasites. By definition, ectoparasites are on (or in) the skin 
surface and are often large and relatively immobile, e.g. ticks. There are, however, 
several species of ectoparasites of humans, companion and production animals which 
remain difficult to diagnose, because of their small size or cryptic lifestyle or because 
the clinical signs that they induce on the host can be confused with other infections 
or conditions, including, for example, those caused by Psoroptes and Sarcoptes mite 
species. Conventional diagnostic tests based on the direct detection of a parasite, for 
example, by microscopic examination of hair plucks or skin scrapings, often lack 
sensitivity and specificity and are usually dependent on expertise in the identification 
of the parasites (Swets, 1988). In addition, conventional tests may not detect 
subclinical infections, which can play a key role in the persistence of ectoparasites 
within host populations (Van den Broek and Huntley, 2003a). Clearly, improved 
methods of diagnosis are required and recently progress in the development of novel 
diagnostic methods and technologies has been achieved for ectoparasites which 
infest humans, companion and production animals and for which differential 
diagnosis is important in the selection of appropriate treatments and disease-
prevention strategies (Wells et al., 2012). 
                                                 
1
 Much of this section is adapted from a recently published review: WELLS, B., BURGESS, S. T., 
MCNEILLY, T. N., HUNTLEY, J. F. & NISBET, A. J. 2012. Recent developments in the diagnosis 
of ectoparasite infections and disease through a better understanding of parasite biology and host 
responses. Mol Cell Probes, 26, 47-53. A copy is included at the end of this thesis. 
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1.5.1.1 ELISA 
Immunodiagnosis by enzyme linked immunosorbent assay (ELISA) has become 
increasingly used for key ectoparasites (Falconi et al., 2010, Ochs et al., 2001) and 
diagnostic tests based on this method may possess increased sensitivity and 
specificity compared to traditional diagnostic methods.  For example, S. scabiei 
(Order Astigmata) is an obligate parasite which burrows into the skin of the host 
causing scabies in humans and topical (sarcoptic) mange in a variety of domestic 
(e.g. dogs, pigs, sheep and goats) and wild animals (e.g., foxes, raccoons, camels and 
wombats) (Bornstein et al., 2006). Globally, S. scabiei is one of the most important 
ectoparasites because of its ability to cause disease in the specific host or following 
zoonotic transmission through infestation of commercially-important as well as 
companion animals (Walton et al., 2004). Diagnosis has been based principally on 
clinical symptoms and the identification of mites from skin scrapings from affected 
areas (Burgess, 1994). Infestations with scabies mites can be difficult to diagnose for 
several reasons. Symptoms are similar to those of other dermatological conditions; 
parasites may not co-localise with the lesions; the mites themselves are cryptic, 
living in burrows and, in the case of classical scabies, only 10-20 parasites may be 
present on the human host (Mellanby, 1944).  
An understanding of the parasite / host interaction has been used to facilitate the 
development of novel immunodiagnostics. The skin lesions and extreme pruritis, 
which are characteristic of infestations with S. scabiei, indicate an immediate-type 
hypersensitivity reaction (Falk and Bolle, 1980b). This response is inflammatory and 
allergic-like in nature with infiltrations of eosinophils, lymphocytes and histocytes 
into the areas surrounding the mite burrows (Walton and Currie, 2007). However, it 
 
Chapter 1: General introduction 
16 
is the humoral immune response against the scabies mites that has allowed the 
development of immunodiagnostic tools. An adaptive immune response, involving 
high serum titres of immunoglobulin E (IgE) and IgG, has been demonstrated in 
human patients with crusted scabies (Roberts et al., 2005) and other studies confirm 
that scabies mite infestation leads to the production of measurable antibody in 
infested hosts (Falk and Bolle, 1980a). Therefore, ELISAs have been developed for 
the detection of mite-specific antibodies in infected goats or sheep (Falconi et al., 
2010), (Rodriguez-Cadenas et al., 2010b, Rodriguez-Cadenas et al., 2010a), pigs 
(Jacobson et al., 1999, van der Heijden et al., 2000), dogs (Lower et al., 2001) and 
foxes (Bornstein et al., 2006). These assays have used native protein preparations 
(i.e. mite extracts) as antigens, with the attendant problems that this might bring (e.g. 
cross-reactivity with other species and batch-to-batch quality control issues). Other 
ELISAs, based on the use of recombinant proteins, or hydrophobic or hydrophilic 
antigen preparations have been evaluated (Hejduk et al., 2011, Kuhn et al., 2008), 
with variable results. 
Microscopic examination of skin scrapings is generally thought to be an inefficient 
method of sarcoptic mange diagnosis (Hengge et al., 2006) and was recently 
compared with an indirect ELISA for detecting mite-specific IgG antibodies in sheep 
(Rodriguez-Cadenas et al., 2010a). There was a marked difference between the 
sensitivities of the two diagnostic tests (ELISA 87.6%; skin scraping 62.8%), but 
there was better agreement between the two tests in terms of their specificity (95.9% 
for ELISA; 100% for skin scraping), when the accuracy of the tests was compared 
with that of a reference method for epidemiological surveys and evaluated using the 
Receiver Operating Characteristic (ROC) curve approach (Rodriguez-Cadenas et al., 
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2010a). The increased sensitivity of the ELISA-based test suggests that it could be 
used to support the diagnosis of the presence of sarcoptic mange, estimate the 
prevalence, indicate mange-free status, and determine the efficacy of control or 
treatment programs (Rodriguez-Cadenas et al., 2010a).  
The diagnosis of sheep scab is also not straight forward as, although clinical 
symptoms of disease are evident in the advanced stages of infestation, during early 
infestation animals may exhibit minimal clinical signs but still represent  a source of 
infestation (Bates, 2000). Mites from these animals are difficult to find, even when 
one suspects their presence, and the efficacy of the microscopic detection of mites in 
skin scrapings from these animals can be as low as 18% (Bates, 2009). In addition to 
P. ovis, other ectoparasites such as ticks and lice can induce skin reactions which 
may appear similar to those seen in early infestation with P. ovis (Sargison et al., 
1995, Bates, 1997), and dual infestations with more than one ectoparasite are 
common, further confusing diagnosis. Researchers in New Zealand have developed a 
highly sensitive and specific assay to detect sheep louse (Bovicola ovis) antigen in 
wool fibres (Patent US 07294477, Ovita Ltd) based on the presence of an antigen in 
louse faeces which are ubiquitously shed as the lice move around on the skin. 
However, a similar test for sheep-scab, based on the detection of parasite antigen is 
unlikely to succeed since mites, unlike lice, do not migrate extensively across the 
skin surface but are generally confined to the lesion/normal skin interface or in 
isolated cryptic sites.  
An alternative method is the detection of anti-P. ovis antibodies in blood; anti-mite 
IgG titres increase from initial detection levels at the end of the lag phase of 
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infestation (approximately 2 weeks post infestation) reaching peak levels at 8-12 
weeks post infestation (Van den Broek et al., 2003c).  Although levels of antibody 
can remain elevated for several months after successful treatment (Bates, 2009, 
Burgess et al., 2012b) serological methods have been employed successfully for the 
effective differential diagnosis of psoroptic mange in cattle and in sheep (Fisher, 
1983, Wassall et al., 1987, Boyce et al., 1991, Lonneux et al., 1996, Ochs et al., 
2001, Bates, 2000, Bates, 2009). An ELISA developed by researchers at the 
University of Zurich has been used both as an immunodiagnostic and an 
epidemiological tool to assess the seroprevalence of sheep scab in Switzerland 
(Falconi et al., 2002, Ochs et al., 2001). Although this assay employed a crude 
mixture of unspecified antigens extracted from the parasites, the test demonstrated 
excellent sensitivity and specificity of 93.7% and 96.5%, respectively.  
These studies have thus demonstrated the potential of an immunodiagnostic assay for 
use in control programmes for sheep scab and encouraged the search for more 
specific or robust assays employing defined antigens and, in particular, recombinant 
proteins. The latter offer potential advantages in terms of uniformity, stability and 
supply of the antigen target as well as reduced production costs, which are 
particularly important for tests which will be produced commercially or widely 
distributed for use in different laboratories. Candidate antigens for such a diagnostic 
test have included house dust mite (HDM) allergen homologues (Huntley et al., 
2004, Lee et al., 2002, Nisbet and Huntley, 2006) and while these allergens have 
regions which are highly conserved between mite species, suggesting important or 
pivotal functions in mite biology, they are sufficiently different to generate species-
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specific antibodies during infestation (Lee et al., 2002, Nisbet and Huntley, 2006, 
Nisbet et al., 2006c). This immunogenicity suggests that they represent good 
candidates for the development of assays to detect specific antibodies against P. ovis 
in the host. Two such HDM allergen homologues have received particular attention, 
namely Pso o 1 and Pso o 2 and it is the latter that is showing particular promise as a 
diagnostic target. Pso o 2 is a 16kDa polypeptide with sequence homology to the 
group 2 allergens Der f 2 and Lep d 2 from Dermatophagoides farinae and 
Lepidoglyphus destructor, respectively (Pruett, 1999, Temeyer et al., 2002).  
In an ELISA developed for diagnosis of sheep scab, the use of a single recombinant 
antigen, Pso o 2, as the diagnostic antigen reliably detected the presence of P. ovis on 
sheep within two weeks of experimental infestation (Nunn et al., 2011) and 
sensitivity and specificity were similar to those reported for the previous native 
antigen extract based assay (Falconi et al., 2002). Perhaps the most important finding 
from these studies was that the test could detect Pso o 2-specific antibodies in a 
natural outbreak before clinical signs were evident (Burgess et al., 2012b).  This 
assay will therefore be of particular use as an aid to control this highly infectious 
mite by monitoring and targeting those flocks that require treatment, for example 
during local eradication campaigns. The use of recombinant proteins also enables the 
development of reliable pen-side detection methods such as lateral flow devices, and 
the targeted use of these in the early and rapid detection of disease will be pivotal to 
effective control.  
The approach to further increasing diagnostic potential using molecular tools in P. 
ovis research has focused on gaining a greater understanding of the local and global 
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host response to infestation. In a recent study using microarray technology, the host 
skin response to infestation with P. ovis was examined and over 1500 host genes 
identified that were significantly differentially expressed within 24 hours post-
infestation (Burgess et al., 2010). Clustering of these genes enabled their 
classification into temporally related groupings and network and pathway analysis of 
these temporal clusters identified key signaling pathways involved in the host 
response to infestation. This analysis resulted in the identification of a crucial role for 
toll-like receptor 4 (TLR4) triggering via nuclear factor-kappa B (NF-kB) to instigate 
the host pro-inflammatory response to P. ovis. Der p 2 has previously been identified 
as a potential trigger for TLR4, putatively acting as a functional mimic of the TLR4 
accessory protein MD-2 (Trompette et al., 2009) suggesting a similar role for its 
homologue Pso o 2.  
1.5.2 Enhancement of diagnostic tools 
Even highly specific and sensitive immunodiagnostics have the limitation that they 
are unable to distinguish antibodies produced during active infestation from residual 
antibody from previous infestations when used at a single time point. For example, 
studies have shown that the host circulating antibody (IgG) response to P. ovis 
infestation in sheep persists for between 3-6 months following successful treatment 
(Bates, 1999c, Ochs et al., 2001, Burgess et al., 2012b). While this limitation may be 
overcome to some extent by taking repeated measurements at different time points, 
this may be inconvenient and provides additional costs. Studies into host biology and 
response to disease have illustrated the potential use of BMs as indicators of disease 
progression and the effectiveness of treatment regimes. Generally BMs are proteins 
which act as indicators of a particular biological state, e.g. active infection, and 
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return to normal circulating levels on disease resolution or treatment (Petersen et al., 
2004). In human medicine, BMs are being studied extensively in diseases such as 
cancer, heart disease and Alzheimer’s disease, (Arnold et al., 2011, Dubois et al., 
2010, Thal et al., 2006), and are useful in early disease diagnosis, improving the 
accuracy of diagnosis and in the selection of therapeutics. In the veterinary field, 
BMs have shown potential as early indicators for a variety of infectious and/or 
inflammatory diseases: for example the APPs are potentially valuable diagnostic and 
prognostic aids in bovine respiratory disease  (Heegaard et al., 2000, Godson et al., 
1996) and caseous lymphadenitis (CLA) (Eckersall et al., 2007).  
The potential for using BMs as an additional tool in the immunodiagnosis of 
ectoparasitic disease is clear; the immunodiagnostic element (e.g. an antigen-specific 
ELISA) can provide the specificity and sensitivity to identify the causative organism 
whereas elevated BM level can indicate whether the disease is active or is resolving 
(for example after successful treatment). 
In a recent example of the use of BMs in the early detection of ectoparasite disease, 
the APP response was studied in Alpine ibex suffering from a natural outbreak of 
sarcoptic mange (Rahman et al., 2010). Serum amyloid A serum titres were increased 
approximately 20-fold in infested compared to control animals, with Hp serum 
concentrations increasing 10-fold during infestation, therefore these APPs were 
considered as having potential as BMs for the detection of disease. This is of 
particular importance in the control of sarcoptic mange in wild ibex as there is a high 
incidence of this condition in the wild population, and early diagnosis is likely to be 
critical for disease control (Rahman et al., 2010).  
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In relation to sheep scab, a diagnostic BM assay, especially if used in conjunction 
with the existing ELISA for increased specificity, would be a highly beneficial tool 
for the sheep industry as it may indicate current disease status post-treatment. This is 
likely to be particularly important in Scotland where sheep scab is notifiable and 
farms with sheep positively diagnosed as P. ovis infested are subject to movement 
restrictions until confirmed as successfully treated. The limitations of antibody 
persistence in this situation, means that the ELISA is not capable of indicating 
current disease status. Other situations where an integrated test including BMs may 
be useful include purchasing sheep from livestock markets when knowledge of the 
current disease status of the animals is desirable and when moving sheep between 
farms such as over-wintering lambs, a common practice in the Scottish upland sheep 
industry. 
One approach to identifying BMs for the development of a diagnostic test for sheep 
scab, is to use data from a microarray study completed recently at MRI (Burgess et 
al., 2012a). Sheep scab infestation induced dramatic changes in circulating 
leukocytes with over 600 genes showing highly significant differential expression 
over the time course of infestation (Burgess et al., 2012a). More than 30 of these 
differentially expressed genes encoded proteins known to be secreted into the plasma 
during inflammatory responses in other diseases or conditions in human and animal 
models (Burgess et al., 2012a). In effect, these genes formed a list of potential BMs 
of inflammation which were also highly up-regulated in a wide range of conditions 
such as arthritis and psoriasis in humans, inflammatory conditions which show 
similarities with the underlying pathology demonstrated in the sheep scab lesion 
(Van den Brook and Huntley, 2003). These inflammatory proteins are highly 
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conserved in sequence between species which has the advantage that, at least for 
some of these potential BMs, there are commercial antibodies available allowing for 
their detection in serum and the development of a test based on their change in serum 
concentration during P. ovis infestation will represent a novel and highly sensitive 
assay for sheep scab. 
 
1.6 Host Immune Response 
1.6.1 Disease progression 
The host immune response to P. ovis is a complex multi-factorial interaction where 
mite antigens play an important role in the initiation of the response of the host 
immune system (Sinclair, 1990). Infestation with P. ovis can be characterised into 
three phases, early, late and decline (Van den Broek and Huntley, 2003a) which is 
reflected by the phases of the host immune response. During the early phase, which 
happens minutes after infestation, the host skin surface becomes reddened and 
inflamed and, histologically, an influx of neutrophils and eosinophils can be detected 
along with blistering of the skin and the appearance of serous exudate on the skin 
surface (Van den Broek et al., 2004), illustrating a rapid host immune response to the 
effects of the mite through an immediate hypersensitivity type response (Van den 
Broek et al., 2000).  In experimentally infested animals this early stage can last for 
10-35 days, compared to 2-8 months in naturally occurring infestations (Bates, 1997) 
during which time clinical symptoms may not be evident or only apparent on close 
inspection (Bates, 2009). Following this pro-inflammatory phase, where mite 
numbers remain relatively low, the late phase begins where mite numbers increase 
exponentially and the lesion size expands allowing clinical diagnosis (Van den Broek 
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and Huntley, 2003a). The host immune response during this stage is characterised by 
a delayed hypersensitivity type response and production of antigen-specific IgE and 
to a lesser extent IgG (Van den Broek et al., 2000) which, in experimental 
infestations, may last for a further 2-4 weeks after which the disease moves into the 
decline phase as the host immune response affects mite numbers and the lesions 
begin to resolve (Van den Broek et al., 2004). This may happen naturally, or more 
commonly, in response to therapeutic intervention. 
1.6.2 Innate immune response 
As previously noted, the mouthparts of P. ovis do not appear to pierce the skin; 
therefore it is likely that the cause of the lesion pathology and the host’s early 
hypersensitivity type response is due to the interaction between physical abrasion by 
the mite, salivary or faecal antigens and host keratinocytes, as the first point of 
contact (Watkins et al., 2009). The initial immune response in sheep to P. ovis 
infestation has previously been characterised as a hypersensitive inflammatory 
response dominated by the infiltration of eosinophils and to a lesser extent 
neutrophils, mast cells and lymphocytes (Rosa and Moschini, 1988, Stromberg and 
Fisher, 1986, Van den Broek et al., 2000). This rapid influx of eosinophils occurs 
during the first 24 hours at the initial site of infestation (Huntley et al., 2005, McNair 
et al., 2009) and it has been suggested that  P. ovis allergens possess eosinophil 
chemo-attractant properties, which may lead to the increase in pro-inflammatory 
cytokines from epidermal cells (Van den Broek et al., 2004).  This response brings 
about changes in the epithelium such as capillary dilation and a reduction in skin 
barrier function resulting in leakage on to the skin of a serous exudate (Burgess et al., 
2010). Keratinocytes may also be activated by mite proteases disrupting tight 
 
Chapter 1: General introduction 
25 
junctions between the cells, increasing permeability  and producing the changes 
observed in the early stages of infestation (Nisbet and Billingsley, 2000; Kenyon and 
Knox, 2002).  
The sheep scab mites are thought to use the host’s innate inflammatory response for 
their own benefit as the exudate, resulting from the keratinocyte response to mite 
allergens, becomes a major food source for the mites (Huntley et al., 2005).  A 
number of these allergens are homologues of house dust mite (HDM) allergens, and 
have been studied extensively (Huntley et al., 2004, Nisbet et al., 2006a). HDM 
allergens are contributing factors in allergic disorders of humans such as asthma and 
atopic dermatitis, where it is thought that allergen protease activity may enhance 
allergenicity (Chapman and Platts-Mills, 1987, Thomas and Smith, 1998). HDM 
extract which includes Der p 1, an immunodominant cysteine proteinase, increases 
the expression of the pro-inflammatory cytokines tumour necrosis factor-alpha 
(TNF) and interleukin 8 (IL8) (Lau et al., 1999). Pso o 1, a major P. ovis antigen, 
shows 64% identity at the amino acid level with Der p 1 (Nisbet et al., 2006b) and 
may therefore demonstrate a similar function (Lee et al., 2002).  
The pro-inflammatory response to P. ovis infestation in sheep has recently been 
further characterised in a study where increased expression levels of genes 
transcribing the pro-inflammatory cytokines TNF; interleukin 1β (IL1β); interleukin 
6 (IL6) and IL8, along with factors involved in immune cell recruitment and 
activation, such as intercellular adhesion molecule 1 (ICAM1), selectin E (SELE) 
and selectin P (SELP), were demonstrated in skin biopsies during P. ovis infestation 
(Burgess et al., 2010). IL8 is also up-regulated in keratinocytes in vitro when 
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exposed to P. ovis excretory/secretory material within an hour of exposure (Watkins 
et al., 2009). It was proposed that, as well as being involved in neutrophil infiltration, 
IL8 has a role in the activation of many immune cells, including eosinophils, T cells 
and B cells, initiated by mites feeding on the skin (Watkins et al., 2009).   
1.6.2.1 Acute phase response (APR) 
The APR is at the core of the mammalian innate immune system with responses to 
infection, inflammation or injury that are central to bringing about the resolution of 
disease or trauma and promoting healing (Cray et al., 2009, Eckersall, 1995). The 
initiation of the APR and the resulting cascade is shown in Figure 1.6, where only the 
positive APPs are shown i.e. those that increase in plasma concentration in response 
to inflammatory disease. This inflammatory cascade leads to the release of APPs, 
under the influence of the pro-inflammatory cytokines IL1, IL6, IL8 and TNF.   
The APPs are plasma proteins which have an important role in the resolution of 
infection in the early stages (Petersen et al., 2004). The high numbers of immune 
cells such as neutrophils, eosinophils and mast cells, which are characteristic of a 
sheep scab mite lesion, are thought to be the main source of pro-inflammatory 
cytokines (Burgess et al., 2010), which in turn activate the APR cascade resulting in 
increased serum concentrations of the APPs (Rahman et al., 2010). The APPs are not 
independent in their actions, but are linked with other innate and adaptive responses, 
such as the complement system, which are activated when parasites infest or invade a 
host.  
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Figure 1.6: The cascade of responses of the mammalian immune system in response 
to disease resulting in the release of APPs and activation of the APR. The cytokines 
and APPs highlighted in red indicate the main pathways of the ruminant APR. Figure 
adapted from Ingenuity Pathway Systems (IPA). SAA = serum amyloid A; AGP = 
alpha-1 acid glycoprotein; C4BP = complement 4 binding protein; HP = haptoglobin. 
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1.6.2.2 The complement system and its interactions with mites 
The complement system is part of both the innate and acquired immune systems of 
mammals, involving approximately 30 complement proteins and receptors, and plays 
a major role in the defence against invading microorganisms by inflammatory and 
lytic activities (Fearon and Locksley, 1996, Fearon, 1998). The complement system 
has principally been studied in vertebrates where it is highly conserved between 
species (Nonaka and Yoshizaki, 2004). It involves three cascade systems– the 
classical, lectin and alternative complement pathways. Activation of the complement 
system, when a complement component in serum binds to the surface of a pathogen, 
results in an enzymatic cascade ultimately leading to pathogen damage or destruction 
(Blom et al., 2004). The combined result of this cascade involving the 3 pathways is 
the tagging of pathogens with opsonins (C3b), production of inducers of 
inflammation (C3a, C5a) and ultimately damage to, or destruction of, the pathogen 
(C5b-C9) (Blom et al., 2004).  
The classical pathway, although mainly activated by the acquired immune system via 
antibody binding, can also be activated by the APP C-reactive protein (CRP) 
triggered by the innate immune response and this additional binding of CRP 
increases the opsonisation of microorganisms (Hebecker et al., 2010). The 
mechanism of allergen induced activation of the complement system in humans due 
to HDM allergens has been described in vitro (Varga et al., 2003). Although IgG was 
required for efficient complement activation, HDM extracts activated the classical 
pathway by enhancing C1q binding to C1, and by binding mannan binding lectin 
(MBL) thereby activating the lectin binding complement pathway (Varga et al., 
2003). The biologically active peptides and anaphylatoxins C3a, C4a and C5a, which 
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are produced in mammalian species as a result of complement activation, may 
contribute to the inflammatory reaction of allergic diseases (Muller-Eberhard, 1988). 
The HDM protease Der p 3 may be a specific activator of the complement system in 
humans resulting in the production of C3a, C4a and C5a, thereby contributing to the 
allergic and inflammatory reaction (Maruo et al., 1997) suggesting there may be 
potential roles for the homologous P. ovis antigens in sheep (S. Burgess Pers. 
Comm.).  
1.6.3 Adaptive immune response 
Acquired immunity is a specialised form of immunity involving antigen-specific 
lymphocytes and memory cells, thus limiting re-infection with the same organism. 
The adaptive immune response takes longer to develop than the innate immune 
response and also displays high antigen specificity, in contrast to the broad action 
displayed by components of the innate immune response (Coico and Sunshine, 
2009).  
In sheep scab, the adaptive immune response has been identified in primary 
infestations during the period of exponential increase in the mite population, where a 
rapid increase in lesion area is apparent and circulating anti-P. ovis specific IgE, IgM 
and IgG antibodies are produced (Bates, 1997, Lee et al., 2002, Van den Broek et al., 
2003c). Secondary infestations were characterised by reduced lesion growth with 
quicker resolution (2 cm² peak lesion size at 1 week post infestation) compared with 
primary infestations ( >3 cm² at 13 weeks post infestation) (Van den Broek et al., 
2000). Mite-specific serum IgG and IgM levels in primary and secondary infestations 
were not significantly different (Van den Broek et al., 2003c) whereas there was a 
rapid, sustained, increase in P. ovis -specific IgE levels in sheep serum after 
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secondary infestations compared to those in primary infestations (Van den Broek et 
al., 2000).  A similar response has been reported to S. scabiei  in sheep where 
primary infestations were characterised by raised and sustained specific IgG levels, 
and a smaller but steady rise in specific IgE (Rodriguez-Cadenas et al., 2010b). In 
secondary infestations, the mite-specific IgE levels were significantly higher than in 
primary infestations and the lesion sizes and mite numbers were reduced, suggesting 
that development of immunity to this parasite is more closely correlated with specific 
IgE antibodies than to IgG (Rodriguez-Cadenas et al., 2010b) .  
Many allergens, which induce the type of hypersensitive response seen in sheep scab, 
have enzymatic activity which typically induces a Th2 type immune response, such 
as those seen in chronic human inflammatory disease (Medzhitov, 2008). This 
response is typical of parasitic infestations, under the influence of interleukin 4 (IL4), 
produced by dendritic cells, which promotes the differentiation of naïve CD4⁺ T cells 
into Th2 cells. The Th2 cells synthesise IL4 and interleukin 13 (IL13), which cause 
B cells to effect an IgE response, and interleukin 5 (IL5) which activates eosinophils, 
a response which has been widely researched in helminth infections (Ludwig-
Portugall and Layland, 2012). It has been suggested in helminth infection that, as the 
host’s Th2 response rarely results in the expulsion of the parasite, the worm 
demonstrates an immuno-modulatory capacity to ensure its survival (Moreau and 
Chauvin, 2010). The induction of regulatory T cells (Tregs) which occurs in the host 
during helminth infection is also thought to contribute to this tolerance (Everts et al., 
2010). Tregs have been described as a subset of T lymphocytes which are important 
to immune homeostasis by controlling harmful immune responses (Sakaguchi et al., 
2008). The expression of Foxp3, a transcription factor required for the generation of 
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Tregs, increases in skin cells in response to the pathogenesis involved in infestation 
with P. ovis and this process is thought to limit the tissue damage during the host 
immune response (McNeilly et al., 2010).  
At the transcription level, our understanding of the host’s response to P. ovis 
infestation has been increased by a study using microarray technology to demonstrate 
differential gene expression in RNA extracted from circulating leukocytes of sheep 
over a 6 week time course of infestation (Burgess et al., 2012a). Due to the time 
period studied, the results have provided information bridging the early response into 
established disease and have demonstrated the increased expression of genes 
involved in complement activation, chemokine signalling, integrin and tight junction 
signalling, and of IL4 and IL13 which are involved in the development of an allergic-
type Th2 biased immune response. In addition decreased expression of those genes 
involved in skin barrier function and those repressed by the Th2 response was shown 
(Burgess et al., 2012a).  
The overall picture of the immune response following mite infestation is that sheep 
scab mite allergens trigger the release of pro-inflammatory cytokines and activate the 
complement pathway, resulting in immune cell recruitment and activation. This leads 
to further inflammation at the infestation site and worsening of the disease 
symptoms, such as serous exudate which aids the establishment of the mites (Burgess 
et al., 2012a). Characterisation of the dominant mite allergens and improved 
knowledge of the host immune response at the transcription level have led to 
development of a immunoassay quantifying the host IgG response to a specific mite 
antigen Pso o 2 (Nunn et al., 2011). Although this assay can diagnose early P. ovis 
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infestation and shows high sensitivity and specificity, it cannot diagnose current 
disease status in recently treated sheep due to antibody persistence. However, by 
using microarray data generated from a study demonstrating differential gene 
expression in circulating leukocytes of sheep over a 6 week time course of infestation 
(Burgess et al., 2012a), it is anticipated that serum BMs can be identified which will 
improve the existing diagnostic assay by indicating current disease status post-
treatment. This concept forms the basis of this study, the aims of which are described 
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1.7 Project aims 
The aims of this study are as follows: 
1. The identification of potential BMs of active sheep scab infestation using data 
from a microarray study which analysed gene expression changes in 
circulating leukocytes in response to infestation with P. ovis (Burgess et al., 
2012a). This will be achieved using bioinformatic analysis software to form a 
ranked list of BMs on defined criteria. 
2. The characterisation and evaluation of the most promising BMs from the 
above list using Western blot analysis as a method for preliminary validation, 
followed by gene sequencing, recombinant protein expression and ELISA 
development for any BM where the preliminary validation showed promise.  
3. Investigation into the response of the major ruminant APPs Hp and SAA to 
P. ovis infestation using existing commercially-available assays to evaluate 
their potential as BMs of current disease status. 
4. The validation of the selected BMs with field samples from natural outbreaks 
of sheep scab and with samples from experimental trials, including an 
infestation and treatment trial designed to establish the changes in serum 
concentration of the selected BMs post-infestation and post-treatment. 
5. Comparison of the changes in serum BM concentration after treatment to the 
host antibody response to the mite antigen Pso o 2 using the existing 
diagnostic ELISA (Nunn et al., 2011) and assessment of the possibility of 
integrating selected BMs with the existing antibody based diagnostic ELISA 
assay. 
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Chapter 2: Bioinformatic selection of potential 
biomarker candidates for diagnosis of current 
disease status in sheep scab infestation and 
their preliminary evaluation by Western blotting 
2.1 Introduction 
 A BM can be described as a characteristic which can be objectively evaluated and 
validated as showing measurable changes in concentration during normal biological 
processes compared to those found during disease or in response to treatment 
(Biomarkers Definitions Working Group (2001).  In practice, changes in BM 
concentration in response to disease or treatment must be measurable and readily 
detectable in biofluids, such as a secreted plasma protein. Ideally BMs should 
circulate at low levels in the biofluids of healthy individuals, increase in titre rapidly 
with a readily detectable magnitude following the onset of disease and return to pre-
infestation levels soon after successful treatment or disease resolution (Atkinson et 
al., 2001).  
In relation to sheep scab, the ultimate objective of the search for potential BMs for 
sheep scab was to include these BMs in an improved diagnostic test in the context of 
the Pso o 2 based ELISA, which does not indicate current disease status post 
treatment due to antibody persistence, to allow pathogen specificity. 
BMs have been applied extensively in the diagnosis of many medical conditions and, 
increasingly, for veterinary diseases in the search for earlier diagnosis, to measure 
the efficacy of treatment and disease prognosis (Kulasingam et al., 2010, Liang and 
 
Chapter 2. Bioinformatics and initial biomarker evaluation 
35 
Chan, 2007, Zhong et al., 2011). Recently the extent of use and range of BMs 
employed have both increased with advances in molecular techniques and 
proteomics (Pang and Argyle, 2010). BMs have had the widest application in 
medical oncology where they are currently used clinically for diagnostic or 
therapeutic purposes (Cooper et al., 2007), and in cardiovascular disease where they 
have become an important tool for clinicians in diagnosis, response to treatment and 
patient prognosis (Hochholzer et al., 2010). Recently, BM discovery has used 
microarray analysis in the identification of potential BMs by establishing gene 
expression profiles during pathogenesis. This technology has been applied to 
establish the occurrence of differential expression of genes in health and disease 
states, e.g. the identification of increased expression of histone-lysine N-
methyltransferase (EZH2) which, in sera, indicates poor prognosis in human prostate 
cancer  patients (Cooper et al., 2007). Microarrays are useful as a prognostic and 
diagnostic tool due to the unbiased approach that they allow and the high number of 
targets, allowing identification of signatures of genes related to disease progression, 
which may provide a more accurate prediction of patient recovery outcome (Cooper 
et al., 2007). This approach has also been used to estimate response to treatment, for 
example in peptide vaccination for human prostate cancer patients, by monitoring 
gene expression profiles in peripheral blood mononuclear cells (PBMCs) throughout 
treatment (Komatsu et al., 2011). Thus, in patients with advanced prostate cancer 
who responded to peptide-based cancer vaccinations approximately half survived 
longer than 900 days post-treatment whereas the remaining patients died within 300 
days. BM identification, to establish patients who would most likely benefit from 
peptide vaccination treatment, was achieved by microarray analysis of PBMCs in 
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blood samples from the two patient types (survivors for >900 days c.f. those who 
died within 300 days) pre- and post-vaccination. Results indicated that a cluster of 
genes associated with abnormal granulocytes which were differentially expressed in 
the two patient types could be used as a BM panel to predict patient prognosis with 
92% accuracy (Komatsu et al., 2011). It is anticipated that this technique may lead to 
improved therapeutic strategies in applying peptide vaccination to patients who 
would most benefit from it.  
The use of microarray analysis in the understanding of the pathogenesis and 
underlying molecular mechanisms of livestock diseases has now also been widely 
applied (Jacobson et al., 2011). For example, in scrapie, data obtained from 
microarray analysis illustrated the differential expression of 148 genes in affected 
sheep compared with healthy controls, using tissue extracted from the medulla 
oblongata (Filali et al., 2011). Some of these differentially expressed genes, which 
are potential BMs of neurodegenerative disease, had previously been identified but 
many were novel (Filali et al., 2011) and, of the newly-identified genes, 43% were 
increased in concentration in tissue extracted from the medulla oblongata and 57% 
decreased in scrapie-affected sheep. These were characterised as immune system 
related genes, ion-transport, nucleotide binding or structural molecule activity genes 
(Filali et al., 2011). Further understanding of scrapie disease progression through 
transcriptional profiling, has come from a study using prescapular lymph nodes and 
spleen cells (Gossner et al., 2011), which confirmed the up-regulation of networks of 
genes associated with cell apoptosis and repression of genes involved in the 
inflammatory response in affected animals. Knowledge from research using 
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microarray technology has therefore contributed to the understanding of pathology in 
disease progression in scrapie which may elucidate disease progression at functional 
protein levels and thereby lead to the identification of potential BMs for further 
investigation as possible diagnostic tools. A model systems approach has also been 
applied to scrapie research using a murine model consisting of eight distinct mouse 
strain-prion strain combinations to track gene expression in the brain. This approach 
has provided a basis for developing models for prion replication and disease, leading 
to possible therapeutic approaches (Hwang et al., 2009).    
Gene expression studies using microarray analysis have also been applied to sheep 
scab to increase understanding of the host: parasite relationship through the course of 
disease progression and, in particular, the mechanisms underlying the host response 
to the mite (Burgess et al., 2010, Burgess et al., 2012a). Many of the genes found to 
be differentially expressed in these studies encoded pro-inflammatory, inflammatory 
and anti-inflammatory proteins, including a number of complement components, e.g. 
complement 4 binding protein alpha (C4BPA) and complement 4 binding protein 
beta (C4BPB), interleukin 1 alpha and beta (IL1A and IL1B), secreted 
phosphoprotein (SPP) and the S100 calcium binding proteins (S100A8 and S100A9) 
(Burgess et al., 2012a). Temporal clustering of gene expression data into time 
intervals (based on sampling 0, 1, 3 and 6 weeks post-infestation) followed by 
pathway analysis, resulted in a clearer picture of the signalling events which occur in 
circulating leukocytes following exposure to P. ovis mites and a better understanding 
of the host systemic response to infestation (Burgess et al., 2012a). 
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The large amount of data obtained from microarray analysis can be a useful tool for 
BM identification (Cooper et al., 2007), but the data requires further filtering to 
enable selection of the more reliable BMs for disease diagnosis. Fortunately, there is 
now a range of computer software available, such as Genespring GX (Agilent 
Technologies UK) and Ingenuity Pathway Analysis (Ingenuity Systems Inc. USA), 
to assist in gene selection by allowing the user to define selection criteria deemed 
important for the proposed function of potential BMs.   
The gene expression study (Burgess et al., 2012a) used as a basis for this present 
study, demonstrated that circulating leukocytes could be used as “sentinels” of 
infection at local sites and it is hypothesised that increased expression of genes in 
these circulating leukocytes may initiate factors detectable in serum which were 
reflective of inflammation. The feasibility of evaluating these BMs therefore required 
the ability to detect the BM in biofluids and hence the requirements for a suitable 
antibody to allow a qualitative evaluation by Western blot analysis, or a quantitative 
one using ELISA. Further refinement of the selected BMs by bioinformatic filtering 
was therefore required based on the availability of commercially produced antibodies 
suitable for preliminary BM evaluation using Western blot analysis, as the most 
practical method due to the time constraints of the present study.  
Western blotting is considered to be an effective technique for the validation of the 
specificity of an antibody, which is an essential step towards clinical translational 
research (Signore and Reeder, 2012). To confirm antibody specificity it is important 
to use a complex biological sample containing the BM, such as blood, rather than a 
purified protein and, when using blood, a single band at the expected MW of the BM 
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protein on the blot is indicative of the presence of the BM and suitability of the 
antibody in terms of specificity (Signore and Reeder, 2012). Western blotting is also 
considered a powerful technique for the immunodetection of low abundance proteins 
as it involves electrophoresis which separates proteins according to their MW, hence 
separating abundant proteins enabling visualisation of the less abundant ones and 
providing potential multiple immunogenic antigens for detection with specific 
antibodies  (Kurien et al., 2011). The ability to detect low abundance proteins is 
further enhanced by the use of sensitive detection methods such as 
chemiluminescence, which depends on incubation of the Western blot with a 
substrate that will luminesce when exposed to the reporter conjugated to the 
secondary antibody. Detection is achieved by either x-ray film, or more recently by a 
charge coupled device (CCD) highly sensitive camera such as the ImageQuant 
LAS4000 system (GE Healthcare, UK). This system also allows automated semi-
quantitative analysis of the bands of interest obtained using densitometry, which is 
useful for comparing bands within a blot, or if appropriate standards are used, it can 
be used to produce effective quantitative comparisons across separate blots (Alegria-
Schaffer et al., 2009). The evolution of these more sensitive detection systems, which 
can be used in the visualisation and interpretation of Western blots, has increased the 
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The aims of this chapter were: 
 To use a bioinformatic filtering approach to produce a ranked list of potential 
BMs for sheep scab based on the list of 621 differentially expressed genes in 
circulating ovine leukocytes through a time course of sheep scab infestation 
(Burgess et al., 2012a).  
 
 To investigate this ranked list of potential BMs for the availability of a 
commercially produced antibody to further refine the list of selected proteins. 
 
 To evaluate, by Western blot analysis, the potential BMs for which there 
were suitable antibodies available, to determine if they were detectable in the 
sera of sheep infested with P. ovis and if they were up-regulated across a 
time course of infestation. If they satisfied these criteria, the BMs would then 
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2.2 Materials and methods 
2.2.1 Microarray study 
The microarray data used in the filtering and selection of potential BMs were 
extracted from a previously published study (Burgess et al., 2012a) in which 6 sheep 
were infested with 50-100 live P. ovis mites, scab lesion sizes measured and whole 
blood samples obtained pre-infestation and then weekly for 6 weeks post infestation. 
The lesion was defined as the area of hardened, crusted scab caused by the dried 
serous exudate from where the mites had been feeding. The edge of the lesion was 
taken as the reddened edge of skin where mites were apparent. Blood samples were 
immediately processed to isolate circulating leukocytes and total RNA was extracted 
(Burgess et al., 2012a). Briefly, microarray analysis (Agilent Bovine expression 
microarrays, 4 x 44K format, Agilent, UK) using a single-dye (Cy3) format 
performed to quantify gene expression differences between circulating leukocytes 
pre-infestation and 1, 3 and 6 weeks post-infestation samples in all animals using the 
Agilent single colour expression format. Probe sets (n=21,520) were filtered to 
remove low quality probes (flags present or marginal) leaving 14,174 probes for 
statistical analysis. To identify genes differentially expressed over the time course of 
infestation a one way analysis of variance (ANOVA) was applied with Benjamini 
and Hochberg False Discovery Rate (FDR) correction at a cut-off of p≤0.05 
(Genespring GX 11.0). This analysis led to the identification of 1,176 significantly 
differentially expressed genes over the time course. This list was further filtered 
using a fold change cut-off of ≥ 1.8 in at least one of the time point combinations (0 
(pre-infestation) vs 1 week post-infestation; 0 vs 3; 0 vs 6; 1 vs 3; 1 vs 6 and 3 vs 6), 
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and provided a final list of 621 genes for the downstream analysis performed and 
described in this chapter. 
2.2.2 Filtering and annotation of potential BMs 
The 621 genes, which were differentially expressed in circulating ovine leukocytes 
over the time course of infestation with sheep scab (0-6 weeks), were sorted based on 
gene expression profile across the individual time points (0, 1, 3 and 6 week pi). The 
flow chart in Figure 2.1 outlines the method followed. Initially, the “biomarker filter” 
function within the Ingenuity Pathway Analysis (IPA) (Ingenuity Systems Inc. USA 
version 7.6) software package was used. Genes were considered as potential BMs if 
the proteins they encoded were known to be detectable in at least one of the 
following biofluids: blood; plasma/serum; saliva or sputum, although this 
information was based on IPA data for humans as there was no ovine or bovine data 
available. The selected genes were filtered using the “find similar entities” function 
within the Genespring GX software package (Agilent Technologies UK version 10.0) 
to assess the quality of the raw microarray data obtained for each gene based on the 
identification of the flags and the log2 normalised intensity data for each sample 
across each time point, as described below. 
The raw microarray data for a gene was considered as being of sufficient quality for 
further analysis if the following criteria were met: 
1. Quality flags for the microarray probes were assessed and accepted if they were 
all present (“P”) except allowing for 1 absent (“A”) per animal at each time point 
but no marginals (“M”).  “P” represents a gene that was expressed to a detectable 
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level; “A” where it was not and “M” where it was not possible to differentiate 
between P and A. 
If this first criterion was met, then a second was imposed:  
2. The gene expression profiles (normalised log [log₂] intensity values) 
demonstrated an increase in gene expression at each time point for all animals 
(n=6).  
 
Figure 2.1: Flow diagram outlining the BM filtering process by depicting the 
bioinformatic functions used to filter the original list of 621 genes differentially 
expressed in circulating leukocytes across a time course of infestation with sheep 
scab to a final filtered and ranked list of 178 genes available for BM evaluation. 
Initial biomarker filtering IPA software “biomarker filter” function 
Data quality filter using “find similar entities” function in Genespring GX  
Genes scanned for extracellular location (IPA) and amino acid sequences batch processed  
through SignalP 3.0 server  
List filtered against genes differentially expressed in sheep during Teladorsagia 
circumcincta infection  
Final Genespring GX assessment allowing ranking of genes 
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By individually investigating the raw expression data for all selected probes the 
analysis described above exceeded the stringency applied during standard approaches 
for microarray data analysis, which rely upon arbitrary fold-change and significance 
value cut-offs to limit false positive results (Dalman et al., 2012, Jeffery et al., 2006). 
This approach was chosen to further reduce the chances of false positive results 
occurring in the downstream analysis. The genes were annotated by scanning for 
known extracellular locations using IPA and batch processing amino acid sequences 
through the SignalP 3.0 server (Centre for Biological Sequence Analysis [CBS]; 
http://www.cbs.dtu.dk/services/SignalP) giving a prediction of the presence of a 
signal peptide sequence, as these two criteria indicated that the protein may be 
secretory and as such potentially more readily detectable in serum.  
All genes were then filtered against a list of 111 genes that were found to be 
differentially expressed (fold change ≥1.5 and p = ≤0.05) in a parallel study in sheep, 
in which host responses to infection with the parasitic nematode Teladorsagia 
circumcincta were analysed (STG Burgess, Unpubl. data). This study analysed gene 
expression in circulating leukocytes in response to T. circumcincta over a 6 week 
time course of infection and the samples were interrogated on the same Agilent 
bovine microarray platform as the sheep scab infestation samples described here. T. 
circumcincta is a common gastrointestinal nematode parasite of sheep (Sargison et 
al., 2012); therefore removing genes differentially expressed during exposure to both 
parasites would increase the specificity of the list for sheep scab BMs. 
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The Genespring “entity inspector” function was used to re-assess the final list 
allowing ranking of individual genes. The rankings were derived from assessments 
based on three criteria:  
1. The effectiveness of each gene to reflect P. ovis infestation over time, i.e. as the 
time course of infestation progressed and the gene expression was consistently 
increased. This criterion was graded on a scale of 1-5, (1 = excellent; 2 = very 
good; 3 = good; 4 = average; 5 =poor), according to the mean response curve (the 
curve describing the change in expression of each gene over the time course of 
infestation) of all animals (n = 6) over time.  
2. The strength of the relationship between lesion size and the changes in gene 
expression through infestation. The curve obtained for the gene expression 
changes over the time course of infestation was examined for each individual 
animal and compared to the recorded lesion size at each time point over the course 
of infestation, thus providing an indication of the relationship between gene 
expression and lesion size. This criterion was graded using the same scale as in 
point 1 above. 
3. Response magnitude (response magnitude Log2) over time was obtained from the 
“entity inspector” function in Genespring GX. The response magnitude refers to 
the overall increase in gene expression over the total time of infestation, i.e. 0-6 
week p.i. The log normalised intensity value for each change in gene expression 
over the time course of infestation was expressed as the mean of all animals 
(n=6). 
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The final selection of potential BMs for evaluation based on the above criteria was 
on the availability of commercially produced antibodies for use in Western blotting 
due to the time constraints of the study. 
 
2.2.3 Western Blotting  
Western blotting was used as a method of determining if the available antibodies 
cross-reacted specifically with the relevant ovine BMs and to estimate if the selected 
BMs increased in relative concentration within sheep serum as the sheep scab 
infestation progressed. The detection of potential BM proteins identified by Western 
blotting was by chemiluminescence (GE Healthcare) and visualisation was on X-ray 
plates or using an ImageQuant LAS4000 camera (GE Healthcare, UK) available 
during the latter stages of the project. Blots visualised by ImageQuant are specified 
in the results. 
2.2.3.1 Polyacrylamide gel electrophoresis (PAGE)  
SDS-PAGE was performed using a total sample volume of 10µl, after the sheep sera 
samples (diluted 1:10 in dH2O) had been incubated with 4X NuPage LDS sample 
buffer (2.5µl) (Invitrogen) and NuPage sample reducing agent (1µl) (Invitrogen) at 
70⁰C for 10 mins. Electrophoresis was performed using NuPage BisTris 4-12% 
Polyacrylamide gels (Invitrogen) using MES buffer described in A2.1.1 at 250V for 
35 mins in a PowerEase 500 electrophoresis cell (Invitrogen). The molecular weight 
marker was 1X SeeBlue Prestained Standard (5µl) (Invitrogen) for X-ray 
development and MagicMark XP (5µl) (Invitrogen) for ImageQuant analysis. 
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2.2.3.2 Blotting 
The Invitrogen iBlot Western Blotting System (programme P2) was used to transfer 
the separated proteins onto a nitrocellulose membrane (Invitrogen) which was then 
blocked with 3% gelatin (diluted using the wash buffer/antibody diluent described in 
A2.1.2.) from cold water fish skin (Sigma-Aldrich) for 30 minutes. Washing between 
all steps employed the wash buffer described in A2.1.2. Primary and secondary 
antibody incubations were performed for 1 hr at room temperature (RT).  
2.2.3.3 Antibodies  
Specific primary antibody information for each candidate protein is shown in Table 
2.4. Each primary antibody was used at a dilution of 1:1000 as determined by 
titration blots, except the antibody for TNF which was used at a 1:500 dilution. 
Antibody diluent was as described in section A2.1.2. The secondary antibodies used 
with each blot are detailed in Table A2.1.  
2.2.3.4 Controls  
Negative controls (no primary antibody controls) were used with each Western blot 
to assess non-specific antigen interactions with the secondary antibodies. IgG 
controls using rabbit anti-sheep IgG HRP (Dako), at a dilution of 1:20000, were used 
instead of positive controls as there were no defined standards, i.e. commercially 
available recombinants, or sera available with known measurable amounts of the 
proteins being investigated. The IgG control was designed to recognise IgG in ovine 
sera thereby indicating that the Western blotting technique was working. The 
exception was C4BPB where a commercially available human recombinant protein 
was used as a positive control (H00000725-P01, Novus Biologicals).  
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2.2.3.5 ECL visualisation and image development 
Western blots were visualised using Amersham ECL Plus Western Blotting 
Detection Reagents (GE Healthcare) following the manufacturer’s instructions and 
the blot transferred to X-ray film with 30s exposure prior to development. 
Development and fixing of film was by automatic tank (Optimax 2010) and band 
densitometry was based on band volume as determined by Quantity One software 
(version 4.6.2, Bio-Rad). C4BPB visualisation was achieved using the ImageQuant 
system (LAS 4000, GE Healthcare) followed by band densitometry analysis by 
ImageQuant TL software (GE Healthcare).  
2.2.3.6 Samples 
The pooled sera samples separated by SDS-PAGE in the initial screening of the 
candidate proteins were obtained from three experimental P. ovis infestation trials 
comprised of the following: 
1. A time course experimental study (as described in Burgess et al., 2012a) where 
weekly serum samples were taken from 6 sheep infested with P. ovis over a 6 week 
period and included pre-infestation samples (week 0). Lesion areas were recorded 
weekly when blood samples were taken. This study is referred to throughout as time 
course (TC)1.  
2. A sheep scab experimental trial with 8 sheep blood sampled by venous extraction 
weekly (weeks 0-6). This study is referred to throughout as TC2. 
3. A group of 6 mite donor sheep experimentally infested and blood sampled pre-
infestation then weekly for 6 weeks. This study is referred to as TC3. 
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In addition, pooled hyper-immune (HI) sera (n = 2) was used from sheep 6 weeks 
post-infestation in a secondary infestation with P. ovis mites. 
2.2.3.7 IgG depletion of sera  
Initial blots (not shown) were difficult to interpret due to the presence of large bands 
of cross-reactivity at approximately 25 and 50 kDa. As this was likely to be IgG light 
and heavy chains, all sera used for blotting were IgG depleted using a NAb™ Protein 
G Spin Kit 0.2ml (Thermo Scientific) following the manufacturer’s instructions. All 
serum used in SDS-PAGE was IgG depleted as this produced blots with reduced 
cross-reactivity which allowed clearer interpretation of results.  
 
Chapter 2. Bioinformatics and initial biomarker evaluation 
50 
2.3 Results 
2.3.1 Bioinformatic analysis 
The original list of 621 differentially expressed genes was sorted in relation to time 
intervals (week post-infestation). The numbers of genes within each interval of the 
time groups were as follows: 0 vs. 1 = 36; 1 vs. 3 = 66; 0 vs. 3 = 51; 3 vs. 6 = 403; 0 
vs. 6 = 606; and 1 vs. 6 = 465. Many of the genes were present in more than one list 
hence the cumulative numbers exceeding the 621 original genes.  
The number of genes in each interval list at each stage of the filtering process (as 
described in section 2.2.2) are depicted in a flow diagram (Figure 2.2) to demonstrate 
how the filtering process progressed from 621 genes in the original list to 178 filtered 
genes in the final list. 
The Genespring “entity inspector” function re-assessment, as described in section 
2.2.2, was not included in Figure 2.2 as no further genes were excluded during this 
step of the analysis. This function considered the strength of the relationship between 
the time course of infestation and individual gene expression; lesion size changes and 
changes in gene expression, and the magnitude of the gene expression changes over 
the total time of infestation. An example of the “entity inspector” function analysis is 



















Figure 2.2: Flow diagram demonstrating gene numbers after each filtering process as 
described in section 2.2.2 and outlined in Figure 2.1. *Only up-regulated genes were 
used in the final analysis. **”Find similar entities” function (Genespring GX). 
***Extra genes added in from those encoding proteins with extracellular locations 
and SignalP peptides. 
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Figure 2.3: An example of an entity inspector analysis of a high ranking gene 
response showing gene expression magnitude responses across all animals and for all 
time points for collectin11 (COLEC11). Response magnitude measured as log2 
normalised intensity values. Week p.i. = week post-infestation with P. ovis. Diagram 
adapted from Genespring GX. 
The protein encoded by COLEC11 has functions within the immune system and was 
considered to be a highly ranked potential BM as the gene expression responses 
increased for all time points in all animals with expanding lesions over time (see 
Table 2.1 for measured lesion sizes for individual sheep across the time course of 
infestation) and the animals with the largest lesions, (sheep 2, 5 and 6), showed the 
greatest response magnitudes.  
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Table 2.1: Lesion sizes (cm²) across the time course of sheep scab infestation for all 
sheep (n=6) from the trial which generated the data for the transcriptomic analysis of 









Week post – infestation  
       0                 1                2                3                4               5                6 
 
R  
0 25 50 100 200 100 50 Yes 
0 6 100 150 250 300 600  
0 16 6 6 4 0 0 Yes 
0 4 16 100 25 32 0 Yes 
0 12 150 400 800 1800 3600  
0 10 150 300 800 2400 2500  
 
The function of the final assessment using the “entity inspector” (Genespring GX), 
was to allow annotation of the BM and data quality filtered genes according to the 
three scores described as “time tracking score”, “response magnitude (Log2)” and 
“lesion tracking score” in Table 2.2. In this table, potential BMs, from the highest 
ranking (i.e. best “time tracking” score which represents the effectiveness of each 
gene to reflect P. ovis infestation over time) to the lowest ranking are presented. The 
“time tracking score”, as opposed to the “response magnitude” or “lesion tracking 
score”, was used for ranking purposes (Table 2.2) as this factor was considered as 
having potentially wider application in the field i.e. all sheep scab cases develop over 
a certain time period, but the extent of the disease and lesion size shows more 
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C3AR1 x 
   
Yes 
 
3 1.5 3 
CASP3 x 
   
Yes 
 



































   
Yes 
 
3 1.2 3 
DOK2 x 
   
Yes 
 
3 0.8 3 
GLIPR2 x 
   
Yes 
 
3 0.5 3 
IL18RAP x 
   
Yes 
 
3 1.5 3 




3 1.3 3 
MSRA x 
   
Yes 
 
3 0.8 3 
PRAM1 x 
   
Yes 
 
3 1.5 3 
PTPN1 x 
   
Yes 
 
3 0.9 3 
RASGRP4 x 
   
Yes 
 
3 0.9 3 
SIRPA x 
   
Yes 
 
3 0.6 3 
STXBP2 x 
   
Yes 
 
3 0.6 3 
TNFSF14 x 
   
Yes 
 
3 0.7 3 
AIG1 
    
Yes Signal Peptide 3 0.7 4 
C11orf24 
    
Yes Signal Peptide 3 0.6 4 
C22orf25 
    
Yes Signal Peptide 3 0.7 4 
ESRRA 
    
Yes Signal Peptide 3 0.6 4 
HEATR7A 
    
Yes Signal Peptide 3 0.8 4 
KCNK7 
    
Yes Signal Peptide 3 0.8 4 
NDUFB11 
    
Yes Signal Peptide 3 0.8 4 
TMED3 
    
Yes Signal Peptide 3 0.6 4 
ACAA1 x 
   
Yes 
 
3 0.8 4 




3 0.7 4 




3 0.9 4 
CD244 x 
   
Yes 
 
3 1.2 4 




3 1.5 4 
CNR2 x 
   
Yes 
 
3 0.6 4 
CTSF x 
   
Yes 
 
3 0.7 4 




3 0.7 4 










































3 0.7 4 




3 0.7 4 
LSP1 x 
   
Yes 
 
3 0.6 4 
LTA4H x 
   
Yes 
 
3 0.8 4 




3 0.7 4 




3 0.6 4 




3 1.5 4 




3 0.5 4 




3 1.2 4 
SLA x 
   
Yes 
 
3 0.9 4 
VASP x 
   
Yes 
 
3 0.4 4 
ADAMTS13 
    
Yes Signal Peptide 3 1.1 5 
RAB26 
    
Yes Signal Peptide 3 1.3 5 
COL4A3BP x 
   
Yes 
 
3 0.9 5 




3 0.7 5 




3 1 5 
MDM2 x 
   
Yes 
 
3 0.8 5 




4 3 2 
MBOAT7 
    
Yes Signal Peptide 4 0.9 3 
PAK1 x 
   
Yes 
 
4 0.5 3 
PTAFR x 
   
Yes 
 
4 0.7 3 
TALDO1 
   
x Yes 
 
4 0.7 3 
ART5 
    
Yes Signal Peptide 4 1.2 4 
CLCN7 
    
Yes Signal Peptide 4 0.7 4 
ITGA2B 
    
Yes Signal Peptide 4 0.8 4 
SLC13A3 
    
Yes Signal Peptide 4 0.6 4 
TMEM185A 
    
Yes Signal Peptide 4 0.7 4 
TSPO 
    
Yes Signal Peptide 4 0.8 4 







































   
Yes 
 
4 0.7 4 
CD34 x 
   
Yes 
 
4 1.5 4 
CDK5R1 x 
   
Yes 
 
4 1.5 4 




4 0.6 4 
NCR3 x 
   
Yes 
 
4 0.7 4 
OSBPL1A x 
   
Yes 
 
4 0.5 4 
PRKCA x 
   
Yes 
 
4 1 4 




4 0.8 4 




4 1 4 




4 1.8 5 
CXADR 
    
Yes Signal Peptide 5 0.8 3 




5 0.6 3 
HSH2D x 
   
Yes 
 
5 0.6 3 




5 1.2 3 




5 1.8 3 
SIVA1 x 
   
Yes 
 







5 0.8 3 
TPM1 x 
   
Yes 
 
5 0.1 3 
CHMP1A 
    
Yes Extracellular 5 0.7 4 
CDH4 
    
Yes Signal Peptide 5 0.8 4 
FAM174A 
    
Yes Signal Peptide 5 0.9 4 
FBXW7 
    
Yes Signal Peptide 5 0.7 4 
RELT 
    
Yes Signal Peptide 5 0.6 4 
RNF144B 
    
Yes Signal Peptide 5 0.5 4 
TP53I11 
    
Yes Signal Peptide 5 0.8 4 




5 0.6 4 




5 0.6 4 
CD97 x 
   
Yes 
 
5 0.6 4 
CYBA x 
   
Yes 
 






































5 1.6 4 




5 0.7 4 
FGR x 
   
Yes 
 
5 0.4 4 
IGF1R x 
   
Yes 
 
5 0.6 4 




5 0.1 4 
NRG1 x 
   
Yes 
 
5 0.2 4 




5 0.7 4 
S100A8 x x x x Yes 
 
5 1 4 




5 0.9 4 




5 0.6 4 
SOCS1 x 
   
Yes 
 
5 0.7 4 




5 0.5 4 
CA4 
    
Yes Signal Peptide 5 0.2 5 
CCNJL 
    
Yes Signal Peptide 5 0.3 5 




5 1 5 




5 0.9 5 




5 0.9 5 
          
                    
          Table 2.2: Final list of 178 filtered and selected BMs. All genes were considered to be significantly differentially expressed with a p-value 
of ≤0.05 following Benjamini & Hochberg FDR correction for multiple testing.
 
HUGO gene symbols obtained from HUGO gene 
nomenclature committee (HGNC). The gene symbols used were ovine where available and otherwise bovine, or human if the bovine 
symbol was not available.  
B
Protein that HUGO gene encodes for was identified from the Ingenuity Pathway Analysis Knowledge Database 
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as being present in the selected biofluid. 
x
Represents protein is present in biofluid. 
C
Raw data and quality flags checked for each gene as 
described in section 2.2.2. 
 D
Location column denotes either the normal location of the protein encoded by the represented gene where not 
previously identified in a particular biofluid, or the presence of a predicted signal peptide sequence (identified from SignalP 3.0 package). 
E
Score assigned for how closely the mean gene expression profile tracked the course of infestation over time or how the individual gene 
expression profile tracked the lesion size over time (1 = excellent; 2 = very good; 3 = good; 4 = average; 5 = poor). 
F
Range of log 
normalised intensity value (Log2) for individual genes based on mean expression profile over all animals over the time course of 
infestation. Blue highlighted genes = encoding proteins for which commercially-available antibodies could be obtained (Table 2.3). 
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The final selection of potential BMs for downstream analysis was based on the 
availability of commercially produced antibodies for the detection of orthologues of 
the highest ranking proteins and included 8 proteins which are listed in Table 2.3 
with antibody source details and highlighted in blue in Table 2.2.  
Table 2.3: The final list of potential protein BMs for downstream analysis for which 
commercially available antibodies could be sourced at the time of study.  *HUGO 





Antibody Source Catalogue 
No 
Osteopontin SSP Rabbit α-human Abcam Ab8448 
Calgranulin-A S100A8 Mouse α-human Novus Biological A01 
Calgranulin-B S100A9 Rabbit α-human Abcam Ab75478 
Complement 4 
binding protein 












KCNQ1 Rabbit α-human Abcam Ab77701 
Solute carrier 
family 7 
SLC7A11 Rabbit α-human 
HRP 
Abcam Ab81948 
Collectin 11 COLEC11 Rabbit α-human Abcam Ab91483 
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In the sheep scab host gene expression study (Burgess et al., 2012a) which provided 
the data used in the BM search described in this chapter, the microarray gene 
expression data were verified using qPCR. It was necessary to perform qPCR 
validation as a routine quality assurance step but also because the microarray probes 
were derived from bovine gene sequence data, as ovine specific arrays were not 
available at the time of study.  
Table 2.4: Correlations between the microarray analysis and qPCR results for 10 
genes included in the bioinformatic analysis. Comparisons shown are between the 
baseline samples (time = 0) and the individual time point samples (WPI = week post-
infestation). *Correlation between qPCR and microarray data for selected validation 
candidates denoted by the Pearson r value. Table adapted from Burgess et al (2012a). 
Gene 
Symbol 
Microarray fold change qPCR fold change Pearson r* 
 1 WPI 3 WPI 6 WPI 1 WPI 3 WPI 6 WPI  
SPP1 2.18 3.27 53.33 5.98 4.48 12.42 0.98 
ALAS2 -1.45 -15.48 -59.17 -1.57 -44.07 -256.53 0.99 
ALOX15 3.1 5.76 17.47 3.43 6.19 7.93 0.89 
IGFBP4 2.23 4.26 12.62 1.45 2.87 2.13 0.57 
MPO 1.13 -2.54 1.05 1.58 -3.40 -3.12 0.56 
C4BPB 2.37 3.56 11.92 2.89 2.25 3.03 0.55 
CTTN 2.23 3.18 3.11 1.53 2.05 1.56 0.66 
PDLIM 4.11 7.21 52.5 6.16 7.65 16.63 0.99 
PLAU 1.59 2.26 6.34 1.08 1.56 2.43 0.97 
ANG 1.76 2.91 10.48 -1.46 -1.15 1.95 0.99 
Mean correlation 0.82 
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Ten genes were selected from the microarray study (Table 2.4) and the mean Pearson 
correlation value across all genes between the microarray and qPCR data was shown 
to be 0.82. This demonstrated that the two methods of assessing differential gene 
expression showed close agreement, giving increased confidence in the microarray 
results and as such the array data was considered to be validated (Burgess et al., 
2012a). 
As there were no ovine specific antibodies available for the assessment of potential 
BMs, ovine or if not available, bovine amino acid sequences for each of the proteins 
to be evaluated were aligned with the corresponding human amino acid sequence to 
indicate identities between the sequences and therefore if cross-reactivity between 
them was likely. The results are shown in Figure A2.1 and a summary (sequence % 
identities) included in Table 2.5. An additional two proteins, tumour necrosis factor 
alpha (TNF) and tenascin C (TNC) were added to the list of potential BMs (Table 
2.6) due to their up-regulated gene response to P. ovis infestation in ovine skin 
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Table 2.5: Amino acid sequence alignment identities of potential BM proteins with 
the species the antibody to be used was raised against. The full sequence alignments 
are included in Figure A2.1. If the ovine sequence was not available the bovine 
sequence was used. *No full ovine or bovine sequence available so the sequenced 
fragment was aligned with the corresponding fragment of the human protein. 
Protein to be 
evaluated 
Ovine amino acid 
% identity against 
human 
Bovine amino acid 













 51 Human P06702 
Bovine P28783 
Complement 4 Binding 
Protein (C4BPB) 








Oxytocin (OXT) 88  Human P01178 
Ovine P13389 
Potassium voltage gated 
channel (KCNQ1) 




Solute carrier family 7 
(SLC7A11) 






 84 Human Q9BWP8 
Bovine Q17QH6 
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Table 2.6: Additional potential BMs for downstream analysis for which 
commercially available antibodies could be sourced at the time of study.  *Human 
genome organisation (HUGO) gene symbols as approved by the HUGO gene 
nomenclature committee (HGNC). *antibody raised against recombinant bovine 
TNF. **antibody raised against a fusion protein, corresponding to amino acids 18-











TNF Mouse α-bovine* ABD Serotec MCA23358 
Tenascin C TNC Chicken α-human** Abcam Ab16290 
 
2.3.2 Western Blots of selected proteins 
2.3.2.1 Osteopontin (SPP) 
The primary antibody used (Table 2.3) had been shown to react with human, rat, dog 
and pig SPP according to the manufacturer’s data sheet (Abcam), but had not been 
previously tested with ovine SPP. Bands at 35.4 kDa on the Western blot of the 
sheep sera were not detected at any point pre or post infestation on repeated blots and 
it is therefore likely that either the human specific SPP antibody used did not bind 
ovine SPP, or SPP was present in very low abundance in sheep sera. 
2.3.2.2 Calgranulin (S100A8 and S100A9) 
There were no bands present at 16kDa, the estimated MW for S100A9. The antibody 
used to detect ovine S100A9 had been indicated in the manufacturer’s data sheet 
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(Abcam) to cross-react with human, mouse and rat S100A9, but had not been 
previously tested with ovine S100A9. No specific band for S100A8 was detected at 
the expected MW of 11 kDa (Figure 2.4). This antibody had only been previously 
tested against human S100A8 as indicated by the manufacturer’s data sheet (Novus 
Biologicals). Bands in the negative control (lane 11) indicated non-specific binding 
between the sheep sera and the secondary antibody. As with SPP, it is likely that 
either the antibodies used in the detection of S100A9 and S100A8 did not bind with 
the ovine proteins, or the proteins were present in low concentrations in sheep sera. 
 
Figure 2.4: X-ray image of a Western blot using pooled sera (n = 6) from sheep 
infested with P. ovis over a 6 week time course (TC1) run on a SDS-PAGE gel. 
Electrophoresis was performed at 250V for 35 mins. Western blot was probed with a 
S100A8 antibody raised in mice against human rS100A8. Conjugate = rabbit anti-
mouse immunoglobulins HRP. Lane 1 = SeeBlue MW Marker (Invitrogen); 2 = pre-
bleed sera; 3 = week 1 pi; 4 = week 2 pi; 5 = week 3 pi; 6 = week 4 pi; 7 = week 5 pi; 
8 = week 6 pi; 9 = hyper-immune (HI) sera; 10 = blank lane; 11 = negative (-ve) (no 
primary antibody) control; 12 = positive control. Positive control (+ve) used pooled 6 









  1      2      3     4    5     6     7     8     9    10    11   12 
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2.3.2.3 Complement 4 binding protein beta chain (C4BPB) 
C4BPB was initially detected using a polyclonal antibody raised in mice against 
human rC4BPB, but this yielded indistinct bands at 28 kDa, the estimated MW for 
human C4BPB. The signal was improved when a monoclonal anti-C4BPB antibody 
raised in mice against human rC4BPB was used (Table 2.3). The results indicated 
that a protein of the expected MW (28 kDa) showed increasing relative concentration 
(as measured by band density) in weeks 5 and 6 post-infestation (Figure 2.5). The 
band obtained pre-infestation was of a higher band density than weeks 1-4 post-
infestation, which may be explained as the pooled sera used in this blot (TC1) came 
from sheep which had been skin biopsied at the same time the pre-bleed was taken 
(Burgess et al., 2010), thereby potentially increasing serum inflammatory proteins. 
The negative control (lane 9) was blank indicating that there was no non-specific 
interactions between the antigen and the secondary antibody and the positive control 
(human rC4BPB) gave an intense band at the expected MW of 28 kDa, suggesting 
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Figure 2.5: Image of a Western blot from a SDS-PAGE gel using sera (pooled n = 6) 
from sheep infested with P. ovis over a 6 week time course (TC1) probed with a 
monoclonal anti-C4BPB (mC4BPB) antibody raised in mice against human rC4BPB. 
The band of interest at 28kDa is indicated by a red arrow. Lane 1 = MW marker 
MagicMark XP (Invitrogen); 2 = pre-bleed sera; 3 = week 1 pi; 4 = week 2 pi; 5 = 
week 3 pi; 6 = week 4 pi; 7 = week 5 pi; 8 = week 6 pi; 9 = -ve (no primary 
antibody) control; 10 = +ve control using human rC4BPB (Abnova). Conjugate used 
was rabbit anti-mouse Ig HRP (Dako). Visualisation was by ECL Plus (GE 
Healthcare) and ImageQuant camera LAS4000 (GE Healthcare). 
As lesion size data was available for the TC1 infestation study, separate Western 
blots were performed using individual sera from two sheep from this trial. One of 
these sheep had a naturally resolving lesion throughout the 6 week infestation trial 
(Sheep 1 in Table 2.1 and labelled Sheep 1 in Figure 2.6 below) whilst the other 
animal had an expanding lesion (Sheep 5 in Table 2.1 and labelled Sheep 5 in Figure 
2.6 below). The results of the densitometry analyses of these blots (Figure 2.6) 
indicated that as the lesion size increased, the 28 kDa band increased in intensity and 
as the lesion resolved, the intensity of the band decreased.
 




Figure 2.6: Densitometry analysis (ImageQuant) from Western blot images using: a) 
serum (TC1) from a sheep infested with P. ovis where the lesion resolved naturally 
(Sheep 1). b) serum from an infested sheep (TC1) where the lesion had expanded 
over the 6 week time course (Sheep 5). The immunoblots were probed with a 
monoclonal antibody raised in mice against human rC4BPB (Abnova) and the 
conjugate used was rabbit anti-mouse immunoglobulin HRP (Dako). The image was 
visualised by ECL Plus and ImageQuant and band densities (at 28 kDa) were 
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2.3.2.4 Tumour necrosis factor alpha (TNF) 
A problem commonly found in Western blot analysis is cross-reactivity between 
samples and secondary antibodies (Signore and Reeder, 2012) indicated by bands in 
the negative control as seen in lane 11, Figure 2.4 (S100A8). A biotinylated primary 
antibody and a streptavidin enzyme conjugate were available for the detection of 
TNF, therefore negating the need for a secondary antibody and eliminating the 
possibility of secondary antibody cross-reactivity. The biotinylated anti-TNF 
antibody used was raised in mice against bovine TNF and was predicted according to 
the manufacturer (ABD Serotec) to react with ovine TNF. Bands were obtained at 
the expected molecular weight of 25.6 kDa, marked with a red arrow as shown in 
Figure 2.7, but as there was no positive control available to confirm the identity of 
the bands, and it is unlikely that the bands would remain at a similar high density 
throughout the 6 weeks of infestation, it is possible that the antibody may have cross-
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Figure 2.7: X-ray image of a Western blot using pooled sera (n = 6) from sheep 
infested with P. ovis over a 6 week time course (TC1) probed with a biotinylated 
antibody raised in mice against bovine TNF. Lane 1= SeeBlue MW Marker 
(Invitrogen); 2 = pre-bleed sera; 3 = week 2 pi; 4 = week 3 pi; 5 = week 5 pi; 6 = 
week 6 pi; 7 = –ve control (no primary antibody); 8 = +ve (sheep IgG) control. 
 
2.3.2.5 Oxytocin (OXT) 
The results from the Western blot analysis, using a polyclonal anti-OXT antibody 
raised in guinea-pigs against human OXT, indicated no 12.7kDa band in pre-bleed 
sera but faint bands were present at weeks 1, 3 and 6 p.i., although these bands did 
not appear to increase in intensity over time (Figure 2.8). The multiple bands 
obtained in all lanes apart from the negative control suggested that the antibody was 
binding to multiple proteins in the sheep sera. 
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Figure 2.8: X-ray image of Western blot using pooled sera (n = 6) from sheep 
infested with P. ovis over a 6 week time course (TC1) probed with a primary 
antibody raised in guinea-pig against human OXT. Lane 1= SeeBlue MW Marker 
(Invitrogen); 2 = pre-bleed sera; 3 = week 1 pi; 4 = week 3 pi; 5 = week 6 pi; 6 = -ve 
control; 7 = +ve (sheep IgG) control  
2.3.2.6 Potassium voltage gated channel (KCNQ1)   
No bands at the predicted MW of 74.7 kDa were obtained for KCNQ1 following 
Western blot analysis. This antibody was predicted to react with bovine KCNQ1 
according to the manufacturer (Abcam), suggesting it may be suitable for use with 
ovine sera, but either it did not react, or KCNQ1 was not present in sufficient 
quantities in the sheep sera to be detected.  
2.3.2.7 Solute carrier family 7 (SLC7A11) 
This protein was highly ranked following the filtering process and an HRP linked 
primary antibody was available which negated the use of a secondary antibody. The 
Western blot showed a band present at 55.4 kDa, the predicted MW of SLC7A11, 
but the band intensities appeared very similar pre-infestation and throughout the time 
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course of infestation, with a slight increase by week 6 post-infestation and also with 
hyper-immune sera as shown in Figure 2.9.  
 
Figure 2.9: X-ray image of a Western blot using pooled sera (n = 6) from sheep 
infested with P. ovis over a 6 week time course (TC1) probed with a HRP labelled 
primary antibody raised in rabbits specific to human SLC7A11. Lane 1= SeeBlue 
MW Marker (Invitrogen); 2 = pre-bleed sera; 3 = week 1 pi; 4 = week 2 pi; 5 = week 
3 pi; 6 = week 4 pi; 7 = week 5 pi; 8 = week 6 pi; 9 = HI sera; 10 = +ve (sheep IgG) 
control. 
2.3.2.8 Tenascin C (TNC) 
Tenascin C was not detected at the predicted MW of 241 kDa. The antibody was 
predicted to react with human, mouse and rat Tenascin C protein according to the 
manufacturer (Abcam), but had not been tested in other species including sheep. It is 
likely, in the absence of bands at the estimated MW of TNC that the antibody used, 
which was raised in chickens against human TNC, either did not bind the ovine 
protein or TNC was not present in sufficient quantities in sheep sera to be detectable. 
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2.3.2.9 Collectin 11 (COLEC11) 
 A faint band was evident at the predicted MW of COLEC11, 28.6 kDa, which did 
not appear to increase in intensity until weeks 5 and 6 post-infestation when a 
marginal increase was observed (Figure 2.10). The banding obtained in the negative 
control was less intense than appeared in any of the sample lanes which may indicate 
weak recognition, therefore COLEC11 should be re-tested when a bovine or ovine 
specific antibody becomes available.   
 
Figure 2.10: X-ray image of a Western blot using pooled sera (n = 6) from sheep 
infested with P. ovis (TC1) probed with an antibody raised in rabbits against human 
rCOLEC11. Conjugate = pig anti-rabbit HRP (Dako). Lane 1 = SeeBlue MW Marker 
(Invitrogen); 2 = pre-bleed sera; 3 = week 1 pi; 4 = week 2 pi; 5 = week 3 pi; 6 = 
week 4 pi; 7 = week 5 pi; 8 = week 6 pi; 9 = -ve (no primary antibody) control; 10 = 
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2.4 Discussion 
This chapter describes the identification of the BM potential of 178 genes from a 
group of 621 genes previously shown to be differentially expressed in ovine 
circulating leukocytes across a time course of sheep scab infestation (Burgess et al., 
2012a), followed by the preliminary evaluation of the selected proteins, for which 
commercially available antibodies were available at the time of study, by Western 
blotting.  
A potential issue with the use of gene expression analysis in the identification of 
diagnostic protein BMs, is that gene expression levels do not necessarily predict 
protein levels accurately (Verma et al., 2006). However, in biological systems, 
energy is generally conserved and it is therefore unlikely that an up-regulation in 
gene expression will not result in an up-regulation of transcribed protein, although 
there may be potentially a time delay between the two events. Protein assays are the 
method of choice for clinical diagnostic tests based on BMs but as proteomic 
technologies, such as mass spectrometry, are currently limited in terms of their 
protein separation capability (Kulasingam et al., 2010) genomic approaches are 
commonly adopted for the identification of novel BMs in clinical research. This is in 
part due to proteomics being at an earlier stage of development compared with 
genomic technologies but they are increasingly being used as complementary to a 
genomic approach and are useful as protein levels give a clearer indication of 
functional differences in cells and organs in health and disease (Verma et al., 2006). 
As such, a similar approach was adopted here in the search for BMs, i.e. potential 
BMs were identified at gene level and finally validated at protein level, to indicate 
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current disease status in sheep infested with P. ovis. Protein assays are also useful as 
they are commonly developed using easily accessible biofluids, such as blood, which 
makes sampling minimally invasive (Kulasingam et al., 2010). Many of the proteins 
transcribed from the highly ranked genes in this study (Table 2.2) are inflammatory 
plasma proteins, which originate from the liver, e.g. C4BPB is synthesised in 
hepatocyte cells. However, it is not practical to sample from tissue as part of a 
routine diagnostic test and as the blood circulation is the transport system of the 
mammalian body, it was anticipated that differences in inflammatory protein levels 
between healthy and diseased animals would be detected in blood.  
The gene expression microarray analysis (Burgess et al., 2012a) on which the 
selection of potential BMs was formed, examined the changes in gene expression in 
circulating leukocytes across a time course of infestation with P. ovis. In sheep, 
blood leukocytes comprise neutrophils (40-60%), eosinophils (1-4%), basophils (0.4-
1%), lymphocytes (25-35%) and monocytes (4-6%) (Alberts et al., 2007), the levels 
of which affects the levels of pro-inflammatory markers at sites of local 
inflammation as well as systemically. Leukocytes may reflect systemic and local 
events during an inflammatory response and can also influence the course of the 
inflammatory response at local tissue sites (Luster, 1998). The host response to 
infestation with P. ovis can be characterised as an initial immediate hypersensitivity-
type response followed by a later systemic inflammatory response (Van den Broek 
and Huntley, 2003a). Increased leukocyte activation and extravasation occurs in 
response to up-regulation of the mediator selectin P ligand (SELPLG) (Burgess et al., 
2012a) and recently it has been illustrated that as leukocytes interact and 
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communicate with every tissue in the body, they can be used as sentinels reflecting 
disease progression at a local level (Burgess et al., 2012a, Liew et al., 2006). 
However, it is not known if gene expression differences in leukocytes correlate to 
protein levels in serum, particularly as the main origin of inflammatory plasma 
proteins is in the liver not within circulating leukocytes. To minimise the effect of 
this, only proteins which were known to be secreted or had an extracellular location 
were included in the final evaluation list as it was anticipated that this would make 
them more accessible for detection in host serum.  
The filtering process performed in this chapter selected for genes which showed an 
up-regulation in expression across the time course of infestation of ≥1.8 fold change 
and was characterised as being present in at least one of the selected biofluids for 
practical reasons of pen-side testing. The rationale of selecting a fold change in gene 
expression of ≥1.8 was to ensure the selected genes showed a detectable expression 
change, in anticipation that the protein transcript would increase to a significant 
degree also, giving higher opportunity for detection of the protein in serum. The 
rationale for selecting up-regulated genes only was that if the protein transcript was 
also up-regulated, the BM protein would be more easily detectable in serum in a 
diagnostic test during a field outbreak at an unknown time post-infestation. In 
addition, it was desirable that the potential BM circulated in serum at a low level in 
healthy animals as it was anticipated that there would be less variation in BM levels 
between animals pre-infestation, compared to a down-regulated protein which may 
be present at a higher level pre-infestation and therefore may show an increased level 
of variation between individuals at its “normal” physiological level. At the protein 
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level, the half life of the potential BM may also be an important factor. For example, 
if a protein has a long half life, a protein which is down-regulated during disease is 
likely to remain at measurable levels for a considerable time after disease onset, 
which is not desirable in a test aimed at early disease diagnosis. 
Following this initial filtering based on mean animal responses, each gene was 
selected based on high quality microarray expression data, after which it was 
important to complete a re-assessment of the remaining genes to determine the 
individual animal responses. Examining individual animal responses allowed the 
filtering out of BMs which were not considered to be robust across all animals. This 
was particularly important as the experiment which provided the data for the 
bioinformatic analysis (Burgess et al., 2012a) contained 3 sheep with naturally 
resolving lesions and 3 with expanding lesions (Table 2.1). This may have led to the 
elimination of genes which were up-regulated only as lesion size increased if the 
results were examined solely as a mean across all animals. It was therefore critical to 
include an individual animal assessment of the ability of each gene to correlate with 
lesion size so that this factor could be taken into account. An example of the gene 
expression across individual animals at each time point for the highly ranked 
COLEC11 was included in Figure 2.3. When this information is compared to the 
lesion size data in Table 2.1, it is evident that the expression of this transcript 
reflected lesion size development. For example, sheep 3 had a naturally resolving 
lesion and the gene expression profile was flat compared with sheep 5 which had an 
expanding lesion illustrated by the steep up-regulation of COLEC11 for this animal. 
The ability of the gene expression to reflect lesion size development was important 
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as lesion size can be used as a measure of disease progression in sheep scab. Genes 
such as OXT and COLEC11, which demonstrated this ability, were likely to encode 
proteins which may reflect current disease status. 
The magnitude of the gene expression response to disease was also an important 
factor to identify as larger magnitude responses, even at the transcript level, may 
provide a greater opportunity for the detection of the protein in serum, as many of the 
blood proteins are known to be present in very small quantities (Kulasingam et al., 
2010). Human plasma proteins are present in a range of concentrations over 12 
orders of magnitude and 99% of plasma protein mass consists of only 22 proteins 
(Anderson and Anderson, 2002) suggesting that many of the proteins, which may 
potentially be of interest, will be present in very small quantities, e.g. tumour 
necrosis factor alpha (TNF-α).  
The final ranking of BMs also included an assessment of the overall change of gene 
expression level at each of the time points measured through the time course of the 
infestation. This was considered to be a major factor in BM selection as, to be 
detected in serum during a field outbreak at an unknown time post-infestation, it 
would be easier to detect and to interpret the test results if the protein was up-
regulated across all time points during an active infestation. However, due to the 
limitations of experimental infestation of sheep with P. ovis, based on animal welfare 
considerations, it was only possible to measure changes for a 6 week period which 
may not fully reflect protein profiles in field outbreaks of sheep scab.   
Due to the time and cost restraints of this project, the final selection of potential BM 
candidates retained for further evaluation depended on the availability of 
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commercially produced antibodies. At the time of study, antibodies were 
commercially available for the detection of eight of the remaining highly ranked 
proteins, as shown in Table 2.3 and these proteins were retained for further 
investigation. There were no ovine specific antibodies available for any of the highly 
ranked BMs at the time of testing. There is a lack of well-characterised tools and 
reagents which are required for veterinary immunology to further understand 
host/pathogen relationships (Entrican et al., 2009) which is currently being addressed 
by the Veterinary Immunology Committee Toolkit (Entrican and Lunney, 2012). It 
was decided therefore, due to the predicted conserved function of many of the 
immune response proteins across mammalian species, to use human specific 
antibodies where there was no other alternative. The proteins encoded by the highest 
ranked genes such as ICAM3, transient receptor potential cation channel, subfamily 
C, member 6 (TRPC6) and adenosine A3 receptor (ADORA3) had no suitable human 
specific antibodies available at the time of study. However, these genes may be 
revisited in the future as commercial antibodies become available and as such, this 
list represents a valuable resource for future investigations.  
The eight proteins retained for further evaluation all showed functions relating to the 
immune system, particularly in response to inflammation. For example osteopontin 
(SPP) has been the subject of a large body of research due to its chemotactic 
properties in mammals, resulting in recruitment of cells such as macrophages and 
neutrophils to sites of inflammation such as those caused by infection, trauma or 
injury (Wang and Denhardt, 2008, Konno et al., 2011). The role of SPP in immune 
function is complex and recent research has concentrated on emerging roles in 
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wound inflammation, repair and fibrosis, through its function in Th1 cell mediated 
skin inflammation and in the Th2 regulation pathway in allergic dermatitis (Seier et 
al., 2010). Human keratinocytes can produce SPP under inflammatory conditions as 
shown by immuno-histochemical staining of skin biopsies from patients with 
psoriasis, an immune mediated inflammatory disease (Buback et al., 2009).  
In relation to sheep scab, the pro-inflammatory response is likely to be initiated 
through the interaction of the mite antigens and the epidermal keratinocytes as P. 
ovis is a surface feeding mite (Watkins et al., 2009). The increase in the transcription 
of SPP during infestation with P. ovis may be explained if ovine keratinocytes, like 
human cells, produce SPP under inflammatory conditions, then the promotion of 
inflammation and resulting prolonged healing time and wound fibrosis would 
enhance the mites feeding capacity. This ability of the mite to use the host’s innate 
inflammatory response for their own benefit has been suggested previously as the 
exudate, resulting from the keratinocyte response to mite allergens, becomes a major 
food source for the mites (Huntley et al., 2005). 
In livestock research, SPP has previously been investigated as a potential early innate 
BM of mastitis in dairy cattle. SPP transcripts were shown to be up-regulated in the 
somatic cells of cows experimentally infected in the udder with E. coli and this 
correlated with the number of milk immune cells and susceptibility to mastitis, 
leading to an interesting possibility for selection of resistance to mastitis in dairy 
cattle using SPP as a selection BM (Alain et al., 2009).   
Related roles in inflammatory disease can be attributed to all the other selected 
potential BMs.  However, with the exception of C4BPB, results from the Western 
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blot analyses in this study showed either a lack of binding between the primary 
antibody and the BM being evaluated; or interaction of primary or secondary 
antibodies with ovine IgG in the sera samples. Serum contains large quantities of 
immunoglobulins which can interfere with the detection of proteins at these specified 
MWs (Signore and Reeder, 2012) for which a recognised method to minimise this is 
the use of immunoglobulin removal techniques, as applied in this study. This was a 
useful technique as it resulted in blots with less non-specific banding which were 
clearer to interpret, but it failed to remove all of the IgG present therefore 
interpretation of the blots remained a problem if the BM protein was of a similar 
MW to IgG, as for example was the case for COLEC11 and TNC at 25 kDa (MW of 
light chain IgG) and SLC7A11 at 50 kDa (MW of heavy chain IgG). In addition, a 
number of serum proteins have been shown to adhere strongly to immunoglobulins 
and therefore IgG removal may also remove potential BMs (Veenstra et al., 2005). 
Another problem with the current study was the lack of commercially available ovine 
specific antibodies. All of the antibodies used were raised against the human version 
of the protein under investigation, except TNF where an antibody raised in mice 
against bovine TNF was used. Table 2.5 contains the comparable amino acid 
sequence alignments and illustrated a large range of percentage identities between 
the species compared. Using S100A9 as an example, the Western blot analysis failed 
to show distinct bands at any time point in the infestation study at the expected MW 
of approximately 16kDa but given the alignment of the human and bovine amino 
acid sequences it is possible that the two sequences showed insufficient identity 
(51%) for the antibody raised against the human recombinant protein to react 
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specifically with the ovine native protein. Previous work (Marchalonis et al., 2001) 
documented a linear correlation between degree of sequence identity and antigenic 
cross-reactivity; therefore it is possible that at 51% the identity between these 
sequences was too low to enable strong, specific antibody binding. However, a cut-
off of 50% identity level between proteins has been used by the Protein Information 
Resource (PIR, Georgetown University Medical Centre) to denote that the proteins 
belong to the same family and are likely to have similar three dimensional structures. 
Taking this into consideration, the human and bovine sequence identities would have 
been marginal for the anticipation of structurally similar proteins and this may, in 
part, explain the lack of binding in the S100A9 immunoblots. As there was no 
available information from the manufacturers on the epitopes used in the production 
of these antibodies, it is difficult to assess their likelihood of cross-reacting. 
The problems arising from the use of cross-species immunoblotting include 
variations in antigenic binding even in situations of high homology between the 
proteins under investigation (Hudgens et al., 2011). For example, unexpected 
differences in antibody binding affinity between species have recently been 
recognised in human cancer research, where pre-clinical models frequently used 
include mice, rats or monkeys as their protein identities, and therefore predicted 
cross-species antibody/antigen binding, to humans are high (Xin et al., 2012). 
However, recent results examining the binding capacity of the human monoclonal 
antibody against neuropilin-1, a membrane bound co-receptor for vascular 
endothelial growth factor in humans, rats, mice and monkeys, gave highly variable 
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binding affinities across these species which was not consistent with the predicted 
binding affinity (Xin et al., 2012).   
A reason which is cited for weak antibody/antigen binding is species variation in 
post-translational modifications such as glycosylation (Pomes, 2010). Tertiary 
protein structure is important for the exposure of conformational epitopes which then 
affects antibody binding site availability and can account for lack of antibody 
binding (Pomes, 2010). However, in this study all the antibodies used were either 
raised against a recombinant or synthetic peptide which would be unlikely to have 
any glycosylation sites, so differences in glycosylation between species would be 
irrelevant in this instance.  
It is evident that the highly ranked potential BMs evaluated in this chapter for which 
specific binding was not obtained using a cross species antibody, such as SPP, 
S100A8, S100A9, OXT and KCNQ1, should be re-examined when specific 
antibodies raised against the ovine or bovine proteins become available. The primary 
antibodies used to detect these proteins had not been tested against the respective 
ovine proteins, therefore in the absence of protein bands at the predicted MW, it is 
likely that the antibodies either did not recognise the protein, or the protein was not 
present in sufficient quantities to be detected. Identification of Western blot bands is 
achieved using positive controls, generally a recombinant protein, or by raising 
species specific antibodies.  For this stage of screening, when multiple potential BMs 
were being evaluated, these techniques would have been impractical in terms of time 
and cost. Using mass spectrometry (MS) techniques to identify blood proteins 
present during infestation may have been an option although as previously 
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mentioned, the techniques of sera separation required for MS cannot as yet cope with 
the complexity of proteins in sera (Kulasingam et al., 2010). The numbers of 
proteins, however, obtained from separation by cation exchange liquid 
chromatography followed by mass spectrometry were increased by 3-5 fold in one 
study and including several low abundance serum proteins (ng/ml range) which 
could have been an alternative approach for the present study (Adkins et al., 2002). 
The immunoblots from this preliminary evaluation indicated that C4BPB may have 
potential as a BM for sheep scab and, as such, warranted further investigation. 
Human C4BPB is a 28 kDa protein consisting of a unique beta chain which 
assembles with seven identical alpha chains (C4BPA) to form the major isoform of 
C4BP, a large (570 kDa) glycoprotein complex (Dahlback, 1983). The C4BP 
molecule, comprising the alpha and beta chains, is assembled in the endoplasmic 
reticulum after which it is secreted into the blood where its plasma level has been 
shown to increase four-fold during inflammatory disease in humans such as systemic 
lupus erythematosus (Barnum and Dahlback, 1990). As shown in Figure A2.2, C4BP 
is a regulator of the classical and lectin pathways of complement and as such is an 
important immune function protein. As the complement pathways are potentially 
destructive to the host, they are tightly regulated by several factors including C4BP 
(Blom et al., 2004). C4BPB, combined with C4BPA in its major isoform C4BP, can 
therefore be described as an inhibitor of the classical complement pathway and 
controls C4b-mediated reactions in three ways. Firstly it is a co-factor to factor 1 
(F1), a serine protease which prevents the formation of the C3-convertase complex 
(C4bC2a) (Scharfstein et al., 1978). C4BP also prevents the C3-convertase assembly 
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by binding directly to C4b and finally, it accelerates the natural decay of the C3-
convertase complex (Gigli et al., 1979).  
At the time of study there was no sequence available for ovine C4BPB, but the 
evaluation of C4BPB as a potential BM for sheep scab by Western blotting using a 
monoclonal C4BPB antibody raised in mice against a human recombinant C4BPB 
protein, gave promising results. The band densities at the estimated MW of C4BPB 
correlated with disease progression showing increasing band intensities through the 
time course of infestation (Figure 2.5) and also correlated with lesion size (Figure 
2.6). However, the immunoblot shown on Figure 2.5 illustrated a problem with using 
Western blot analysis to evaluate BMs, as multiple bands at various MWs can be 
identified. It is acknowledged that often proteins of different MWs, in addition to the 
expected MW, can be detected in Western blotting which can be due to post-
translational modification of the target protein, splice variants, protein dimers or 
cross-reactivity between different proteins (Signore and Reeder, 2012).  
To minimise the chances of the band of interest belonging to a different protein from 
the target, a commercially available human rC4BPB was used as a positive control, 
which confirmed the bands obtained in the immunoblots were likely to be C4BPB as 
shown in Figure 2.5. This recombinant protein also provided a standard against 
which the densities of the C4BPB bands at each time point across the course of 
infestation and lesion size could be quantified and compared (Figure 2.6). This 
showed that the band densities detected in the sera of two sheep experimentally 
infested with P. ovis correlated with lesion size development. This is an important 
factor in the search for a BM to indicate current disease status, as it suggests that 
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C4BPB may decrease to low circulating levels as the disease resolves, a finding 
which agrees with previous work on C4BPB where it was shown to track the severity 
of the APR in several human inflammatory diseases (Zadura et al., 2009, Ma et al., 
2010).    
However, further evaluation is required to clarify the potential of C4BPB as a BM 
for sheep scab. It is critical that it can be quantified across both experimental and 
field positive and negative sample sets and that it can be shown to increase 
significantly during early P. ovis infestation, returning to baseline levels rapidly post-
treatment or with disease resolution. In order to further evaluate the potential of 
C4BPB as a BM of sheep scab in the next chapter, the ovine C4BPB gene is 
sequenced and a recombinant protein expressed, enabling an ovine specific anti-
C4BPB antibody to be raised in rabbits. An ELISA is then developed to facilitate the 
cost effective screening of the many positive, negative and field samples required to 
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2.5 Conclusions 
Prior to this project, microarray analysis was used to examine gene expression in 
circulating leukocytes across a time course of infestation with P. ovis (Burgess et al., 
2012a). The current project commenced with the bioinformatic filtering and ranking 
of differentially expressed genes from this study, to provide a list of potential BMs 
for sheep scab which fulfilled the criteria described in this chapter.  
The final 178 genes, having passed the criteria applied and ranked according to BM 
potential, were selected for evaluation according to list ranking and on the 
availability of suitable commercial antibodies. This was essential to permit 
visualisation of the BM proteins by Western blotting in the sera of sheep infested 
with P. ovis compared to that of non-infested sheep sera. However, there were no 
ovine specific antibodies available for the selected proteins at the time of study 
which is a general issue with ruminant reagents, and the problems of using non-
species specific antibodies to probe for the proteins being evaluated as potential BMs 
led to the conclusion that many of the highly ranked proteins obtained from the 
bioinformatic analysis should be re-examined as and when antibodies raised against 
the ovine (or bovine) proteins become commercially available.  
However, results from the initial evaluation of C4BPB showed bands at the expected 
MW of 28 kDa which increased in density through the time course of infestation and 
with lesion size development. This suggested there was an increasing concentration 
of C4BPB in ovine sera and that this may correlate with the degree of disease 
progression. Band densities, and hence sera protein concentration, were also shown 
to decrease as the lesion of one experimentally infested sheep resolved naturally. 
 
Chapter 2: Bioinformatics and initial biomarker evaluation 
89 
However, due to the semi-quantitative nature of this initial evaluation, and the small 
number of experimentally infested sheep involved, further evaluation is required to 
quantify C4BPB levels in non-infested and infested sheep (experimental and field 
samples) and post-treatment. This will be achieved by raising an ovine specific anti-
C4BPB antibody, as described above, to allow development of an ELISA and is the 
subject of Chapter 3. 
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Chapter 3: Characterisation of C4BPB as a 
potential biomarker for sheep scab  
3.1 Introduction  
In the search for BMs which would indicate current disease status in sheep infested 
with P. ovis, complement 4 binding protein, beta chain (C4BPB) was one of the 
highest ranking genes examined in the bioinformatic analysis of potential BMs 
(Chapter 2) based on the following criteria: the C4BPB transcript level was highly 
up-regulated across the time course of P. ovis infestation; this up-regulated response 
occurred across all the time points examined (0, 1, 3 and 6 weeks post-infestation) 
with a “very good” time tracking score, a “good” lesion tracking score across 
individual animals and a high response magnitude (Chapter 2, Table 2.2) . 
The results of the preliminary evaluation of C4BPB as a potential BM by Western 
blot analysis, using a 6 week time course of infestation pooled sera (n=6) (TC1) and 
a monoclonal antibody raised in mice against human C4BPB, confirmed that the 
density of bands obtained, at the predicted molecular weight of 28 kDa for human 
C4BPB, increased with disease progression (Chapter 2, Figure 2.5). Further to this 
the density of the bands and, accordingly, the concentration of C4BPB in serum, 
increased for one sheep experimentally infested with P. ovis (TC1) with an 
expanding lesion across a six week time course of infestation, whereas the band 
densities increased then decreased in a sheep with a naturally resolving lesion 
(Chapter 2, Figure 2.6). Although only based on two animals, this result indicated 
that C4BPB serum concentration may be an effective indicator of disease progression 
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and therefore was a potential BM indicating current disease status during P. ovis 
infestation.  
C4BPB is an important immune function protein due to its role as an inhibitor in the 
complement cascade (Blom et al., 2004) but it also has been implicated in the 
activation of B cells through its interaction with CD40, a protein receptor required 
for the activation of antigen presenting cells (APCs) (Banchereau et al., 1994). 
C4BPB has also recently been investigated as a potential BM for several human 
inflammatory conditions. Along with SAA, serum C4BPB levels were significantly 
increased in patients with Takayasu arteritis, compared with unaffected controls (Ma 
et al., 2010). C4BPB sera concentration has also been shown to correlate positively 
with the severity of the APR in human patients with primary Sjögren’s syndrome 
(pSS) and as such C4BPB has been identified as a possible marker of disease 
severity (Zadura et al., 2009). Through its binding with protein S, a vitamin K 
dependant  plasma glycoprotein, C4BPB has been linked with susceptibility to 
venous thrombosis (VT) where recent work has provided evidence that genetic 
susceptibility for VT is found in the C4BPB/C4BPA locus (Buil et al., 2010). 
Although the exact mechanism has not been elucidated as yet, this locus to VT 
appears independent of the protein S regulation, opening a new research area 
focusing on the C4BP regulatory pathway (Buil et al., 2010). 
Human C4BPB can also circulate bound to the vitamin-K dependant protein S, an 
anti-coagulant protein (Hessing, 1991). This association has been shown in vitro to 
enhance the interaction of C4BPB with neutrophils, which has been suggested as a 
mechanism by which neutrophils are protected from complement damage 
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(Furmaniak-Kazmierczak et al., 1993). There has recently been a rapid expansion in 
knowledge regarding complement evasion strategies by pathogens. Pathogens such 
as viruses, bacteria and parasites can bind C4BP, and other complement inhibitors 
such as factor H, to avoid clearance and destruction by the host’s complement system 
(Blom et al., 2009). Complement is considered particularly important during the 
early stages of infection and is activated not only in blood, but on mucosal surfaces 
such as the bronchial and epithelial linings early in the immune response. Therefore 
the ability of pathogens to avoid killing by complement is an important determinant 
of their pathogenicity (Blom et al., 2009). For example, Staphylococcus aureus is the 
major cause of human skin and soft-tissue infections as well as invasive infections 
like post-operative wound infections and septic arthritis. It has been demonstrated 
that S. aureus M proteins (bacterial virulence factors) can bind C4BP from the host 
serum to the bacterial surface, reducing phagocytosis and suggesting a previously 
undescribed immune evasion strategy for this pathogen (Hair et al., 2012). Similar 
mechanisms for complement evasion have recently been described for Yersinia 
pseudotuberculosis (Ho et al., 2012), Escherichia coli (Tseng et al., 2012) and 
Leptospira interrogans (Domingos et al., 2012). Having described a similar evasion 
strategy in many pathogens, research is now being directed on finding vaccine 
candidates from bacterial proteins that interact with complement and in identifying 
methods of manipulating the complement system to develop novel therapeutic 
approaches (Blom et al., 2009).  
As infestation with P. ovis results in the development of a rapid inflammatory 
response (Van den Broek et al., 2000), it is anticipated that one of the early host 
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responses to disease will be activation of the complement cascade and as this is 
potentially damaging to the host, inhibitors such as C4BPB are likely to be up-
regulated (Blom et al., 2004). As such, C4BPB is a potential BM for sheep scab, due 
to its biological functions, its proposed use in tracking the severity of infection in 
other diseases and based on the results of Chapter 2 of this study. 
To progress further with the evaluation of ovine C4BPB as a BM for current disease 
status in sheep scab, a quantitative approach was required involving the development 
of an ELISA test for ovine C4BPB. It is advantageous to use this approach compared 
with Western blotting techniques which, although useful in the preliminary stages of 
BM validation (Signore and Reeder, 2012), can only provide semi-quantitative 
values. In order to provide sufficient evidence of a protein’s potential as a BM and to 
be able to incorporate it into a diagnostic test, quantitative measurements are required 
and, as such, assay development is a routine method of achieving BM validation 
(Brookes et al., 2010). In addition, ELISA development is also required due to the 
high number of sera samples, from both experimental and field positives and 
negatives, which need to be analysed in the validation of a potential BM 
(Kulasingam et al., 2010). 
During the Western blot evaluation of C4BPB in Chapter 2, an antibody raised in 
mice immunized with full length human recombinant C4BPB (rC4BPB) was used to 
detect ovine C4BPB as there was no commercially-available antibody with 
specificity for ovine or bovine C4BPB. This antibody bound C4BPB in sheep serum 
in immunoblots and the cross-reactivity obtained may be a result of high levels of 
conservation between the sequences of some immune inflammatory proteins in 
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mammalian species (Aggarwal and Gurney, 2002). Comparisons between the bovine 
(as there was no ovine sequence available) and human C4BPB protein sequences 
showed a 49% amino acid identity (Chapter 2, Table 2.5) which is very close to the 
50% identity level cut-off used by the Protein Information Resource (PIR, 
Georgetown University Medical Centre) to denote that proteins may belong to the 
same family, are likely to have similar three dimensional structures and hence cross-
react. In addition, the cost of further BM validation using commercially-available 
antibodies alone would be prohibitive to screening the high quantity of samples 
required in the validation of a potential BM. Therefore the production of an ovine 
specific antibody was advantageous to the further evaluation of C4BPB as a potential 
BM. 
The aims of this chapter were therefore to clone, sequence and characterise the ovine 
C4BPB gene; express a recombinant C4BPB protein based on this sequence; raise 
antibodies in rabbits specific to recombinant ovine C4BPB and to develop an ELISA 
allowing quantification of C4BPB in the sera of sheep prior to infestation with P. 
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3.2 Materials and methods 
3.2.1 C4BPB cloning and sequencing 
The methods described in this section involved gene amplification using degenerate 
primers, followed by Rapid Amplification of cDNA ends (RACE) to generate full-
length sequence of the transcript encoding ovine C4BPB. 
3.2.1.1 Partial gene sequencing 
3.2.1.1.1 RNA extraction and cDNA synthesis 
Complementary DNA (cDNA) to be used as a template in the amplification of the 
ovine C4BPB gene, was prepared from RNA derived from ovine circulating 
leukocytes of sheep 6 weeks post-infestation with P. ovis (see chapter 2, section 
2.2.3.6 (TC1) for sample description). The RNA used was extracted from leukocytes 
by filtering whole blood (Burgess et al., 2012a) as described in that study. cDNA was 
synthesised using SuperScript™ II Reverse Transcriptase (Invitrogen), following the 
manufacturer’s protocol, with the following reaction: Oligo(dT)₂₃ primer (Sigma) at 
500µg/ml; dNTPs (10mM) (Invitrogen) and RNA template (480ng) to a total volume 
of 12µl were incubated at 65⁰C for 5 mins. RNaseOUT (Invitrogen) was added at 40 
units/µl to inhibit the action of RNases on the template RNA, before incubating at 
42⁰C for 2 mins. Superscript II (Invitrogen) (200 units) was added prior to a final 
incubation at 42⁰C for 15 min and 70⁰C for 15 min. 
3.2.1.2.2 Amplification of gene fragment by PCR 
Nucleotide sequences, available from the National Centre for Biotechnology 
Information (NCBI), representing porcine C4BPB (Accession number: AK 346434), 
bovine (NM 174253) and human (NG 029386) were aligned using ClustalW2 
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[European Bioinformatics Institute, (EBI)]. Areas of high sequence similarity were 
identified as possible oligonucleotide primer binding sites to enable the design of 
degenerate primers (Figure 3.1).  
 
AK 346434 Pig        AGTGCAGTGAGCATTACATCCTCAAGGGCAGCAATTGGAGCCGGTGCCGAGACGACCACA 303 
NG 029386 Human      TGTGCAATGACCACTACATCCTCAAGGGCAGCAATCGGAGCCAGTGTCTAGAGGACCACA 373 
NM 174253 Bovine     AATGCAATGAGCATTGCATCTTTAAGGGCAGCAATTGGAGCCAGTGTCGAGAAAACCACA 480 
                       **** *** ** * **** * ************ ****** *** * ***  ****** 
 
AK 346434 Pig        CCTGGGTGCCTCCCTTTCCCATCTGTAAAAGCAAAGACTGTGGCCCTCCTGAGAATCCAA 363 
NG 029386 Human      CCTGGGCACCTCCCTTTCCCATCTGCAAAAGTAGGGACTGTGACCCTCCTGGGAATCCAG 433 
NM 174253 Bovine     CCCGGGTGACTCACTCTCCTGTGAGCAAAAGCAGAGACTGTGGCCCTCCTGAGACTCCAA 540 
                     ** ***   *** ** ***  *  * ***** *  ******* ******** ** ****  
 
AK 346434 Pig        TTCATGGCTATTTTGAAGGAATCGATTTCAACTCAGGGTCTACCATTACTTATTACTGTA 423 
NG 029386 Human      TTCATGGCTATTTTGAAGGAAATAACTTCACCTTAGGATCCACCATTAGTTATTACTGTG 493 
NM 174253 Bovine     CTCATGGCTATTTTGAAGGAAGAGATTTCAAGTCAGGATCTACCATCACTTATTACTGTC 600 
                      ********************   * ****  * *** ** ***** * **********  
 
AK 346434 Pig        AAGCGAGGTACCGCCTGGTGGGCACACAGCACCAACAGTGCATTGATGGGGAGTGGAGTG 483 
NG 029386 Human      AAGACAGGTACTACTTAGTGGGCGTGCAGGAGCAGCAATGCGTTGATGGGGAGTGGAGCA 553 
NM 174253 Bovine     AAGCAAGGTACCGCCTGGTGGGCACACAGCACCAACAGTGCATTGATGGGGAGTGGACCA 660 
                     ***  ******  * * ******   *** * ** ** *** ***************    
 
AK 346434 Pig        GTGCAATTCCAGTCTGTGAGCTGATCCCAGAAGCTCCCAAGGCAGCTTTGCAGATTGAGT 543 
NG 029386 Human      GTGCACTTCCAGTCTGCAAGTTGATCCAGGAAGCTCCCAAACCAG------------AGT 601 
NM 174253 Bovine     GTGCCCCTCCCATCTGTGAGTTGATCCAAGAAGCTCCCAAACCAGCCG---AATTAGAGT 717 
                     ****   ***  ****  ** ******  ***********  ***            *** 
 
AK 346434 Pig        TTGAGAAGGCCCTTCTTGCCTTTCAGGAAAGTGAGGAACTGTGCAAAGCCACTGAGAACT 603 
NG 029386 Human      GTGAGAAGGCACTTCTTGCCTTTCAGGAGAGTAAGAACCTCTGCGAAGCCATGGAGAACT 661 
NM 74253 Bovine      TGGAGAAGGCATTTCTTGCCTTTCAGGAGAGTAAGGAACTTTGCAAAGCTATAAAGAAAT 777 
                       ********  **************** *** ** * ** *** **** *   **** * 
 
                          
 
Figure 3.1: Aligned porcine, human and bovine C4BPB sequences with high 
homology sequence areas for degenerate primer design, highlighted in red. Only 
partial gene sequences are shown, representing the portion used for primer design. 
Actual primer sequences used are presented in Table A3.1 *Marks the position of 
identical nucleotide bases in the sequences for all three species. 
 
Using these degenerate primers, in combination with cDNA prepared as described 
above (section 3.2.1.1.1), a portion of the ovine C4BPB gene was amplified by 
polymerase chain reaction (PCR) with the following reaction: primers at a final 
dilution of 2µM; template cDNA (106.5µg); dNTPs (Roche) at 10mM and 5 units 
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Taq polymerase (Roche) combined in a final volume of 30µl. PCR amplification was 
performed using a GeneAmp PCR System 2700 (Applied Biosystems). Cycling 
conditions were: 94°C for 5 min; 30 cycles of 94°C for 30s, 57°C for 30s, 72°C for 1 
min; 72°C for 10 min final extension. PCR products were separated by 
electrophoresis on a 1% agarose gel incorporating GelRed stain (as described in 
A3.1.2) and the PCR amplicon was purified using a QIAquick PCR Purification Kit 
(Qiagen) following the manufacturer’s protocol.  
 
3.2.1.2 Cloning PCR product into the pGEM-T plasmid 
The purified PCR product was ligated into the cloning vector pGEM-T (Promega) 
using T4 DNA ligase (Promega) transformed by heat shock (42⁰C for 40s) into 
Escherichia coli JM109 High Efficiency Competent Cells (Promega) and cultured in 
Luria Bertani (LB) medium prior to selection on LB agar containing ampicillin (100 
g/ml), 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 80 g/ml 5-
bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal) as described in A3.1.3. Colonies 
with plasmids containing the cloned partial gene sequence for C4BPB were selected 
using the principle of alpha complementation, isolated and plasmid DNA extracted 
using a Wizard® Plus SV Miniprep kit (Promega) following overnight culture in LB 
medium containing ampicillin (100 g/ml). The purified plasmid DNA was 
sequenced by Source Bioscience (Life Sciences, UK) with Sanger sequencing using 
T7 oligonucleotide primers. Sequencing results were aligned in the CAP3 Sequence 
Assembly Programme [Pole Bioinformatique Lyonnaise (PBIL)] and the contiguous 
sequence obtained used in homology searches using the NCBI Basic Local 
Alignment Search Tool (BLASTx) programme.   
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3.2.1.3 Generation of full-length sequence for ovine C4BPB using Rapid 
Amplification of cDNA Ends (RACE)  
To extend the partial gene sequence for ovine C4BPB and obtain a full coding 
sequence (CDS), RACE was employed using primers designed to allow conventional 
PCR for 5’ RACE and touchdown PCR for 3’ RACE. Using the primer design 
protocol in the SMARTER™ RACE cDNA Amplification User Manual (PT4096-1, 
Clontech) and the software Primer 3 Output (SourceForge), gene specific primers 
(GSPs) for 5’ and 3’ RACE were designed, based on the partial C4BPB gene 
sequence. Nested primers were designed in the same way but selected from 
sequences positioned between the GSPs (see Figure 3.2).  
1   K  G  S  N  W  S  Q  C  R  E  N  H  I  W  V  T  H  S  P  V       
1   TTAAGGGCAGCAATTGGAGCCAGTGCCGAGAAAACCACATCTGGGTGACTCACTCTCCTG 
1            10        20        30        40        50          
21  C  K  S  R  D  C  G  P  P  E  T  P  T  H  G  Y  F  E  G  R         
61  TCTGCAAAAGCAGAGACTGTGGCCCTCCTGAGACTCCAACTCATGGCTATTTTGAAGGAA 
61           70        80        90        100       110         
41  D  F  K  S  G  S  T  I  T  Y  Y  C  E  A  R  Y  H  L  V  G       
121 GAGATTTTAAGTCAGGATCTACCATCACTTATTACTGTGAAGCAAGGTACCACCTGGTGG 
121          130       140       150       160       170         
61  T  Q  H  Q  Q  C  I  D  G  E  W  T  S  A  P  P  I  C  E  L      
181 GCACACAGCACCAACAGTGTATTGATGGGGAGTGGACCAGTGCCCCTCCCATCTGTGAGT 
181          190       200       210       220       230         
81  I  Q  E  A  P  K  P  A  E  L  A  L  E  K  A  L  L  A  F  Q     
241 TGATCCAAGAAGCTCCCAAACCAGCCGAGTTAGCGTTGGAGAAGGCCCTTCTTGCCTTTCA 
241          250       260       270       280       290    
 
Figure 3.2: Nucleotide sequence and translation map (Sequence Manipulation Suite, 
Bioinformatics Organisation) of the C4BPB gene fragment generated using the 
degenerate primers showing the position of the gene specific primer (GSP) (yellow 
background) and nested primers (internal primers with blue background for the 
forward primer and green for reverse) used for 5’ RACE. Primer names and 
sequences are described in Table A3.1. 
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Primers were obtained from MWG Eurofins. RACE- ready cDNA was generated 
from total RNA extracted from sheep leukocytes (see section 3.2.1.1.1) using the 
SMARTER™ RACE cDNA Amplification kit (Clontech, US) and following the 
manufacturer’s protocol. To obtain a 5' RACE product, PCR amplification was 
performed using 1 unit SMARTIIA oligonucleotide (Clontech) in conjunction with a 
GSP (see Table A3.1 and Figure 3.2) at a final concentration of 10µM, 1 unit 50X 
Advantage 2 polymerase, Advantage 2 dNTPs (10µM) and 5’RACE Ready cDNA 
(244ng). Reaction parameters were as follows: 20 cycles at 95⁰C for 30s; 68⁰C for 
30s; 72⁰C for 3 mins. To further amplify the 5’ RACE reaction product, it was 
purified using a QIAquick PCR Purification Kit (28704, Qiagen) and 3µl used as 
template in a PCR amplification reaction with the “Nested reverse RACE 
primer“(10µM) as shown in Table A3.1, nested universal primer (NUP) (Clontech), 
Advantage 2 polymerase and Advantage 2 dNTPs (Clontech) as per manufacturer’s 
protocol, with reaction parameters as follows: 20 cycles: 95⁰C for 30s; 56⁰C for 30s; 
72⁰C for 3 mins. 
The purified PCR product was ligated into the cloning vector pGEM-T (Promega) 
using T4 DNA ligase (Promega), transformed by heat shock (42⁰C for 40s) into E. 
coli JM109 High Efficiency Competent Cells (Promega) and plasmids containing the 
5’ RACE product were amplified, purified and sequenced using M13 uni (-21) 
primers. 
Sequence results were aligned using CAP3 (PBIL) and translated in the Sequence 
Manipulation Suite (Version 2, Bioinformatics Organisation). Homology searches 
were performed using the NCBI BLASTp program and the translated sequence was 
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aligned with the bovine C4BPB protein sequence (accession number NM 174253) in 
ClustalW2 (EBI) to determine sequence homology. 
The remainder of the ovine C4BPB gene was amplified using a GSP for 3’ RACE 
(see Table A3.1) based on the 5’ RACE product sequence, and used at a final 
concentration of 10µM in a touchdown PCR reaction with 1 unit SMARTIIA 
oligonucleotide (Clontech), 3' RACE-ready DNA (244ng), 1 unit 50X Advantage 2 
polymerase and 10µM Advantage 2 dNTPs (Clontech). The reaction parameters were 
as follows: 5 cycles at 94⁰C for 30s, 72⁰C for 3 min; 5 cycles at 94⁰C for 30s, 70⁰C 
for 30s, 72⁰C for 3 min; 25 cycles at 94⁰C for 30s, 68⁰C for 30s and 72⁰C for 3 min. 
The purified PCR product (3µl) was ligated into the cloning vector pGEM-T 
(Promega) using T4 DNA ligase (Promega) as per manufacturer’s protocol, 
transformed by heat shock (42⁰C for 40s) into E. coli,  JM109 High Efficiency 
Competent Cells (Promega) and plasmids containing the 3’ RACE product were 
sequenced using M13 uni(-21) and M13 rev(-29) primers by MWG Eurofins. 
3.2.2 Expression of recombinant ovine C4BPB 
Two different strategies were employed to express recombinant ovine C4BPB 
protein in bacteria. In the first, an Advantage InFusion HD Cloning kit (Clontech, 
US) was used to subclone the full-length CDS into the expression vector pET22b(+) 
(Novagen). In the second, the CDS was subcloned into pET SUMO (Invitrogen) 
vector using TA cloning. 
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3.2.2.1 Expression using pET22b(+) 
Primers were designed using the full CDS of ovine C4BPB derived as described 
above and modified at their 5’ termini with 15 nucleotide bases homologous to the 
insertion site of the multiple cloning site (MCS) of the vector. The InFusion forward 
primer (highlighted in green in Figure 3.3) was not designed to start at the initiating 
codon but 52 bases into the sequence, because the sequence between the initiation 
codon and base 52 encoded a signal peptide (highlighted in red in Figure 3.3), as 
established by the SignalP package (4.0 Server). PCR was performed using these 
primers at a final concentration of 10µM, with 108ng pGEM-T plasmid containing 
the full length ovine C4BPB CDS as template, 10mM Advantage 2 dNTPs and 1 unit 
50X Advantage 2 Polymerase (Clontech) with reaction conditions as follows: 94⁰C 
for 5 mins; 30 cycles at 94⁰C for 30s, 55⁰C for 30s, 72⁰C for 1 min and a final 
extension at 72⁰C for 10 mins. The pET22b(+) vector (Novagen) was linearised 
using 2 units of the restriction enzyme Xho1 (Roche) in a 2hr incubation at 37⁰C and 
linearised vector product was purified using a QIAquick PCR Purification Kit 
(Qiagen) following the manufacturer’s protocol. 
For cloning, the PCR product obtained using the InFusion primers described above, 
was used in a 10:1 molar ratio with the digested plasmid and incubated with 5X 
InFusion HD Enzyme Premix, at 37⁰C for 15 min then 50⁰C for 15 min. The 
plasmids, with integrated ovine C4BPB CDS were then transformed, by heat shock 
into E. coli, JM109 High Efficiency Competent Cells (Promega) and cultured in LB 
medium prior to selection on LB agar plates containing ampicillin (100 g/ml). 
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       1 M  F  F  W  L  M  C  H  L  V  D  V  W  L  I  S  A  S  D  V   
       1 tgtttttttggcttatgtgccatcttgtggatgtgtggctgatttctgcctcagatgtg 
       1          10        20        30        40        50          
      21 G  H  C  P  D  P  L  L  V  T  D  E  F  S  S  L  E  P  V  N   
      61 gccactgtcctgaccccttgctggtaactgatgaattcagttccttggagcctgtgaat 
      61          70        80        90        100       110         
      41 V  N  D  T  F  M  L  K  C  N  E  H  C  I  L  K  G  S  N  W   
     121 tgaatgacactttcatgttaaaatgcaatgagcattgcatcctcaagggcagcaattgg 
     121          130       140       150       160       170         
      61 S  Q  C  R  E  N  H  I  W  V  T  H  S  P  V  C  K  S  R  D   
     181 gccagtgccgagaaaaccacatctgggtgactcactctcctgtctgcaaaagcagagac 
     181          190       200       210       220       230         
      81 C  G  P  P  E  T  P  T  H  G  Y  F  E  G  R  D  F  K  S  G   
     241 gtggccctcctgagactccaactcatggctattttgaaggaagagattttaagtcagga 
     241          250       260       270       280       290         
     101 S  T  I  T  Y  Y  C  E  A  R  Y  H  L  V  G  T  Q  H  Q  Q   
     301 ctaccatcacttattactgtgaagcaaggtaccacctggtgggcacacagcaccaacag 
     301          310       320       330       340       350         
     121 C  I  D  G  E  W  T  S  A  P  P  I  C  E  L  I  Q  E  A  P   
     361 gtattgatggggagtggaccagtgcccctcccatctgtgagttgatccaagaagctccc 
     361          370       380       390       400       410         
     141 K  P  A  E  L  A  L  E  K  A  L  L  A  F  Q  E  S  K  E  L   
     421 aaccagccgagttagcgttggagaaggcacttcttgcctttcaggagagtaaggaactt 
     421          430       440       450       460       470         
     161 C  K  A  I  K  K  F  T  Q  R  L  K  K  S  D  L  T  M  E  K   
     481 gcaaagccataaagaaatttacacaaagattaaagaaaagtgacttgacaatggagaaa 
     481          490       500       510       520       530         
     181 V  K  Y  F  L  E  R  K  K  A  K  L  K  A  K  M  L 
     541 gtaaaatattttctggaaagaaagaaggctaaattgaaggcaaaaatgttgc 
     541          550       560       570       580       590        
      
Figure 3.3: Translation map (Sequence Manipulation Suite, Bioinformatics 
Organisation) of full CDS of ovine C4BPB with nucleotide bases used in primer 
design highlighted in green. Full primer sequences used are included in Table A3.1 
and are named “InFusion forward” and “InFusion reverse” primers. Signal peptide 
highlighted in red. 
The purified plasmids containing the C4BPB CDS were sequenced using T7 primers 
prior to transformation into BL21 codon plus (DE3) E. coli cells (Agilent 
Technologies) by heat shock (42⁰C for 40s) and cultured on LB agar containing 
ampicillin (100mg/ml) and chloramphenicol (50mg/ml). Colonies containing the 
C4BPB-encoding plasmids were isolated and cultured overnight in 10ml LB medium 
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containing both antibiotics as described above and 750µl of this overnight culture 
were used to seed 50ml of LB medium, followed by incubation with shaking at 
200rpm at 37⁰C until the optical density at 600 nm (OD600) was 0.6. To obtain an 
“uninduced” sample, 1ml of the culture was removed before IPTG was added to the 
flask to a final concentration of 1mM and incubated at 37ºC for 3 hours, after which 
0.6ml was removed (“induced”). Both uninduced and induced fractions were 
centrifuged for 10 mins at 19000g and the pellets, containing the E. coli cells with 
C4BPB-encoding plasmids, were retained at -80⁰C. 
The pellets (uninduced and induced) were re-suspended in 100µl binding buffer, 
(A3.1.4) with 20% Triton-X 100 (Sigma-Aldrich) centrifuged at 22000g for 10 mins 
and the supernatant retained (soluble phase), with the pellets being re-suspended in 
100µl binding buffer containing 8M urea (Appendix A3.1.5) (insoluble phase). 
Polyacrylamide gel electrophoresis (SDS-PAGE) (NuPage BisTris 4-12%, 
Invitrogen) was run using a total volume of 20µl of each sample (i.e. uninduced 
soluble, induced soluble, uninduced insoluble and induced soluble) after samples had 
been incubated with  5µl 4X NuPage LDS sample buffer (Invitrogen) and 2µl 
NuPage sample reducing agent (Invitrogen) at 70⁰C for 10 mins. Electrophoresis was 
performed at 250V for 35 minutes, before Coomassie staining using SimplyBlue 
Safestain (Invitrogen). 
3.2.2.2 Expression using pET SUMO 
The ovine C4BPB CDS sequence was cloned into an alternative expression vector, 
pET SUMO, using the Champion pET SUMO Protein Expression System 
(Invitrogen). The Advantage PCR Kit (Clontech) was used to amplify the CDS 
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(minus signal peptide) for ovine C4BPB, with the following parameters: 108ng 
pGEM-T plasmid containing the C4BPB CDS as template; pET SUMO forward and 
reverse primers 10µM (See Table A3.1), Advantage dNTPs 50mM; 1 unit 50X 
Advantage 2 polymerase; cycling parameters were as follows: 94⁰C for 5mins; 30 
cycles at 94⁰C for 30s, 58⁰C for 30s, 72⁰C for 1 min and a final extension at 72⁰C for 
10 min.  
The resulting PCR product was purified using a QIAquick PCR Purification Kit 
(Qiagen) and, following ligation of the vector and plasmid (1:1 ratio) with 4 units T4 
DNA Ligase (Invitrogen), transformation was by heat shock (42⁰C for 30s) into One 
Shot Mach1-T1 E. coli competent cells (Invitrogen) and incubation on LB agar 
containing 50µg/ml kanamycin. Colonies with plasmids containing the C4BPB gene 
sequence (minus signal peptide) were isolated; plasmids extracted using Wizard® 
Plus SV Minipreps (Promega) following the manufacturer’s protocol and sequenced 
using T7 primers. Following confirmation of successful cloning, plasmid DNA was 
transformed into BL21 codon plus (DE3) E. coli cells (Agilent Technologies) and 
protein expression and analysis performed as described in section 3.2.2.1 above. 
3.2.2.2.1 Matrix-assisted laser desorption ionization (MALDI) 
To confirm the identity of the expressed recombinant protein, the band of interest 
(ca. 40kDa) in the induced, insoluble fraction lane was excised from a SDS-PAGE 
gel of the induced bacterial expression products and mass spectrometry (MS) using 
MALDI - time of flight (ToF) – ToF was performed at the MRI Proteomics facility. 
Briefly, proteins were destained and reductively alkylated using DTT and 
iodoacetamide. Gel pieces were digested overnight with porcine trypsin (Promega) at 
 




C. Digests were analysed on a Bruker Ultraflex II MALDI-ToF-ToF mass 
spectrometer (Bruker Daltonics), scanning the 600 to 5000 dalton region in reflectron 
mode producing monoisotopic resolution.  The spectra generated were mass 
calibrated using known standards and masses obtained were searched using primary 
sequence databases (Mascot, Matrix Science) (K. McLean, Pers. Comm.). 
3.2.2.2.2 Recombinant Protein purification 
Pellets containing the induced, insoluble fraction of a 50ml culture were re-
suspended in 1ml binding buffer containing 8M urea as described in A3.1.5. As 
cloning into pET vectors adds an N-terminal (pET SUMO) or C-terminal 
(pET22b(+) polyhistidine (6 x His) fusion tag to the recombinant protein, a 1ml 
HisTrapFF (GE Healthcare) column was used for protein purification by nickel-
affinity chromatography using the manufacturer’s protocol. Purified rC4BPB was 
eluted using solutions of increasing imidazole concentration in binding buffer at pH 
7.4 as described in A3.1.6, and dialysed overnight against dialysis buffer (described 
in A3.1.7) prior to protein quantification by Bicinchoninic acid (BCA) assay using 
bovine serum albumin (BSA) standards (Pierce) as per manufacturer’s protocol. 
3.2.3 Anti-ovine C4BPB antibody production 
Blood samples were taken, by venous extraction, from two 12 week old New 
Zealand White rabbits prior to immunisation by injection with 52.8µg recombinant 
C4BPB (rC4BPB) in 25µg Quil A adjuvant (Guinness Products). Immunisation was 
performed three times at three week intervals. Blood samples were taken two weeks 
after the second immunisation and both rabbits were culled for the terminal bleed 
two weeks after the final immunisation. This work was carried out at MRI under the 
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guidelines of the MRI experimental ethics committee (Experiment E38/11) and 
according to Home Office legislation.  
To test the immune response of the rabbits following immunisation with rC4BPB, an 
SDS-PAGE gel [NuPage BisTris 4-12% (Invitrogen) using buffer described in 
A2.1.1] was performed using 13.74µg ovine rC4BPB incubated with 2.5µl 4X 
NuPage LDS sample buffer (Invitrogen) and 1µl NuPage sample reducing agent 
(Invitrogen) at 70⁰C for 10 mins and 10µl added to the gel wells. After 
electroblotting onto nitrocellulose membrane, the blot was probed with rabbit sera 
(obtained 2 weeks post second immunisation) from each immunised rabbit, at a 
dilution of 1:400. Sera from the rabbits pre-immunisation were used as negative 
controls. The secondary antibody used was swine anti-rabbit IgG HRP conjugate 
(Dako) at a 1:2000 dilution and the blot was visualised by staining with DAB (3, 3 – 
Diaminobenzidine) (Sigma Aldrich) according to the manufacturer’s instructions.  
To assess binding of immunoglobulins in the sera from the immunised rabbits to 
native ovine C4BPB, SDS-PAGE gel electrophoresis was used to separate 6 week 
post-infestation pooled sheep sera (1:10 dilution of sera from TC 1 experimental P. 
ovis infestation study as described in Chapter 2, section 2.2.3.6). Following this 
separation of the serum proteins by electrophoresis, they were electroblotted onto 
nitrocellulose membranes. This blot was then probed with sera (at a dilution of 
1:100) obtained at terminal bleed (2 weeks after 3
rd
 immunisation) from rabbits 
immunised with rC4BPB. Serum from the same rabbits, prior to immunisation, was 
used as a negative control. A positive control using 21.14 µg ovine rC4BPB was 
included. As a secondary antibody, swine anti-rabbit IgG HRP conjugate (Dako) was 
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used at a dilution of 1:2000 and visualised by using ECL Plus Western Blotting 
Detection Reagent (GE Healthcare) followed by X-ray plate development and 
visualisation on an ImageQuant LAS4000 (GE Healthcare) camera.  
 
3.2.4 Development of a C4BPB ELISA 
The reagents developed in sections 3.2.2.2 – 3.2.3 were combined for use in an 
ELISA to detect C4BPB in sheep sera: The work flow for the development of an 
ELISA to enable detection of ovine C4BPB in the sera of infested sheep is described 
in Figure 3.4. As the improved sandwich ELISA using a biotinylated conjugate 
yielded the most promising results, the detailed methodology for this ELISA is 
included in A3.1.10. All optical densities were read at 450nm (OD₄₅₀) using a 630nm 








Figure 3.4: Work flow for ELISA development including the main steps and 
reagents used from the initial direct assay to the improved sandwich ELISA. 
Polyclonal C4BPB from rabbits immunised with ovine rC4BPB (as described in 
section 3.2.3) used at 1:100 dilution; mC4BPB raised in mice against human 
rC4BPB (Novus Biologicals) used at 1:100; swine anti-rabbit HRP IgG (Dako) used 
at 1: 2000 dilution; all ovine sera was diluted 1:10; biotinylated mouse anti-rabbit 






•Coating = Pooled 6 wpi ovine sera (n=6) (TC1) 
•Detection = polyclonal antibody raised in rabbit against ovine rC4BPB 
•Conjugate =  swine anti-rabbit HRP 
•Substrate = 3, 3’, 5, 5’-Tetramethylbenzidine substrate solution (TMB)  
Sandwich 
ELISA 
•Coating = capture monoclonal antibody raised in mice against human rC4BPB 
•Antigen = Pooled 6 wpi ovine sera (n=6) (TC1) 
•Detection =  polyclonal antibody raised in rabbit against ovine rC4BPB 
•Conjugate =  swine anti-rabbit HRP 





•Coating = capture monoclonal antibody raised in mice against human C4BPB 
•Antigen = Pooled 6 wpi ovine sera (n=6) (TC1) 
•Detection =  polyclonal antibody raised in rabbit against ovine recombinant C4BPB 
•Conjugate =  biotinylated mouse anti-rabbit  + streptavidin HRP  
•  Substrate = TMB 
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3.2.5 Measurement of C4BPB in sheep sera by ELISA  
The optimised sandwich ELISA was tested using pooled sera from P. ovis infested 
sheep (n = 12) in an experimental primary infestation and treatment trial (TCT1 as 
described in A3.1.11). This testing was comprised of two components: 
1) An initial comparison of ELISA OD₄₅₀ between sera from sheep which had not 
been previously exposed to P. ovis (controls) and sera from the same sheep after a 
six week P. ovis infestation period (infested) was performed using pooled sera from 
12 animals obtained from each of the groups in the experimental trial described in 
A3.1.11.  
2) ELISAs were then performed using pooled sera from 12 animals from each 
sampling point of the trial described in A3.1.11, across a time course including pre-
infestation, weekly samples from a 6 week infestation and sera taken from animals 
twice-weekly for 3 weeks post-treatment. 
3.2.5.1 Statistical analyses  
To analyse the difference in OD₄₅₀ in the ELISAs comparing “control” sera (i.e. sera 
obtained pre-infestation with P. ovis) with “infested” sera (sera obtained 6 weeks 
post-infestation with P. ovis), a Student’s paired t-test was used (GraphPad Prism, 
version 5.05, GraphPad Software Inc.). 
In the analyses of the time course ELISA OD₄₅₀, the statistics used were repeated 
measures one-way ANOVA with Tukey’s post-hoc test as calculated by GraphPad 
Prism (Version 5.05, GraphPad Software Inc.). 
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3.3 Results 
3.3.1 Ovine C4BPB sequencing 
3.3.1.1 Amplification of ovine C4BPB gene fragment by PCR 
As a result of PCR amplification, using the degenerate primers described in section 
3.2.1.2.2, a single amplicon was obtained of approximately 300bp. The results from 
sequencing and alignment using CAP3 (PBIL) confirmed that the sequences of 4 
individual plasmids containing the cloned 301bp amplicon were identical. Homology 
searching using BLASTx (NCBI) confirmed that the contig obtained was a fragment 
of the gene representing C4BPB and that the translated amino acid sequence 
displayed 99% homology to that of the corresponding fragment of bovine C4BPB 
[accession number NM 174253 (EBI)]. The nucleotide sequence length obtained was 
301 base pairs (bp), which when compared to the published bovine C4BPB sequence 
(594 bp), equated to approximately half of the putative CDS. 
3.3.1.2 Generation of full-length sequence for ovine C4BPB using Rapid 
Amplification of cDNA Ends (RACE) 
5’ RACE was successful in generating PCR products of 500+ bp in length (Figure 
3.5). Cloning and sequencing of these products produced a consensus sequence 
representing the 5' end of the ovine C4BPB sequence. Following the successful 
identification of the 5’ region of the ovine C4BPB sequence, 3’ RACE was 
performed and the results of the initial 3’ amplification are shown in Figure 3.6.  
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Figure 3.5: Gel image of the colony PCR of the cloned products of 5’ RACE 
indicating four plasmids (circled), containing longer inserts, which were 
subsequently sequenced.        
 
 
Figure 3.6: Gel image of the PCR results of 3' RACE using primers designed on the 
5' RACE sequence. Lane 1 = Molecular weight marker X (Roche); Lane 2 = PCR 
product from 3’ RACE ready cDNA and GSP for 3’ RACE; Lane 3 = single primer 
control (GSP for 3’ RACE only); Lane 4 = single primer control (UPM only); Lane 5 







     1         2         3       4        5 
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In lane 2 there was a band evident at ca. 700bp and a weaker band at ca. 1200bp. By 
analogy to the bovine C4BPB nucleotide sequence, the lower molecular mass band 
was most likely to represent the ovine C4BPB and therefore this band was gel-
purified, cloned and sequenced. There was 95% amino acid homology between ovine 
C4BPB1 and the published sequence for bovine C4BPB and, as such all further work 
focused on ovine C4BPB1 (Figure 3.7). 
 
OvineC4BPB1      MFFWLMCHLVDVWLISASD----------------------------VGHCPDPLLVTDE 32 
OvineC4BPB2      MFFWLMCHLVDVWLISASDGCGYSWTWENTRSLNTRSQAKRHYEGDSMGRCPDPLLVTDE 60 
BovineC4BPB      MFFWLMCYLVDVWLISASD----------------------------VGHCPDPLLVTDE 32 
                 *******:***********                            :*:********** 
 
OvineC4BPB1      FSSLEPVNVNDTFMLKCNEHCILKGSNWSQCRENHIWVTHSPVCKSRDCGPPETPTHGYF 92 
OvineC4BPB2      FSSLEPVNVNDTFMLKCNEHCILKGSNWSQCRENHIWVTHSPVCKSRDCGPPETPTHGYF 120 
BovineC4BPB      FSSLEPVNVNDTFMFKCNEHCIFKGSNWSQCRENHTRVTHSPVSKSRDCGPPETPTHGYF 92 
                 **************:*******:************  ******.**************** 
 
OvineC4BPB1      EGRDFKSGSTITYYCEARYHLVGTQHQQCIDGEWTSAPPICELIQEAPKPAELALEKALL 152 
OvineC4BPB2      EGRDFKSGSTITYYCEARYHLVGTQHQQCIDGEWTSAPPICELIQEAPKPAELALEKALL 180 
BovineC4BPB      EGRDFKSGSTITYYCEARYRLVGTQHQQCIDGEWTSAPPICELIQEAPKPAELELEKAFL 152 
                 *******************:********************************* ****:* 
 
OvineC4BPB1      AFQESKELCKAIKKFTQRLKKSDLTMEKVKYFLERKKAKLKAKML  197 
OvineC4BPB2      AFQESKELCKAIKKFTQRLKKSDLTMEKVKYFLERKKAKLKAKML  224 
BovineC4BPB      AFQESKELCKAIKKFTQRLKKSDLTMEKVKYSLERKKAKLKAKMLL 198 
                 ******************************* *************  
 
Figure 3.7: Clustal alignment of two contigs (C4BPB1 and C4BPB2) derived from 
PCR amplification of the ovine C4BPB gene with the published bovine C4BPB 
sequence (accession number NM 174253) (Uniprot, EBI). Asterisks represent 
identity, colons represent high similarity, full stops represent low similarity and 
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3.3.2 Expression of recombinant C4BPB 
3.3.2.1 Expression using pET22b(+) 
Following InFusion cloning of the ovine C4BPB CDS into pET22b(+), a colony PCR 
of the resulting transformation products was performed using pET22b forward and 
reverse primers. From this PCR, a single colony was identified which included the 
pET22b(+) vector plus ovine C4BPB CDS insert as shown in Figure 3.8. Sequencing 
of the plasmid derived from this clone confirmed that the full C4BPB sequence 
(minus signal peptide) had been successfully cloned into the pET22b(+) vector in 
frame.  
  
Figure 3.8: Gel image of InFusion cloning of ovine C4BPB CDS with pET22b(+) 
showing one positive colony in lane 7 (circled). Lane 1 = DNA molecular marker X 
(Roche); Lanes 2-11 = colony PCR (using pET22b forward and reverse primers) of 
individual colonies from transformed plasmids with lane 7 showing a positive colony 
including ovine C4BPB CDS. All other lanes illustrated negative colonies i.e. 
pET22b(+) vector contained no C4BPB insert. Lane 12 = +ve control (pET 22b 
vector template); Lane 13 = -ve control (no sequence template). 
1000
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This plasmid was used to transform BL21 codon plus (DE3) E. coli cells (Agilent 
Technologies) to express the recombinant ovine C4BPB protein. Following induction 
of recombinant protein production with IPTG, no induced protein bands at the 
predicted molecular mass of rC4BPB (23kDa) were seen by SDS-PAGE in either the 
soluble or insoluble phases (Figure 3.9). 
As rC4BPB was not successfully expressed using pET22b(+) as a vector system, 
expression was then attempted using pET SUMO. 
 
Figure 3.9: Protein expression profiles of ovine rC4BPB in pET 22b separated on a 
SDS-PAGE gel stained with SimplyBlue Safestain (Invitrogen). Lane 1= SeeBlue 
marker (Invitrogen); 2= uninduced, soluble fraction; 3=induced, soluble fraction; 
4=uninduced, insoluble fraction; 5=induced, insoluble fraction. 
3.3.2.2 Using pET SUMO as an expression vector 
Ligation of the ovine C4BPB sequence into pET SUMO was successful and 
sequencing of the resulting plasmid confirmed the full sequence was inserted in the 
correct orientation. This plasmid was used to transform BL21 codon plus (DE3) E. 
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coli cells (Agilent Technologies) to express the recombinant ovine C4BPB protein. 
Following induction of recombinant protein production with IPTG, the BL21 cells 
expressed rC4BPB with the pET SUMO fusion protein attached as shown in Figure 
3.10. Using pET SUMO has the advantage over other expression systems that 
subcloning relies on a simple TA cloning step rather than cutting either plasmid or 
PCR product with restriction enzymes but has the disadvantage that the resulting 
recombinant protein has a large (14kDa) SUMO fusion protein attached. The fusion 
protein at ca. 40 kDa therefore represents the rC4BPB, present in the “induced, 
insoluble” fraction only (Figure 3.10). 
 
 
Figure 3.10: Coomassie stained SDS-PAGE gel of rC4BPB expression using pET 
SUMO expression in BL21 cells, with band of interest circled at ca 40 kDa. Lane 1 = 
SeeBlue marker (Invitrogen); 2 = uninduced, soluble fraction; 3 = induced, soluble; 4 
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3.3.2.2.1 Protein identification by MALDI 
The results of the MALDI analysis of the recombinant fusion protein obtained in 
section 3.3.2.2 confirmed its identity as ovine C4BPB, as shown in Figure 3.11. 
 
Figure 3.11: Results of MALDI analysis of the excised 40 kDa band from lane 5 in 
Figure 3.10 confirming the expressed protein identity as rC4BPB. Amino acids in red 
lettering denote sequence homology between the known ovine rC4BPB sequence and 
the protein obtained by MS. Shades of grey boxes denote the level of intensity 
coverage obtained during the MS process from weak (pale grey) to strong (black).  
 
When compared to the predicted ovine C4BPB fusion protein sequence, the intensity 
coverage was 91.1% and the sequence coverage 51.2%. 
3.3.2.2.2 Protein purification and dialysis 
The rC4BPB-SUMO fusion protein was purified by nickel affinity chromatography 
(Figure 3.12) and the band from this protein is evident in the pre-purification sample 
(lane 2) at approximately 40 kDa and, as a purified recombinant protein, in the three 
main elution samples (lanes 6-8). Dialysis of the expressed protein after purification 
was carried out to remove the imidazole from the protein solution and to reduce the 
urea concentration from 8M (used in the binding buffer for re-suspending the 
induced pellets for an insoluble protein) to 2M. The protein remained in solution 
following dialysis and the concentration of the recombinant protein was determined 
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by BCA assay as 211.4 µg/ml. The total yield therefore was approximately 500µg of 
rC4BPB from a 50ml culture.  
 
 
Figure 3.12: Image of SimplyBlue Safestain (Invitrogen) stained SDS-PAGE gel 
showing eluted fractions during the purification of rC4BPB by nickel affinity 
column. Lane 1 = SeeBlue marker (Invitrogen); 2 = pre-purification sample; 3 = 
unbound protein fractions; lanes 4-9 = eluted fractions with lanes 6-8 containing 
most rC4BPB. 
 
3.3.3 Production of polyclonal antibodies in rabbits against 
ovine C4BPB 
An immunoblot was used (shown in Figure 3.13) to illustrate that each of two rabbits 
immunised with rC4BPB produced antibodies which bound to the ovine rC4BPB, as 
bands were obtained at ca 40 kDa in the post-immunisation lanes (2 and 4) which 
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When immunoblots of sera from P. ovis-infested and non-infested sheep were probed 
with sera raised in rabbits immunised with rC4BPB, an immunopositive band was 
obtained at 23 kDa, the estimated MW of native ovine C4BPB which was not present 
in the negative control as shown in Figure 3.14. A further, unidentified, 
immunoreactive band was present at ca. 50kDa, which may represent either an 
oligomer of C4BPB, or a further C4BPB-like protein.   
 
Figure 3.13: Image of immunoblot showing binding of IgG in immunised rabbit sera 
to ovine rC4BPB. The rC4BPB was separated by electrophoresis on a SDS-PAGE 
gel, blotted onto nitrocellulose and probed with post 2
nd
 rC4BPB injection sera from 
each rabbit. Lane 1 = MagicMark (Invitrogen); 2 = rabbit 1 post 2
nd
 injection; 3 = 
rabbit 1 control sera (prior to immunisation); 4 = rabbit 2 post 2
nd
 injection; 5 = 
rabbit 2 control sera. Secondary antibody conjugate was swine anti-rabbit HRP IgG 
(Dako). Visualisation was achieved using ECL Plus (GE Healthcare) and 
ImageQuant LAS4000 camera (GE Healthcare).  
1     2    3     4     5 
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Figure 3.14: Immunoblot of pooled sera from sheep (n = 12) infested with P. ovis (6 
wk p.i) (TC1), separated by electrophoresis on a SDS-PAGE gel and probed with 
serum raised in rabbits immunised with rC4BPB (lane 2).  Lane 1 = MagicMark 
(Invitrogen); 3 = over exposed rC4BPB +ve control and lane 4 = -ve (no primary 
antibody) control for lane 2. The immunoreactive band which putatively represents 
native ovine C4BPB is circled. The conjugate was swine anti-rabbit IgG HRP (Dako) 
diluted 1:10000. Visualisation was by ECL (GE Healthcare) and X-ray development.  
 
3.3.4 Development of a C4BPB ELISA 
The optimal concentrations of all the individual assay components in the final 
sandwich ELISA (as a result of the checkerboard ELISAs) are listed in Table A3.2. 
Three different ELISA formats were compared in the development of an optimised 
ovine C4BPB ELISA: 
1) Direct ELISA 
2) Sandwich ELISA with secondary antibody HRP conjugate 
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The results of each of these assay formats for the detection of ovine C4BPB in the 
sera of P. ovis infested sheep, at optimal performance, are summarised in Table 3.1. 
Table 3.1: Summarised results [± standard error of the mean (SEM)] from the main 
steps in the ELISA development to detect C4BPB in serum of P. ovis infested sheep. 
“Infested” samples comprised pooled sera from sheep (n = 12) 6 weeks p.i, whereas 
“control” samples used pooled sera from the same sheep (n = 12) prior to exposure to 
P. ovis. Normalised OD₄₅₀ was calculated by subtracting the negative (no primary 
antibody) control from the sample OD₄₅₀. 
 Mean normalised 
OD±SEM 





Direct ELISA 0.232±0.04 0.147±0.07 









The differences between the mean normalised OD₄₅₀ using pooled sera from sheep 
infested with P. ovis compared with sera from non-infested sheep were not 
significant in the direct ELISA and, in the initial sandwich ELISA, the OD₄₅₀ values 
were very low when an HRP-conjugated secondary antibody was used. When a 
biotinylated secondary antibody was used with a streptavidin-conjugated HRP at the 
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established optimal concentration, the OD₄₅₀ increased more than ten-fold and the 
differences between the infested and control sera were statistically significant, 
P=0.0495, as shown in Figure 3.15.  All of the optimisation ELISAs included 
positive controls using ovine rC4BPB for coating; negative sera controls (sera from 
rabbits prior to immunisation) and negative (no primary antibody) controls as 
detailed in section 3.2.4. The mean OD₄₅₀ for the positive controls, used in the 
ELISAs summarised in Table 3.1, was 2.173±0.262 and that of the negative (no 



































Figure 3.15: Mean normalised OD₄₅₀ obtained from the optimised sandwich ELISA 
to detect C4BPB in the pooled sera of P. ovis infested sheep (n = 12; 6 week p.i) 
compared with control sheep comprising the same group of sheep prior to exposure 
to P. ovis. Normalised OD was calculated by subtracting the negative control OD 
(background) from the sample OD. Variance bars represent ±SEM. 
 
Chapter 3: C4BPB 
122 
3.3.4.1 Use of the sandwich ELISA to quantify ovine C4BPB in sera 
across a time course of infestation with P. ovis and post-treatment in an 
experimental trial 
Pooled sera were used from the TCT1 trial described in A3.1.11 to validate the 
optimised ELISA. Briefly, blood samples were taken by venous extraction from12 
sheep with no previous exposure to P. ovis and the sheep were then infested with P. 
ovis mites. Throughout the subsequent 6 weeks of infestation, lesion sizes were 
measured and blood samples taken by venous extraction weekly. The sheep were 
treated with the injectable endectocide Dectomax (Pfizer Animal Health) at the end 
of week 6 post-infestation. Following treatment blood samples were taken by venous 
extraction twice each week for a month and then weekly for a further 10 weeks.  
The results (Figure 3.16) illustrate that the OD₄₅₀ values derived by ELISA were 
significantly higher when sera from infested sheep were compared to those in pre-
infestation samples (P≤0.001) by 3 weeks post-infestation and OD₄₅₀ values 
continued to increase until the sheep were treated 6 weeks post-infestation. Within 
three days of being treated the mean OD₄₅₀ was significantly lower than the mean 
values before treatment (P≤0.001) and the mean OD₄₅₀ then continued to decline 
until it had reached pre-infestation levels by 2 weeks post-treatment. The positive 
controls mean OD₄₅₀ for the ELISA plates completed in this experiment (coating 
with ovine rC4BPB and detecting with rabbit anti-serum) was 1.847±0.055. 
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Figure 3.16: Mean normalised OD₄₅₀ obtained from the ovine C4BPB sandwich 
ELISA using pooled sera sampled from sheep (n = 12) across a time course of 
infestation with P. ovis and post-treatment. Time 0 = pre-infestation.  Bar A denotes 
a significant difference between weeks 0 and 3 and bar B between point of treatment 
and 3 days post-treatment. ***denotes P≤0.001 as calculated by Repeated Measures 
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3.4 Discussion 
An initial PCR amplification using degenerate primers yielded approximately half of 
the predicted ovine C4BPB nucleotide sequence, with the remainder of the sequence 
being obtained in stages using RACE technology. RACE is a widely used PCR based 
method employed to capture the 5’ and 3’ ends of mRNA sequences where only 
partial sequences have resulted from initial PCR (Schaefer, 1995). It has the 
advantages of being simple to perform while yielding rapid results, but it often 
requires extensive optimisation before accurate identification of cDNA ends are 
achieved (McGrath, 2011). In order to obtain the ovine C4BPB sequence, new 
primers were designed at each step of the RACE sequence extension, based on 
partial sequences as they were obtained. This increased the specificity and efficiency 
of each reaction and due to this process of step by step optimisation, the complete 
sequence was obtained.   
The expression of ovine rC4BPB in bacterial cells using pET22b(+) as a vector was 
unsuccessful. This vector had been selected due to its high success rate in the cloning 
and expression of recombinant proteins and its ability to maintain the transcription of 
target genes minimal in the uninduced state (User Protocol TB055, Novagen). 
Although the C4BPB sequence was shown to be inserted in the vector following 
subcloning, rC4BPB was not expressed on induction. This may have been due to 
basal expression of T7 RNA polymerase, even in the absence of the IPTG inducer, 
which induces target gene transcription (User Protocol TB055, Novagen) therefore 
the rC4BPB expressed in E. coli may have been affecting the vector detrimentally. 
On induction, as the concentration of rC4BPB increased, the protein may have 
become toxic to some degree to the bacteria, which is a possibility with C4BPB as it 
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is known to be tightly regulated in humans where it is potentially damaging to cells 
(Blom et al., 2004).  
Ovine rC4BPB was, however, expressed successfully in the pET SUMO vector 
system, which may be due to the reported effect of the SUMO fusion protein 
enhancing functional protein production in prokaryotic expression  systems and 
significantly improving protein stability (Panavas et al., 2009). The expressed 
rC4BPB was insoluble which has been reported previously as being an issue when 
expressing mammalian proteins in a bacterial system (Demain and Vaishnav, 2009). 
A further disadvantage of using E. coli to express a mammalian protein is that E. coli 
cannot prepare or attach mammalian glycosylation chains (Swartz, 2001). As ovine 
C4BPB has three glycosylation sites, and it is probable that the rC4BPB expressed in 
the bacterial system would not have any, rC4BPB is therefore likely to show 
differences in its tertiary structure when compared with native C4BPB. This 
differential glycosylation and tertiary structure phenomenon has been cited as the 
main reason why some antibodies produced from bacterially expressed recombinants 
fail to bind their target proteins (Demain and Vaishnav, 2009, Vervelde et al., 2002) 
and also the reason why some recombinant vaccine antigens are ineffective in cases 
where the native proteins afford protection (Geldhof et al., 2004, 2007, 2008). A 
similar phenomenon in the present study may account for the sub-optimal binding of 
antibody raised against rC4BPB to native ovine C4BPB obtained in the Western blot 
results and low OD₄₅₀ values in the ELISAs in the development stages of the assay. 
A recent review has also highlighted that it is often difficult to isolate the relative 
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importance of glycosylation from other post-translational modifications such as 
protein folding in recombinant antigen immunogenicity (Ellis et al., 2012).  
There is clearly a requirement for systems that can modify and glycosylate expressed 
recombinant antigens in a similar fashion to the native molecule and mammalian 
expression systems are an attractive alternative to bacterial and yeast-based 
expression systems for the production of mammalian proteins which require post-
translational modifications, such as glycosylation and correct folding (Demain and 
Vaishnav, 2009). Compared to bacterial expression systems, mammalian systems are 
expensive, time consuming and difficult to execute (Demain and Vaishnav, 2009) but 
may have produced better results in this study and should be considered for any 
future work with C4BPB protein expression.  
The results of the direct ELISAs (section 3.3.4 and Table 3.1) showed very low 
normalized OD₄₅₀ with no statistically significant difference between the OD₄₅₀ of 
the sera from infested sheep and that of the sera from sheep with no previous 
exposure to P. ovis, suggesting either that the antibody raised in rabbits immunised 
with ovine rC4BPB had limited specific binding to native C4BPB or that C4BPB 
was present in very low concentrations in ovine sera.  
A sandwich ELISA was therefore designed to increase the specificity and sensitivity 
of the detection of C4BPB in the sera of sheep infested with P. ovis. The technique 
of using two antibodies raised against the antigen to be detected is a frequently used 
method of achieving increased sensitivity and specificity (Luo et al., 2012). A 
commercially available monoclonal C4BPB (mC4BPB) antibody, raised in mice 
immunised with human rC4BPB, was used as the coating antibody, as this antibody 
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had previously been shown to cross-react with ovine C4BPB (Chapter 2). A 
polyclonal C4BPB antibody raised in rabbits against ovine rC4BPB was used as the 
detection antibody with a swine anti-rabbit conjugated HRP secondary antibody. 
However, the normalised OD₄₅₀ values for sera from sheep infested with P. ovis and 
control sera from non-infested animals were very low reinforcing the possibility that 
there were very small quantities of C4BPB circulating in sheep sera. Alternatively 
there may have been weak binding of the antibody (raised in rabbits against ovine 
rC4BPB) to native ovine C4BPB. To increase the signal, the secondary antibody 
HRP conjugate was replaced with a biotinylated secondary antibody coupled with a 
streptavidin HRP conjugate. This is a commonly used method of increasing the 
sensitivity of an assay (van Gijlswijk et al., 1996) and in this instance increased the 
mean OD₄₅₀ of the samples from the sheep infested with P. ovis by more than 10-
fold. Signal enhancement has recently been used to develop a more reliable 
diagnostic test for S. scabiei in humans. Diagnostic sensitivity has generally been 
low using current methods of skin scraping due to the low numbers of mites present 
in ordinary scabies (Walton and Currie, 2007). In a study measuring IgE levels in 
140 plasma samples from scabies-infested and control subject groups to a 
recombinant S. scabiei antigen, Sar s 14.3, by dissociation enhanced lanthanide 
fluorescent immunoassay (DELFIA), high sensitivity and specificity were obtained 
(Rose and Wall, 2012). The DELFIA assay enhances signal up to 2-fold when 
compared to ELISA by using a Europium (Eu) labelled antibody instead of an 
enzyme (PerkinElmer Technical Support). For future C4BPB immuno-assay 
development, this method may be useful if signal enhancement is required. 
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The results of the experiment using the improved sandwich ELISA (Figure 3.16) to 
detect C4BPB in sera of sheep across a time course of infestation with P. ovis and 
after treatment with an injectable endectocide (as described in A3.1.11), suggested 
that C4BPB was a potential BM for the indication of current disease status in the 
diagnosis of sheep scab. The mean normalised OD₄₅₀ increased significantly between 
pre-infestation sera and 3 week post-infestation sera indicating that C4BPB up-
regulation in sheep sera occurs in early infestation. However, this was one week later 
than the specific detection of the host antibody response to the mite antigen Pso o 2 
by antibody based ELISA (Nunn et al., 2011) which occurs within 2 weeks of 
infestation. More importantly for the required function of the BM diagnostic test for 
sheep scab, the highly significant decrease in mean OD₄₅₀ between the time of 
treatment and 3 days post-treatment highlighted the potential of C4BPB to provide 
information on current disease status. The mean OD₄₅₀ at 2 weeks post-treatment 
was of the same magnitude as that at pre-infestation. This may have a practical 
implication for assessing disease status on farms where sheep scab has been 
confirmed. On such farms, the Sheep Scab Order (Scotland) 2010 imposes sheep 
movement restrictions for 16 days after treatment at which point a veterinary 
inspection is required to declare the animals/flock free of active infestation. As it is 
difficult to diagnose a flock as free of active infestation so soon after treatment when 
relying on clinical observations and skin scraping samples (Bates, 1999c) and the 
existing assay for diagnosing sheep scab relies on an antibody which can be detected 
for 3-6 months post-treatment  (Bates, 1999c, Ochs et al., 2001, Burgess et al., 
2012b), this may be a useful characteristic of the C4BPB response if further 
validated as a BM for sheep scab. 
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These initial observations indicate the potential of C4BPB as a BM for sheep scab 
and also the potential use of the sandwich ELISA as an assay to determine C4BPB 
levels in sheep sera. However, to progress with this ELISA as a diagnostic tool, 
further validation and optimisation will be required. In the first instance, many field 
samples need to be analysed. The gold standard set by the World Organisation for 
Animal Health (OIC) for the validation of diagnostic assays for infectious diseases is 
500 known positive samples, confirmed by skin scraping in the case of sheep scab 
diagnosis, and 1500 known negative samples as described by the Validation and 
Certification of Diagnostic Assays determined by the OIC. Further validation of the 
ELISA would then be required to determine assay sensitivity, specificity, intra- and 
inter-assay variation and an optimal cut-off point to discriminate between positive 
and negative ODs (Nunn et al., 2011). An optimal cut-off can be described by a 
receiver operator characteristic (ROC) curve analysis which optimises the cut-off 
value required in diagnostic tests based on continuous outputs such as sensitivity and 
specificity (Pepe, 2003).  
It has been widely reported from work in the medical field that method validation is a 
critical component of BM research and it is often at this point that clinical BM 
validation fails (Brookes et al., 2010). Stringent assay validation and standardised 
sampling handling are critical if the variation found inter- and intra-assay is to be 
minimised and meaningful serum BM concentration changes in healthy and diseased 
states are to be reported accurately to the clinician (Brookes et al., 2010) and it would 
therefore be crucial to further validate the diagnostic ELISA on these criteria. 
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The assay developed in this study relied on one recombinant protein to produce a 
singleplex sandwich ELISA. However, as C4BPB is an inflammatory protein 
involved in the regulation of the complement cascade, its increase in concentration in 
the sera of sheep infested with P. ovis is unlikely to be specific to sheep scab. Indeed, 
the up-regulation of C4BPB has been described in several human inflammatory 
diseases as previously discussed (Ma et al., 2010, Zadura et al., 2009). It has recently 
been reported that a “cocktail” of recombinant proteins were useful while developing 
a diagnostic assay for neosporosis, the major cause of abortion in dairy cattle 
worldwide (Dong et al., 2012). This study used three recombinant proteins, 
expressed in E. coli, to detect specific antibodies in infected cattle sera. When used in 
combination in an indirect ELISA, they improved the sensitivity and specificity of 
the assay compared to when used individually. This is consistent with other studies 
(Chiswick et al., 2012, Cooper et al., 2007, Komatsu et al., 2011) where a 
“signature” of BMs or antigens tested for clinical application provided a more 
accurate platform for diagnostic testing, treatment development and therapy 
outcomes when compared with a single entity and may be a useful technique to apply 
in the further development of an ELISA to diagnose current disease status for sheep 
scab. C4BPB could be used alongside other protein BMs to provide a signature 
response to sheep scab, or in conjunction with the Pso o 2 assay currently being 
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3.5 Conclusion 
In this chapter, the ovine C4BPB gene was successfully sequenced and a 
recombinant form of this protein was expressed in E. coli. Antibodies, raised in 
rabbits against ovine rC4BPB, appeared to bind to native C4BPB in Western blots. A 
direct ELISA using the rabbit antisera against the sera of sheep infested with P. ovis 
did not yield positive results, possibly due to limited binding of the antibody raised 
against rC4BPB to native C4BPB or to the lack of abundance of C4BPB in sheep 
sera. The development of a sandwich ELISA, where the use of an additional capture 
antibody increased the signal sufficiently to amplify the differences in OD₄₅₀ 
between sera from sheep infested with P. ovis and control sera from non-infested 
sheep, gave promising results. This was further improved by the addition of a 
biotin/streptavidin detection system which further increased the signal obtained. 
Evaluation of the ELISA using sera from a time course of infestation with P. ovis 
and post-treatment suggested the potential of C4BPB as a BM for sheep scab as it 
indicated current disease status, but further evaluation and validation are required 
before this could be used as a diagnostic tool. 
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Chapter 4: Evaluation of selected acute phase 
proteins (APPs) as potential biomarkers (BMs) 
for sheep scab 
4.1 Introduction 
4.1.1 Ruminant APPs  
Psoroptes ovis infestation in sheep produces an intense cutaneous and systemic 
inflammatory response involving many aspects of the immune system, including the 
complement cascade and APR (Van den Broek et al., 2000) as shown by the 
differential expression of genes involved in the regulation of the complement system, 
such as C4BPB and C4BPA in circulating leukocytes, and those involved in the 
initiation of the APR, such as IL1β, IL6 and TNF, in skin biopsies of sheep infested 
with P. ovis (Burgess et al., 2010, Burgess et al., 2012a). The involvement of the 
complement cascade and APR in the host immune response to P. ovis infestation has 
previously been discussed in Chapter 1. However, as the APR to P. ovis infestation 
in sheep had not previously been characterised, it was decided to investigate the sera 
concentrations of the two major ruminant APPs; Hp and SAA and also a moderate 
APP alpha-1 acid glycoprotein (AGP) as potential BMs of sheep scab.  
In ruminants, Hp and SAA are considered to be major APPs as their concentrations 
in sera increase during infection, inflammation or tissue injury by up to 1000-fold for 
SAA and up to 100-fold for Hp, whereas AGP is considered a moderate APP 
showing serum increases of up to three-fold during similar inflammatory events 
(Murata et al., 2004, Petersen et al., 2004). The fold increase from baseline levels is 
generally higher for SAA than for Hp in mammalian species (Gabay and Kushner, 
1999), such as that reported for cattle with bovine respiratory syncytial virus (BRSV) 
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and mastitis where increased SAA levels were 10-fold higher than that of Hp 
(Eckersall and Bell, 2010). However, these responses are known to vary between 
species and disease (Mackiewicz, 1997) and, to date, there has been very little 
research relating to APPs in sheep (Eckersall and Bell, 2010). It is widely 
documented however that APPs are highly conserved across species and the amino 
acid sequence of SAA in sheep shows a high degree of homology with SAA from 
other mammalian species (Syversen et al., 1994). For example the amino acid 
sequence identity between bovine and ovine SAA is 70.8% (Uniprot, EMBL-EBI). 
The APR in ruminants is unique in that Hp is a major APP which can increase in 
serum within two days of infection (Eckersall and Bell, 2010) and in sheep, as for 
cattle, high sera concentrations of Hp and SAA are characteristic of acute 
inflammatory disease (Horadagoda et al., 1999). In cattle, these APPs are synthesised 
only in response to inflammation and are present in very low concentrations in the 
serum of healthy animals (Dobryszycka, 1997). As such, they represent potential 
BMs and have been used in this context to monitor acute inflammatory disease in 
cattle, including the diagnosis and prognosis of mastitis, enteritis, pneumonia, 
peritonitis, endometritis and endocarditis (Murata et al., 2004, Petersen et al., 2004, 
Bannikov et al., 2011). SAA, in particular, is useful in the diagnosis of mastitis in 
dairy cattle as a mammary isoform (M-SAA3) of SAA is synthesised in infected 
mammary glands and can be detected in milk samples enabling subclinical detection 
of mastitis without the need for invasive sampling (Gerardi et al., 2009). 
In ruminants a third APP, AGP has been studied as a potential marker of infection 
for disease diagnosis. In an experimental model of ovine caseous lymphadenitis 
(CLA), AGP concentrations in the sera of infected sheep increased to a peak four 
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times that of the control group, with a more gradual increase and a slower decline 
than either Hp or SAA suggesting its potential role as a marker of chronic 
inflammation (Eckersall et al., 2007) .  
The three APPs introduced in this chapter have previously been suggested as 
potential BMs for inflammatory disease in goats (Gonzalez et al., 2008); for 
diagnosis of infestation with Sarcoptes scabiei in Alpine ibex (Rahman et al., 2010) 
and, recently, the presence of an APR has been established in sheep with clinical 
scrapie, as determined by increased sera concentrations of Hp, SAA and 
ceruloplasmin at disease onset suggesting the potential of these APPs as diagnostic 
BMs (Meling et al., 2012). 
 
4.1.2 The application of APPs as BMs in veterinary diagnosis 
Hp and SAA sera concentrations increase rapidly from low circulating levels in 
response to inflammatory disease, trauma or injury, and as they are present in most 
body fluids (e.g. serum, urine, saliva, amniotic fluid), they have been used in human 
medicine as markers for inflammatory disease and in general health profiles for 
several decades e.g. C-reactive protein (Eckersall and Bell, 2010). The use of an 
index, involving the combined response of positive and negative APPs with those 
showing rapid and slow responses, as a prognostic inflammatory and nutritional 
marker in human cancer has increased the sensitivity and specificity of the test as a 
clinical marker (Gruys et al., 2006). This index has also been adapted for cattle as an 
acute phase index (API) and has been used as an indicator of health and welfare at 
slaughter (Toussaint et al., 1995). 
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Despite the wide body of research indicating the potential role of these APPs as 
markers of health and welfare in many domestic animals, they remain under-used in 
veterinary medicine (Eckersall and Bell, 2010, Cray et al., 2009). This may be due to 
the difficulties in developing commercially viable antibodies suitable for inclusion in 
commercial kits, such as producing an antibody against Hp which is a highly 
glycosylated protein (D. Eckersall, Pers. Comm.); or the assays are too expensive for 
veterinary practioners to use routinely on commercial farms. Many of the assays that 
have been used to date are also species-specific, therefore adding to the time and cost 
constraints of testing (Skinner and Roberts, 1994). Current commercially available 
assays rely on either ELISA for measuring sera SAA and Hp in cattle (e.g. Alpha 
Diagnostic International) or a colorimetric assay for Hp analysis based on the 
binding of Hp to haemoglobin (Hb) (e.g. Tridelta Development Ltd.). This latter 
assay relies on the innate peroxidase activity of the Hp-Hb complex and the level of 
peroxidase activity is directly proportional to the quantity of Hp present in the 
specimen (Eckersall et al., 1999). This indirect method of Hp measurement has the 
advantage of being relatively quick and easy to analyse and can be performed on all 
species, but it is expensive and can be inaccurate if the sera samples are haemolysed. 
However, high throughput Hp analysis is now available due to the development of an 
automated assay by the commercial laboratory ReactivLab (University of Glasgow) 
which may increase the commercial use of Hp as a marker of health and welfare in 
ruminants (D. Eckersall, Pers. Comm.). The ELISAs used for SAA analysis, in 
comparison, require lengthy processes and are generally species specific; although 
the SAA ELISA manufactured by Tridelta Development Ltd is predicted to cross 
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react with SAA in sheep due to the high identity of SAA between these species, 
according to the manufacturer. 
4.1.3 Biological functions of the APPs under evaluation 
4.1.3.1 Haptoglobin (Hp) 
At the time of this study, although the ovine Hp gene had not been sequenced, the 
bovine sequence was known. Bovine Hp is 401 amino acids in length and has a 
predicted MW of ~45 kDa (Uniprot, EMBL-EBI). It is a highly glycosylated serum 
glycoprotein complex consisting of a tetramer of two alpha and two beta chains and, 
although expressed predominantly by hepatocyte cells, it can also be expressed by 
adipocytes, lung cells and in mammary tissue (Dobryszycka, 1997, Hiss et al., 2004). 
A major function of Hp is the binding of free haemoglobin to reduce oxidative 
damage associated with haemolysis (Yang et al., 2003) and the subsequent loss of 
iron through the kidneys. Haptoglobin also has immune response regulatory 
functions through its inhibitory effect on granulocyte chemotaxis thus allowing 
granulocyte aggregation, promotion of phagocytosis and bactericidal activity by 
association with iron-binding microbial proteins thereby providing a mechanism to 
assist the destruction of intracellular pathogens (Dobryszycka, 1997). 
4.1.3.2 Serum amyloid A (SAA) 
Unlike Hp, the ovine SAA gene had been sequenced at time of study and the protein 
comprises 112 amino acids with a predicted MW of ~ 13 kDa (Uniprot, EMBL-EBI). 
SAA is an APP, expressed in the liver, and two isoforms are produced in sheep 
(Syversen et al., 1994). Its functions, although not fully understood, are related to the 
APR and host defence during inflammatory conditions (Murata et al., 2004). Recent 
studies confirmed that mRNA encoding SAA was predominantly expressed in the 
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liver, but other organs, such as lung, mammary gland, uterus, and the gastro-
intestinal tract, showed moderate SAA mRNA expression, supporting the hypothesis 
that SAA has a possible role in innate defence against invading pathogens (Berg et 
al., 2011). There are two reported main functions of SAA in vertebrates: induction of 
collagenase and matrix metalloproteinases 2 and 3 which are important enzymes for 
repair processes following tissue damage; and the ability to act as a chemoattractant 
for immune cells such as monocytes, leukocytes, mast cells and T lymphocytes 
(Uhlar and Whitehead, 1999). 
4.1.3.3 Alpha-1 acid glycoprotein (AGP) 
The ovine AGP gene had not been sequenced at the time of study, but the bovine 
AGP protein has 202 amino acids  (Uniprot, EMBL-EBI) and has a predicted MW of 
~ 23.5 kDa. It is also expressed by hepatocytes and secreted into the blood where it 
has two major functions: firstly it is an effective binding protein and involved in the 
transport of molecules such as heparin, histamine, serotonin and steroids (Fournier et 
al., 2000); and secondly it is an immune regulatory protein, contributing to the 
maintenance of homeostasis by reducing tissue damage associated with inflammation 
(Murata et al., 2004). As with other ruminant APPs, veterinary diagnostic use has 
been limited due to the lack of commercially available assays. However, as new 
techniques are developed this may change as, for example, a specific ovine AGP 
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The aims of this chapter were: 
 To investigate serum concentrations of Hp and SAA, two of the major 
ruminant APPs, in response to P. ovis infestation in sheep. This was 
performed using commercially available assays to assess their potential in the 
diagnosis of current disease status in sheep scab outbreaks and in particular, 
to assess their levels following treatment for sheep scab.  
 To indicate the specificity of Hp and SAA to P. ovis infestation by measuring 
their serum concentrations during other common acquired diseases and 
conditions of sheep in the UK. 
 To evaluate AGP as a potential BM for sheep scab.  
 To analyse APP profiles following acaricidal treatment of sheep for P. ovis 
infestation and to compare the duration of these responses to that of the ovine 
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4.2 Materials and Methods 
4.2.1 Samples used in APP analysis  
4.2.1.1 Sera samples 
The serum levels of Hp and SAA during infestation of sheep with P. ovis were 
measured using samples from the experimental trials described in Chapter 2, section 
2.2.3.6 i.e. TC1, TC2 and TC3, and in Chapter 3, A3.1.11 (TCT1). Briefly, these sera 
were derived from sheep which had samples taken by venous extraction prior to 
infestation, then weekly post-infestation for 6 weeks (TC1, TC2 and TC3) and 
additionally after treatment with an injectable endectocide (Dectomax, Pfizer Animal 
Health) for TCT1. The primary infestation and subsequent treatment performed in 
trial TCT1 was followed by a secondary infestation and treatment component, as 
described in Chapter 3, A3.1.11. 
In addition, the samples listed below were included to test the APP response during 
other common diseases and conditions of sheep:  
 sera from individual sheep (n = 6) experimentally infected with multiple 
species of endemic gastro-intestinal nematodes (GINs), including T. 
circumcincta and Nematodirus battus, from the MRI Firth Mains Farm;  
 sera from an experimental infestation of chewing (Bovicola ovis) (n = 4) and 
sucking (Linognathus spp) (n = 4) lice, kindly supplied by Prof. Neil 
Sargison, The Royal (Dick) School of Veterinary Studies, University of 
Edinburgh;  
 sera from sheep (n = 6) during a natural infection with the liver fluke 
Fasciola hepatica from Minsca Farm, Dumfriesshire and kindly supplied by 
Dr H. MacDougall, MRI;  
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 sera from sheep (n = 10) during early gestation then from late gestation in the 
same sheep from MRI and kindly supplied by Prof. G. Entrican;  
 sera from sheep infected experimentally with orf virus (n = 6) (kindly 
supplied by Dr C. McInnes) and Johnes disease (n = 6) kindly supplied by Dr 
C. Watkins from MRI;  
 sera from sheep clinically confirmed by examination with field-acquired 
sheep scab infestations (n = 12). Sera were available for these animals pre-
infestation, at point of clinical diagnosis and two months post-treatment from 




4.2.1.2 Lesion size measurements 
Lesion size measurements were recorded weekly for the TC1 trial and are shown in 
Chapter 2, Table 2.1. They were also recorded weekly for the TCT1 trial detailed in 
A3.1.11 by measuring the length and width of the main lesion on each sheep and 
recording the result as average mean lesion area (cm
2





Chapter 4: Acute phase proteins 
141 
 
Figure 4.1: Weekly mean lesion areas (±SE) for sheep (n = 12) from the TCT1 trial 
(A3.1.11) over a 6 week time course of infestation with P. ovis and 2 weeks post-
treatment with an injectable endectocide. *All animals were treated with Dectomax 
(Pfizer Animal Health) at 6 weeks p.i. 
4.2.2 Haptoglobin (Hp) 
SDS-PAGE, MALDI analysis and Western blot analysis were performed, as detailed 
below, to assess the qualitative relationship between serum Hp concentration and 
sheep scab lesion size development through a time course of P. ovis infestation. 
Following this a quantitative Hp assay was used to further define the relationship 
between serum Hp concentrations and current disease status in sheep. 
4.2.2.1 Polyacrylamide gel electrophoresis (SDS-PAGE)  
SDS-PAGE electrophoresis was used to separate pooled sheep sera (TC1 
experimental P. ovis infestation study as described in Chapter 2, section 2.2.3.6). 
Sheep sera (diluted 1:10) were added to 4X NuPage LDS sample buffer (2.5µl) 
(Invitrogen) and NuPage sample reducing agent (1µl) (Invitrogen) to a total volume 
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NuPage BisTris 4-12% Polyacrylamide gels (Invitrogen) with MES buffer as 
described in A2.1.1 at 250V for 35 mins in a PowerEase 500 electrophoresis cell 
(Invitrogen). The molecular weight marker used was SeeBlue Prestained Standard 
(Invitrogen).  
4.2.2.2 MALDI analysis 
Gels were stained in SimplyBlue Safestain (Invitrogen) following the manufacturer’s 
protocol. The bands of interest, identified as they increased in intensity through the 
time course of infestation, were excised from the lane containing week 5 post-
infestation sera and mass spectrometry (MS) using MALDI performed at MRI 
Proteomics facility as described in Chapter 3, section 3.2.2.2.1.  
4.2.2.3 Hp Western blot analysis 
SDS-PAGE and immunoblotting were performed, as described in Chapter 2, section 
2.2.3, using samples from two individual sheep in the TC1 trial described in section 
2.2.3.6. Sheep 1 had a naturally resolving lesion, which was at maximum size at 
week 4 post-infestation, whilst the lesion from Sheep 5 showed a gradual expansion 
over the time course of infestation (Chapter 2, Table 2.1). The primary antibody used 
for detecting Hp in the electrophoresed serum samples was a rabbit polyclonal anti-
human Hp (Abcam) and was used at a dilution of 1:1000. The secondary antibody 
conjugate used was a swine anti-rabbit IgG HRP (Dako) and was used at a dilution of 
1:2000.Visualisation was by ECL Plus (GE Healthcare) using the ImageQuant 
system (GE Healthcare) as described in Chapter 2, section 2.2.3.5.  
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4.2.2.4 Hp assay 
Haptoglobin concentration was quantified in the sera of sheep from the experimental 
trials TC1 (n = 6) and TC2 (n = 8) described in Chapter 2, section 2.2.3.6, and TCT1 
(n = 12) described in A3.1.11. Haptoglobin concentration was also quantified in the 
samples described in section 4.2.1.1 from sheep with other common diseases and 
conditions. All sera samples were analysed by ReactivLab (Glasgow University) 
using a colorimetric assay measuring absorbance at 600nm. The analyser was an 
ABX Pentra 400 (Horiba Medical) with a limit of detection for Hp of 0.02 mg/ml. A 
high Hp standard of 1.48 mg/ml was used therefore samples with Hp values above 
this value were automatically diluted. All samples were tested in duplicate.  
4.2.3 Serum Amyloid A (SAA) 
As for Hp, a qualitative assessment was made of the relationship between SAA band 
intensity and lesion size development by Western blot analysis using a commercially 
available antibody raised in rabbits against human SAA. Following this, a 
quantitative analysis was performed by SAA ELISA (Tridelta Development Ltd.) 
Western blot analysis was performed as described in section 4.2.2.1. The sera 
samples used were from the time course trial (TC1) as described in section 2.2.3.6, 
from two individual sheep (animals 1 and 6) as described in section 4.2.2.3 except 
sera from sheep 6 was used instead of sheep 5, as it also had an expanding lesion 
throughout the period of infestation. The primary antibody was a rabbit polyclonal 
anti-human recombinant SAA (rSAA) (Abcam) and was used at a dilution of 1:500 
as established by titration. The conjugate used was a swine anti-rabbit HRP IgG 
(Dako) and was used at a dilution of 1:2000. X-ray films were used for image 
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development, which were scanned and band densities estimated using the Quantity 
One software 4.6.2 (Bio-Rad) as described in Chapter 2, section 2.2.3.5. 
A commercially-available sandwich ELISA kit (TP805B, Tridelta Development Ltd) 
was then used to quantify SAA in sheep sera. This assay was based on a monoclonal 
anti-bovine SAA antibody raised in mice which had been previously shown by the 
manufacturers to cross-react with ovine SAA (Tridelta Development Ltd). The 
manufacturer’s protocol was followed using the same sera as for Hp described in 
section 4.2.1.1, with the addition of TC3 sera. Briefly, 96-well plates were pre-coated 
with an anti-bovine SAA monoclonal antibody raised in mice and samples, including 
standards of known SAA concentration included with the assay, were added to the 
wells along with a biotinylated anti-bovine SAA antibody, before adding a 
streptavidin-HRP conjugate. A 3, 3’, 5, 5’-Tetramethylbenzidine (TMB) substrate 
was added and the reaction stopped using the stop solution provided with the kit and 
the OD measured at 450nm (OD₄₅₀) using a 630nm filter as reference, on a Sunrise™ 
96-well plate absorbance reader (Tecan). Samples were tested from individual 
animals in duplicate, including the standard samples included with the ELISA kit and 
all serum was diluted 1:500 in sample diluent buffer (Tridelta Development Ltd). 
The upper level of the range of the bovine standards used was 300 ng/ml therefore all 
sera samples showing SAA values above this level, were further diluted as required 
and re-analysed.  
4.2.4 Alpha-1 acid glycoprotein (AGP) 
In the absence of a suitable quantitative commercially-available assay at the time of 
study, AGP was evaluated using Western blot analysis, which was performed as 
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described in section 4.2.2.1 and Chapter 2, section 2.2.3. The primary antibody was a 
mouse monoclonal anti-bovine AGP (Abcam) and was used at a dilution of 1:500. 
The secondary antibody conjugate was a rabbit anti-mouse IgG HRP (Dako) used at 
a dilution of 1:2000. Visualisation was by ECL Plus (GE Healthcare) and X-ray film. 
4.2.5 Analysis of antibody levels to the specific P. ovis 
antigen Pso o 2  
To allow comparison of the ovine IgG response to Pso o 2 with serum levels of Hp 
and SAA post-infestation with P. ovis and post-treatment with an injectable 
endectocide, an optimised ELISA, currently being commercialised for the diagnosis 
of sheep scab (Nunn et al., 2011) and described in the general introduction of this 
thesis, was used. Serum samples from the TCT1 experimental trial (described in 
A3.1.11) were assayed and due to previously reported persistence in antibody levels 
after treatment (Ochs et al., 2001, Burgess et al., 2012b) serum samples were 
analysed to 14 weeks post treatment after primary infestation. The ELISA was 
performed as previously described (Nunn et al., 2011) with the following 
modifications: All sera samples were assayed for individual animals in duplicate and 
were diluted 1:200 in PBS with 0.5% Tween80 prior to use. Positive, inter-plate 
controls were hyper-immune serum samples used in the validation of the ELISA 
obtained from sheep (n = 2) which had been re-infested with P. ovis for 6 weeks 
following a primary infestation (6 weeks) and effective treatment. Negative controls 
consisted of the pre-infestation sera from the TCT1 trial sheep. 
4.2.6 Statistical analysis 
Initial statistical analyses of results of the time course trials, TC1, TC2, TC3 and 
TCT1 for Hp and SAA were performed using repeated measures one-way ANOVA 
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with Tukey’s post-hoc test and performed in Graph Pad Prism (Version 5.05, 
GraphPad Software Inc). 
Further statistical analysis was performed by Biomathematics and Statistics Scotland 
(BioSS) using the R Statistical Package (R Core Team, 2012) and the Hp, SAA and 
Pso o 2 assay results from the TCT1 primary infestation and treatment trial 
(described in A3.1.11). The statistical analysis examined the relationship between 
Hp, SAA and Pso o 2 relative to each other and to disease progression with time and 
lesion size development. Briefly, this assessment included the following factors:  
 analyzing the correlation between the duplicated results from each of these 
assays;  
 identifying best fit models to describe Hp, SAA and Pso o 2 trends over the 
time course of infestation and post-treatment. The best fit model for 
describing the response of anti-Pso o 2 to P. ovis infestation and treatment 
was that log mean OD₄₅₀ increased linearly over time. This model showed 
poor fit to the Hp and SAA results so in these analyses the animals were 
described as being “normal” as in day 0 (pre-infestation) or “elevated”. As 
the results showed a normal distribution, all values above the 0.999 quantile 
of the distribution were considered to be elevated, giving a 99.9% specificity 
and undefined sensitivity;  
 calculating half life values (time taken for the assayed value to decrease by 
half following treatment). A generalised linear mixed model was used to 
describe the exponential decay of the BMs and Pso o 2 and incorporated a 
random effect of animal on the decay constant, and the initial value. Thus the 
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decay constant (and the half-life derived from it) represented the mean of all 
the population of animals from which the group sampled came. By using all 
the data, a more robust estimate of the half-life was obtained; 
 calculating optimised cut-off values, where the objective was to obtain as 
high sensitivity and specificity as possible to keep false results to a minimum. 
This was achieved using a generalised linear mixed model for binomial data, 
with a logit link which required the use of the library "lme4" (Bates et al., 
2011). This model used day 0 results as known negatives and week 6 post-
infestation as known positives;  
 calculating the numbers of sheep which would require to be tested at selected 
levels of disease prevalence using the obtained cut-off values. Weeks 0, 1, 2, 
3 post-infestation and days 10 and 14 post-treatment were taken as Hp having 
no P. ovis induced response and weeks 5 and 6 post-infestation, plus days 3 
and 7 post-treatment when there was a response. SAA was calculated in the 
same way, except there were no post-treatment days where it was considered 
there was a P. ovis induced SAA response. The individual BM test sensitivity 
and specificity obtained were applied to selected levels disease prevalence in 
flocks of 20, 50, 100 and 200 sheep and the numbers of sheep were estimated 











The results of the SDS-PAGE analysis of the TC1 sera across a time course of 
infestation are shown in Figure 4.2. This image identified that the band densities of 
two proteins at MWs of 17 and 38 kDa increased through the time course of 
infestation with P. ovis, in particular in lanes 7 and 8, depicting sera from week 5 and 
6 post-infestation. To establish the identity of these two proteins, bands at 17 and 38 
kDa from week 5 post-infestation were excised from the gel for MALDI analysis.  
 
Figure 4.2: Image of SDS-PAGE gel of pooled sera from sheep (n = 6) infested with 
P. ovis over a 6 week time course (TC1) and stained with SimplyBlue Safestain 
(Invitrogen). Bands excised for MALDI analysis at 17 and 38 kDa are circled in red. 
Lane 1 = SeeBlue MW Marker (Invitrogen); Lane 2 = pre-infestation sera; Lane 3 = 
week 1 p.i sera; Lane 4 = week 2 p.i sera; Lane 5 = week 3 p.i sera; Lane 6 = week 4 
p.i sera; Lane 7 = week 5 p.i sera; Lane 8 = week 6 p.i sera; Lane 9 = hyper immune 
sera.                                                                                  
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4.3.1.2 MALDI  
MALDI analysis was performed by MRI Proteomics on the bands excised from the 
SDS-PAGE gel (Figure 4.2, lane 7 at 17 and 38 kDa) and the results are shown in 
Figure 4.3, which identified both samples as fragments of Hp. As the ovine Hp gene 
had not previously been sequenced, the closest match to sample A (17kDa band), 
when a Mascot (Matrix Science) database was interrogated was Capra ibex Hp with 
sequence coverage of 35.7% and intensity coverage of 79.7%. For sample B (38 
kDa) the closest match from the Mascot database was Cervus elaphus Hp with an 
intensity coverage of 11.3% and sequence coverage of 14.5%. Sample A was given a 
Mascot score (Probability Based Mowse Score) of 127 and sample B a score of 202, 
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A) 17 kDa band 
 
B) 38 kDa band 
 
Figure 4.3: MALDI analysis results from the excised 17 kDa and 38 kDa bands (lane 
7 in Figure 4.2) confirming the band identities as Hp fragments. Amino acids in red 
lettering denote sequence homology between the Hp sequence of the closest matched 
species and the protein fragments obtained by MS from the excised gel bands. 
Shades of grey boxes denote the level of intensity coverage obtained during the MS 
process from weak (pale grey) to strong (black).  
4.3.1.3 Western blot analysis 
Western blot and densitometry analysis was performed to compare the band densities 
of Hp with lesion size development in two sheep as described in section 4.2.2.3 
through a time course of infestation. The results indicated that as the lesion size 
increased the band density of Hp increased and as the lesion resolved the intensity of 
the bands decreased (Figure 4.4). 
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Figure 4.4: Densitometry analysis (ImageQuant) from Western blot images using: a) 
the serum (TC1) from a sheep infested with P. ovis where the lesion resolved 
naturally after 4 weeks (Sheep 1) and b) serum from an infested sheep (TC1) where 
the lesion had continued to expand during the 6 week time course (Sheep 5). 
Immunoblots were probed with a rabbit polyclonal anti-human Hp antibody (Abcam) 
and the secondary antibody conjugate used was a swine anti-rabbit IgG HRP (Dako). 
The image was visualised by ECL Plus and ImageQuant and band densities (at 45 
kDa) were quantified by ImageQuant analysis. *Band density was estimated by 
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4.3.1.5 Haptoglobin Assay 
A colorimetric Hp assay (ReactivLab) was used to analyse sera Hp from two 
experimental P. ovis infestation trials (TC1 and TC2 as described in Chapter 2, 























Figure 4.5: Mean sera Hp concentrations (±SE) (n = 6 TC1; n = 8 TC2) as 
determined by a colorimetric Hp assay (ReactivLab) across a 6 week time course of 
P. ovis infestation in two experimental trials (TC1 and TC2). Samples from 
individual animals were analysed in duplicate. No sample was available for time 0 in 
the TC2 trial. 
Statistically significant increases in mean Hp concentration in TC1 were observed 
between weeks 0 and 5; 1 and 5; 2 and 5; and 3 and 5 (p≤0.01). However, there were 
no statistically significant differences between any of the time points in TC2 due to 
the large between animal variations in sera Hp, particularly at higher Hp 
concentrations. The results of the experimental trial TCT1 (12 sheep infested over a 
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6 week time course, treated and left for 14 weeks prior to another 6 week secondary 
infestation) are shown in Figure 4.6 and tabulated in Table A4.2. 






















 Figure 4.6: Mean Hp concentrations (±SE) through the time course of primary 
infestation with P. ovis and post-treatment over 14 weeks, followed by secondary 
infestation for a further 6 weeks and post-treatment for 2.5 weeks. Sera samples (n = 
12) from individual sheep in the experimental trial TCT1 (described in A3.1.11) 
were analysed in duplicate using a colorimetric Hp assay (ReactivLab). Bar A 
denotes a significant difference between weeks 4 and 5 post-infestation and B 
between point of treatment and 1 week post-treatment. *** p≤0.001 
The mean Hp concentration pre-infestation was 0.295±0.060 mg/ml and Hp levels 
did not increase significantly during the primary infestation until after 4 weeks p.i. 
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3.327±0.890 mg/ml (p≤0.001). Following treatment of the primary infestation, mean 
Hp concentrations fell significantly (p≤0.001) from 3.533±0.638 mg/ml at the point 
of treatment to 1.566±0.351 mg/ml one week post-treatment and had returned to pre-
infestation levels between 10 and 14 days after treatment.  
The Hp profile, illustrated in Figure 4.6, for the secondary infestation showed that 
serum Hp levels increased earlier to a challenge infestation with P. ovis. The 
maximum Hp concentration measured during the secondary infestation was at 2 
weeks post-infestation (week 22) with a value of 1.246±0.270 mg/ml. Hp levels had 
doubled by 24 hours p.i in the secondary infestation compared with the much slower 
increase in levels during the primary infestation. By week 3, following secondary 
infestation, Hp levels had reduced to pre-infestation levels and they remained at low 
levels for the remainder of the trial.  
The results of the statistical analysis using the R statistical package (R Core Team, 
2012) (described in section 4.2.6) to define the nature of elevation and half-life of Hp 
concentrations in sera are shown in Table 4.1. The proportion of animals showing 
elevated Hp started to increase between weeks 4 and 5 post-infestation and all except 
one had returned to normal by 10 days post-treatment. The half life of Hp post-
treatment was calculated as 2.3 days [95% confidence interval (CI) = 1.9-2.9]. The 
optimised range below which an animal was considered “normal” or above it 
“elevated” was 0.445-1.260 mg/ml for Hp and as all the values within that range 
gave the same outcome for specificity and sensitivity, a cut-off of 1.26 mg/ml was 
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Table 4.1: Distribution of animals (n = 12) after statistical analysis using the R 
statistical package (R Core Team, 2012) into normal and elevated groups for Hp sera 
concentration across the time course of primary infestation and treatment (TCT1 
trial). *All sheep were treated with an injectable endectocide at week 6 p.i. 
Week 0 1 2 3 4 5 6* 6.5 7 7.5 8 
Normal 12 11 11 11 10 4 2 2 7 11 12 
Elevated 0 1 1 1 2 8 10 10 5 1 0 
 
Based on this cut-off value denoting the serum Hp level of a “normal” or an 
“elevated” animal, the number of sheep which it would be considered necessary to 
test in a flock is shown in Table 4.2. These results indicate that at higher disease 
prevalence fewer animals in a flock would require testing and the proportion of 
animals in a flock which would require testing decreased as the flock size increased 
up to 200. In addition, irrespective of the flock size analysed, the probability of 
obtaining false positive results in sheep scab negative flocks decreased as disease 
prevalence increased. 
To further establish Hp concentration in the sera of sheep known to be sheep scab 
negative, 19 sera samples from sheep scab naive animals were tested for Hp by 
colorimetric assay (ReactivLab) and the mean Hp concentration was determined as 
0.61±0.186 mg/ml. This was a higher mean than that established in the pre-
infestation results described in Figure 4.6 and Table A4.2 which showed a mean Hp 
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concentration of 0.295±0.060 (n = 12), indicating a range of Hp serum levels in 
animals prior to infestation with P. ovis. 
Table 4.2: Statistical analysis of Hp results to indicate the number of sheep in a flock 
which would require testing at selected levels of disease prevalence. This analysis 
was carried out using R statistical package (R Core Team, 2012) using previously 
defined test values of sensitivity (0.83) and specificity (1). Sera Hp results from the 
TCT1 primary infestation and treatment trial were used in this analysis. *Level of 
accuracy refers to the true detection rate in a positive flock. ** Probability that a 
















20 1 0.95 20 NA 
 5  20 NA 
 10  20 NA 
 20  16 0.55 
50 1 0.95 42 0.88 
 5  34 0.82 
 10  26 0.73 
 20  16 0.55 
100 1 0.95 49 0.91 
 5  36 0.83 
 10  26 0.73 
 20  16 0.55 
200 1 0.95 53 0.93 
 5  37 0.84 
 10  26 0.73 
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4.3.2 Serum Amyloid A (SAA) 
4.3.2.1 SAA Western Blotting 
To clarify the relationship between serum SAA levels and sheep scab infestation, 
Western blot analysis was performed using individual sera samples from the time 
course trial (TC1) where lesion sizes were recorded on a weekly basis (Chapter 2, 
Table 2.1). The densities of bands obtained in the Western blots, at the estimated 
MW of SAA (14 kDa), were measured at each time point during infestation using 
Quantity One software (Bio-Rad). This enabled comparisons to be made for each 
sheep as lesions grew or resolved as shown in Figure 4.7 which identifies a clear 
relationship between SAA band density and lesion size i.e. band density increased as 
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Figure 4.7: Densitometry analysis (Quantity One software, Bio-Rad) from Western 
blot images using: a) the serum (TC1) from a sheep infested with P. ovis where the 
lesion resolved naturally after 4 weeks (Sheep 1) and b) serum from an infested 
sheep (TC1) where the lesion had continued to expand during the 6 week time course 
(Sheep 6). The blots were probed with an anti-SAA antibody raised in rabbits against 
human rSAA (Abcam) and the secondary antibody conjugate was swine anti-rabbit 
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4.3.2.2 SAA ELISA        
Using samples of known SAA concentration provided with the ELISA kit, a standard 
curve was produced and a linear relationship established between OD and SAA 
concentration. The R² value for this curve was 0.963, demonstrating an excellent 
degree of correlation for the assay. The results from the 3 separate sera sets 
(described in Chapter 2, section 2.2.3.6 as TC1, TC2 and TC3) from sheep 
experimentally infested with P. ovis over a 6 week time course demonstrated 
increases of over 200-fold in the level of circulating SAA as disease progressed, with 
























Figure 4.8: Mean SAA concentrations (±SE) as determined by SAA ELISA 
(Tridelta Development Ltd) in sera from sheep (TC1 n=6; TC2 n = 8; TC3 n = 6) 
experimentally infested with P. ovis over three separate 6 week time course trials. 
Samples were analysed for individual animals and tested in duplicate. Sera were 
diluted 1:500 in diluent buffer (supplied with the ELISA kit) unless SAA 
concentration was >300ng/ml and thereafter it was diluted 1:2000. 
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Mean serum SAA concentrations continued to increase between weeks 3 and 6, with 
the exception of the TC1 trial sera where SAA concentration at 6 weeks p.i had 
fallen to 81.99±16.597 µg/ml. This may be explained in this trial (TC1) as three out 
of the six sheep had naturally resolving lesions by week 6 post-infestation (Chapter 
2, Table 2.1). Statistical analysis of the results depicted in Figure 4.8 was performed 
with a one-way ANOVA (Graph Pad Prism) and indicated that there were no 
significant differences in mean SAA serum concentrations until week 4 post-
infestation in TC1 (p≤0.001) and by week 5 in TC2 (p≤0.01) and TC3 (p≤0.01).  
The SAA ELISA results of the experimental trial TCT1 are shown in Figure 4.9 and 
tabulated in Table A4.4. SAA levels pre-infestation were 0.82±0.53 µg/ml and 
remained at this level over the first 3 weeks of primary infestation. By week 4 post-
infestation, they had increased to 95.24±54.4 µg/ml and, by week 5, to 
284.75±71.144 µg/ml which was the highest level recorded as, by week 6 post-
infestation, there was a slight decrease in SAA levels to 217±46.36 µg/ml. Using a 
one-way ANOVA with Tukey’s multiple comparison post-hoc test, the changes in 
SAA levels between time points were analysed and these data are shown on Figure 
4.9. The increase in serum SAA levels between weeks 3 and 4 was not statistically 
significant, however between weeks 3 and 5 post-infestation it was highly significant 
(p≤0.001). Post-treatment, serum SAA levels fell within 3 days of treatment to 
57.282±34.750 µg/ml (p≤0.05) and continued to decrease reaching pre-infestation 
levels within 10 days post-treatment. The secondary infestation was characterised by 
a rapid increase in SAA concentration of the same magnitude of the primary 
infestation peak, but within 24 hours post-secondary infestation. Within 2 weeks of 
 
 
Chapter 4: Acute phase proteins 
161 
infestation, however, SAA levels were 2.256±2.464 µg/ml and they remained at this 

























Figure 4.9: Mean SAA concentrations (± SE) through the time course of primary 
infestation with P. ovis for 6 weeks, and post-treatment over 14 weeks, followed by a 
further 6 week infestation and post-treatment for 2.5 weeks. Sera samples (n = 12) 
from individual sheep in the experimental trial TCT1 (described in A3.1.11) were 
analysed in duplicate by SAA ELISA (Tridelta Development Ltd). Bar A denotes a 
significant difference between weeks 4 and 5 post-infestation and bar B between 
point of treatment and 3 days post-treatment (primary infestation). Bar C denotes a 
significant difference between point of infestation and 24 hours post-infestation and 
bar D between 24 hours and 1 week post-infestation (secondary infestation). ** 
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Further analyses, as described in section 4.2.6, were used to define the changes in 
SAA levels following P. ovis infestation and treatment, and are presented in Table 
4.3. The proportion of animals showing elevated serum SAA increased between 
weeks 4 and 5 post-infestation and all except one animal had returned to normal by 7 
days post-treatment. The half life of SAA post-treatment was estimated at 0.84 days 
(95% CI = 0.73-0.99). The optimised range below which an animal was considered 
“normal” or above it “elevated” was 5.5-29.5µg/ml for SAA and a cut-off value of 
29.5µg/ml was selected to optimise assay specificity. This cut-off value provided 
assay sensitivity of 1.0 and a specificity of 1.0, equating to a test accuracy of 100%.  
Table 4.3: Distribution of animals (n = 12) following statistical analysis using the R 
statistical package (R Core Team, 2012) (described in section 4.2.6) into normal and 
elevated groups for SAA sera concentration across the time course of primary 
infestation and treatment (TCT1). *All sheep were treated with an injectable 
endectocide at week 6 p.i. 
Week 0 1 2 3 4 5 6* 6.5 7 7.5 8 
Normal 12 9 10 11 4 0 0 7 11 12 12 
Elevated 0 3 2 1 8 12 12 5 1 0 0 
 
The numbers of sheep which it would be considered necessary to test, based on the 
above analysis, in selected flock sizes and levels of disease prevalence are shown in 
Table 4.4. The trends in results were as for Hp, i.e. at higher disease prevalence 
fewer animals required testing and the probability of obtaining false positive results 
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in sheep scab negative flocks decreased. However, as the SAA assay showed higher 
sensitivity than the Hp assay, the probability that a negative flock would test positive 
at a given level of disease prevalence and test accuracy, was lower for SAA than Hp.  
Table 4.4: Statistical analysis of SAA results to indicate the number of sheep in a 
flock which would require testing at selected levels of disease prevalence. This 
analysis was carried out using R statistical package (R Core Team, 2012) using 
previously defined test values of sensitivity (1) and specificity (1). Sera SAA results 
from the TCT1 primary infestation and treatment trial were used in this analysis. 
*Level of accuracy refers to the true detection rate in a positive flock. ** Probability 

















20 1 0.95 19 0.33 
 5  18 0.32 
 10  17 0.3 
 20  12 0.22 
50 1 0.95 44 0.6 
 5  35 0.52 
 10  24 0.4 
 20  13 0.24 
100 1 0.95 70 0.77 
 5  42 0.59 
 10  25 0.41 
 20  13 0.24 
200 1 0.95 90 0.85 
 5  43 0.6 
 10  25 0.41 
 20  13 0.24 
 
4.3.3 Alpha-1 acid glycoprotein 
The results of the Western blot analysis of AGP in sera from sheep infested with P. 
ovis across a time course of infestation (Figure 4.10) showed bands at ~24 kDa, the 
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estimated MW of AGP, which increased in density particularly by weeks 5 and 6 
post-infestation. However, the band density in lane 2 which contained the pre-
infestation sera was also high, suggesting that AGP could be circulating at higher 
levels than optimal for a potential BM. The negative control (lane 6) suggested that 
the secondary antibody was not cross-reacting with IgG in the ovine sera. 
 
Figure 4.10: X-ray image of Western blot using pooled sera from sheep (n = 6) 
infested with P. ovis over a 6 week time course (TC1). The primary antibody was a 
monoclonal raised in mice against bovine AGP (Abcam) and used at a dilution of 
1:500. The band of interest at 24 kDa is marked with a red arrow. Secondary 
antibody conjugate was rabbit anti-mouse HRP (Dako) used at a dilution of 1:5000. 
Visualisation was by ECL Plus (GE Healthcare) and X-ray development. Lane 1 = 
SeeBlue Marker (Invitrogen); Lane 2 = pre-infestation sera; Lane 3 = week 1 p.i sera; 
Lane 4 = week 3 p.i sera; Lane 5 = week 6 p.i sera; Lane 6 = -ve (no primary 
antibody) control; Lane 7 = +ve (ovine IgG) control using pooled 6 wk p.i sera (as in 
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4.3.4 Assessment of serum SAA and Hp concentrations 
during other common diseases and conditions of sheep 
As APPs are known to be non-specific indicators of inflammatory disease, serum Hp 
and SAA levels were measured by colorimetric analysis or ELISA, respectively, 
from serum samples taken during other common conditions of sheep. The serum Hp 
and SAA levels measured during most common sheep infections were of the same 
magnitude as those measured in sheep prior to infestation with P. ovis (Table 4.5).  
Table 4.5: Mean serum Hp and SAA concentrations in other common sheep diseases 
and conditions. Hp (mg/ml ± SE) measured by colorimetric assay (ReactivLab) and 
SAA (µg/ml ± SE) assessed by SAA ELISA (Tridelta Development Ltd). All 
samples were assayed for individual animals in duplicate. Early gestation was 1 week 
post-conception and late gestation was 1 week prior to expected lambing date. 
*species included T. circumcincta and N. battus. 
Infection Mean Hp (mg/ml)±SE Mean SAA (µg/ml)±SE 
Early gestation 0.33±0.008 9.34±2.136 
Late gestation 0.52±0.083 17.089±7.774 
Gastro-intestinal nematodes* 0.04±0.034 0.297±0.007 
Liver Fluke (Fasciola hepatica) 2.85±0.024 0.223±0.002 
Sucking lice (Linognathus spp.)  0.52±0.508 68.47±22.325 
Chewing lice (Bovicola ovis) 
 
0.65±0.313 193.356±135.807 
Orf 0.21±0.009 0.930±0.526 
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For example Hp and SAA levels during experimental gastro-intestinal worm 
infections were 0.04±0.034 mg/ml and 0.297±0.007 µg/ml respectively. The 
exceptions to this were during liver fluke infection and Johnes disease, where Hp 
levels were 2.85±0.024 mg/ml and 2.25±0.344 mg/ml respectively, which is of the 
same magnitude as those measured 4-5 weeks post-infestation with P. ovis. SAA 
levels in chewing and sucking lice also showed the same magnitudes as 4-5 weeks 
post-infestation with P. ovis at 193.356±135.807 µg/ml and 68.47±22.325 µg/ml 
respectively, but Hp levels in both chewing and sucking lice were low.  
 
4.3.5 Assessment of APP levels in clinically positive sheep 
during a field outbreak of sheep scab 
As described in section 4.2.1.1, a natural field outbreak of sheep scab occurred at the 
MRI Firth Mains Farm (Burgess et al., 2012b) and samples from 12 sheep at three 
time points were available. These were pre-infestation, at the point of clinical 
diagnosis (two months later) and two months after treatment. Samples from the sheep 
identified as clinically positive were used to assess the levels of Hp and SAA in a 
field outbreak situation and were analysed using the assays as previously described 
in sections 4.2.2.4 and 4.2.3. 
4.3.5.1 Haptoglobin 
The results of the Hp assay for the 12 clinically positive sheep in the field outbreak 
of P. ovis are shown in Figure 4.11 and Table A4.5. The pre-infestation levels of Hp 
at 0.228±0.219 mg/ml were comparable to those pre-infestation in the TCT1 
experimental trial (0.295±0.060 mg/ml) although the between animal variation was 
greater in the results from the natural outbreak samples when compared to the 
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experimental trial samples. Also lower levels of Hp during infestation and higher 
variation in sera Hp concentration between animals were obtained in the results from 
the natural outbreak samples compared with the experimental trial summarised in 


























Figure 4.11: Mean serum Hp concentration ( ± SE) from sheep (n = 12) pre-
infestation, at clinical diagnosis as positive for sheep scab and 2 months post-
treatment in a field outbreak of sheep scab. Hp measurement by commercial assay 
(ReactivLab); sera from individual sheep tested in duplicate. **p≤0.01 as determined 
by a one-way ANOVA (Graph Pad Prism). 
In the natural outbreak results, the increase in Hp from pre-infestation to the point of 
clinical diagnosis was statistically significant (p≤0.01) but the decrease in Hp levels 
2 months post-treatment was not significant. The low mean Hp at the point of 
diagnosis, compared to P. ovis infested sheep in experimental trials, may have been 
due to a large proportion of the clinically positive sheep having low clinical scores, 
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i.e. they had very small lesions as it was early in the infestation. The data for the 
clinical scoring is described in the published paper (Burgess et al., 2012b) 
4.3.5.2 Serum Amyloid A 
The mean serum SAA levels of the clinically positive field infestation sheep are 
shown in Figure 4.12 and Table A4.6. The pre-infestation levels of SAA 
(1.068±0.237 µg/ml) in the field samples were higher than those in the TCT1 






















Figure 4.12: Mean serum SAA concentration (± SE) from sheep (n = 12) pre-
infestation, at clinical diagnosis as positive for sheep scab and 2 months post-
treatment in a field outbreak of sheep scab. SAA measurement by commercial 
ELISA (Tridelta Development Ltd); sera from individual sheep diluted 1:50 and 
assayed in duplicate. **p≤0.01; *p≤0.05 as determined by a one-way ANOVA 
(Graph Pad Prism). 
At point of clinical diagnosis the recorded mean SAA (10.686±2.659 µg/ml) was 
lower than those during weeks 4, 5 and 6 p.i of the experimental trial TCT1, but 
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higher than those up to week 4 p.i (Table A4.4). This would have been expected as 
the lesions in the field outbreak sheep were small compared to those of the 
experimental trial sheep. In the field results, the increase in SAA from pre-infestation 
to the point of clinical diagnosis was statistically significant (p≤0.01) and unlike Hp, 
the decrease in SAA post-treatment was also statistically significant (p≤0.05) 
possibly due to the lower between animal variation in SAA when compared to Hp. 
4.3.6 ELISA measurement of serum anti-Pso o 2 (specific mite 
antigen) IgG levels in sheep following infestation with P. ovis  
The results of the ELISA analysis to determine the serum anti-Pso o 2 IgG responses 
in trial TCT1 are summarised in Figure 4.13 and in Table A4.7. By week 3 post-
primary infestation the mean OD₄₅₀ had increased from 0.573±0.019 pre-infestation 
to 1.197±0.115 (p≤0.05) and continued to increase until week 6 post-primary 
infestation. After treatment, the mean OD₄₅₀ decreased from a 2 weeks post-
treatment value of 2.663±0.066 to 1.727±0.098 by 3 weeks post-treatment (p≤0.001). 
After this the OD₄₅₀ values continued to decline slowly and did not return to pre-
infestation levels until the start of the secondary infestation trial, which was 14 
weeks after treatment of the primary infestation. Applying the statistical analysis 
using the R statistical package (as described in section 4.2.6) to define the response 
of ovine antibody raised against Pso o 2, illustrated that the antigen-specific IgG 
level increased, exponentially, over time during the primary infestation period up to 
the point of treatment by 0.034 OD450 units per day (95% CI = 0.032-0.037). 
Following treatment the antibody response to Pso o 2 showed an exponential decay 
rate of 0.012 OD450 units per day (95% CI = 0.011-0.014) and the half life of the 
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antibody levels to Pso o 2 was estimated as being 56 days after treatment (95% CI 49 
– 65 days). 


























Figure 4.13: Mean normalised OD₄₅₀ values (±SE) from ELISA to measure the 
ovine antibody response to Pso o 2 (a mite antigen) across the time course of primary 
infestation and then post-treatment using sera from sheep (n = 12) infested with P. 
ovis and treated with an injectable endectocide, followed by a secondary infestation 
and subsequent treatment (TCT1 trial). Coating antigen used was a recombinant Pso 
o 2 (rPso o 2) at 75µg/ml; conjugate used was a rabbit anti-sheep IgG HRP (Dako) at 
a dilution of 1:2000. Bar A denotes a significant difference between weeks 0 and 2 
post-infestation; bar B between 3 and 4 weeks post-treatment (primary infestation) 
and bar C between 24 hours and 1 week post-infestation (secondary infestation). 
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Positive inter-plate controls had previously been performed for this ELISA using HI 
sera analysed over 5 plates giving a mean OD of 2.5 (Nunn et al., 2011). The results 
obtained here were normalised by multiplying the mean sample OD by 2.5 and 
dividing by the mean positive control OD obtained for that plate. 
  
By week 2 post-infestation 8 out of 12 animals (Table 4.6) showed an IgG response 
to Pso o 2 and more than half the animals continued to show elevated antibody levels 
to Pso o 2 at 19 weeks post-treatment. As the anti-Pso o 2 antibody levels increased 
at approximately three times the rate at which they decreased, it is evident that 
antibody levels were not an accurate measure of current disease status post-
treatment, but were effective for the early diagnosis of sheep scab during this trial. 
 
Table 4.6: Distribution of animals (n = 12) after statistical analysis using the R 
statistical package (R Core Team, 2012) (described in section 4.2.6) into normal and 
elevated groups for host antibody response to Pso o 2 across a time course of primary 
infestation with P. ovis and subsequent treatment (TCT1). * All animals were treated 
with injectable endectocide (Dectomax, Pfizer Animal Health) at week 6 post-
infestation. 
Week 0 1 2 3 4 5 6* 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Normal 12 9 4 3 1 1 0 0 0 0 0 0 0 1 1 1 2 4 5 5 6 
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4.4 Discussion 
Two fragments of Hp, present in the sera of sheep infested with P. ovis at week 5 
post-infestation, were identified by MALDI analysis, following which Western blot 
analyses indicated a clear relationship between the band densities of Hp and SAA 
and lesion size; and the band densities of AGP over time during P. ovis infestation. 
Although the evaluation of AGP was preliminary, the results of Western blot analysis 
of AGP levels in the sera of P. ovis infested sheep indicated that this APP also had 
potential as a BM for sheep scab, although the differences between levels in pre-
infestation and post-infestation sera may not be sufficient. AGP has previously been 
suggested as a potential marker for chronic conditions in sheep due to its low levels 
of <0.1 mg/ml in healthy, control sheep compared with a peak level of 0.4 mg/ml in 
the chronic phase of the disease (Eckersall et al., 2007) and the continued production 
of AGP during the transition from acute to chronic phase in CLA in sheep (Eckersall 
et al., 2007). This difference in the profile of AGP in comparison to Hp and SAA has 
also been found in cattle where it was shown to be useful in discriminating between 
acute and chronic conditions (Horadagoda et al., 1999) and in goats showing an 
inflammatory response due to subcutaneous injection of turpentine oil (Gonzalez et 
al., 2008). As sheep scab has a chronic phase of disease, following the initial acute 
inflammatory stage (Van den Broek and Huntley, 2003a), further work should 
include evaluation of AGP as a potential marker for P. ovis infestation and, as there 
is now a commercially-available ovine AGP assay (Tridelta Development Ltd), 
quantitative validation of AGP could be performed.   
Following the promising preliminary Western blot analysis results for Hp and SAA, 
these APPs were quantified using commercially-available assays. This analyses 
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demonstrated that Hp and SAA increased in serum concentration as P. ovis 
infestation progressed showing statistically significant increases (p≤0.001) by week 
4-5 post-infestation, confirming previous studies showing increases in serum Hp and 
SAA levels during a range of inflammatory diseases in ruminants (Heegaard et al., 
2000, Petersen et al., 2004, Eckersall and Bell, 2010).  
Considering first the magnitude of the increases in Hp and SAA serum 
concentrations in response to P. ovis infestation, the results obtained agreed with a 
previous study investigating the response of Hp and SAA in Alpine ibex (Capra 
ibex) to a natural outbreak of S. scabiei infestation (Rahman et al., 2010). Over an 
experimental six week time course of infestation with P. ovis, Hp levels in sheep 
serum increased by more than 10-fold (up to a maximum level of 3.53±0.89 mg/ml)  
compared with pre-infestation levels, whereas SAA levels increased approximately 
350-fold in the same period to a maximum level of 284.75±71.14 µg/ml. These 
results demonstrated a similar trend to the levels of Hp and SAA measured in Alpine 
ibex infested with S. scabiei where mean Hp levels during infestation increased to 
3.72±0.65 mg/ml compared with healthy controls (0.58±0.09 mg/ml) and 130.7±0.16 
µg/ml and 8.7±0.13 µg/ml in infested and control animals respectively for SAA 
(Rahman et al., 2010). The increase in serum concentrations of Hp were of a similar 
magnitude in both studies, although the S. scabiei infestation was a natural outbreak 
whilst the P. ovis study used experimental infestations. This may be explained as the 
S. scabiei outbreak was well established and animals tested as positive for Sarcoptic 
mange exhibited clear clinical symptoms as determined by skin lesions (Rahman et 
al., 2010). Hp was concluded to be a minor APP in Alpine ibex by the authors due to 
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the smaller fold change increases when compared with SAA (Rahman et al., 2010) 
which may also be concluded when describing the increase in Hp levels in sheep 
responding to P. ovis infestation. Compared to the increase in Hp in both Alpine ibex 
and sheep during Sarcoptic and Psoroptic mange infestations respectively, the larger 
fold change increases measured for SAA would classify it as a major APP and the 
increase from baseline levels in many inflammatory diseases in ruminants has been 
reported as being generally higher for SAA than for Hp (Gabay and Kushner, 1999). 
The levels of Hp measured in this study prior to exposure to P. ovis ranged from 
0.29±0.06 to 0.61±0.19 mg/ml. APPs have been reported as being present at 
undetectable, to very low levels in the serum of healthy animals (Cray et al., 2009) 
but, recently, a study investigating the APP response to scrapie in sheep found large 
individual animal variation in Hp and SAA prior to clinical disease onset and 
suggested this may be due to underlying subclinical conditions (Meling et al., 2012). 
Previous work has indicated that Hp and SAA are non-specific in terms of 
inflammatory disease, injury or infection, but highly sensitive, effective markers of 
inflammation in ruminants (Petersen et al., 2004, Eckersall and Bell, 2010) 
suggesting that any inflammatory event in the animal may cause a temporary rise in 
Hp or SAA. In comparison to Hp prior to P. ovis infestation, serum SAA was 
measured at lower levels, for example, mean SAA concentration pre-infestation 
during the time course trial (TC1) was below the limits of detection compared with 
Hp which was 0.55±0.19mg/ml, suggesting that SAA may potentially be a more 
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Compared to a previous study which investigated the Hp, SAA and AGP response in 
sheep to infection with bacteria causing CLA, the magnitude of increased levels of 
Hp and SAA to P. ovis infestation was larger. For example, peak Hp and SAA in 
sheep with CLA was 1.65±0.21 mg/ml and 18.1±5.2 µg/ml, respectively. However, 
these peaks were achieved by day 7 post-infection, which is considered to be the 
point at which the acute disease becomes a chronic infection (Eckersall et al., 2007), 
whereas in the APP response to P. ovis infestation, sera Hp concentration was still 
increasing at the point of treatment or slaughter (6 weeks p.i) with peak Hp levels of 
3.53±0.64 mg/ml and peak SAA levels of 284.75±71.14 µg/ml. Hp and SAA have 
been previously reported to be measurable by day two post-infection in acute 
inflammatory diseases such as mastitis and metritis (Eckersall and Bell, 2010). In 
contrast to this, in the work presented herein, the proportion of animals with a P. 
ovis-induced elevation in APPs did not occur until weeks 4-5 post-infestation in the 
case of Hp (Table A4.1), or marginally earlier at week 4 for SAA (Table A4.3). A 
possible explanation for this is that disease initiation in sheep scab has been 
described as having a “lag phase” at the start of infestation and lasting for several 
weeks as the mites become established, after which the mite numbers increase 
exponentially (Bates, 1997). Lesion size development follows this pattern in mite 
numbers, as the increasing numbers of mites move out from the margins of the lesion 
onto healthy skin, as shown by the lesion size data recorded in the TCT1 trial (Figure 
4.1).  
In order to diagnose current disease status in sheep exposed to P. ovis, it is crucial 
that any potential BM declined rapidly upon treatment or disease resolution and this 
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study has demonstrated that Hp and SAA return to pre-infestation levels rapidly, with 
estimated half life of less than 3 days, illustrating the potential of including either or 
both of these APPs in an improved diagnostic test for sheep scab where current 
disease status is important. This is likely to be the case in Scotland due to the Sheep 
Scab 2010 Order, where confirmation of successful treatment is required before 
movement restrictions are removed from the affected farm. The legislation allows 
this to occur 16 days post-treatment when it is still extremely difficult to assess by 
clinical examination if any active infestation remains. However, if Hp and /or SAA 
were used as BMs of current disease status as demonstrated herein, they would have 
returned to baseline levels before 16 days indicating successful treatment.  
Comparing the two APPs quantified here, SAA responded more rapidly to treatment 
of P. ovis-infested sheep than Hp, which was also observed in a previous study 
investigating the response of these APPs to CLA in sheep (Eckersall et al., 2007). 
The SAA response to P. ovis infestation was of a higher magnitude (350-fold 
increase compared to 10-fold increase for Hp) and more rapid in its initiation and in 
its resolution (as determined by the half life) than Hp which suggests that if a single 
APP BM was to be used for indicating current disease status, SAA would be the 
more suitable. In addition, the SAA response was a more accurate discriminatory 
indicator of current disease status in the TCT1 study than Hp, due to the higher 
sensitivity obtained for the optimised cut-off values which were estimated using the 
data from the primary infestation and post-treatment element of the TCT1 trial. 
Applying these cut-off values and the test sensitivities and specificities obtained, the 
SAA test resulted in fewer false positives in negative flocks, when compared to Hp 
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(see Tables 4.2 and 4.4). Minimising false positive results is recognised as a critical 
factor for a sheep scab diagnostic assay due to the problems associated with treating 
non-infested sheep in terms of cost, time and selecting for resistance (Burgess et al., 
2012b). This is therefore an important consideration when comparing the accuracy of 
SAA and Hp as BMs to indicate current disease status during P. ovis infestation and 
after treatment. 
When Hp and SAA levels were investigated during other common field diseases and 
conditions of sheep, they were predominantly found to be at levels equivalent to the 
sheep scab negative values, remaining below 0.6 mg/ml for Hp and 22 µg/ml for 
SAA. Importantly, as GINs commonly affect sheep with no clinical symptoms, Hp 
and SAA levels were not elevated during the GIN experimental infections tested 
here. Although Hp was elevated in liver fluke and Johnes disease and SAA was 
elevated in lice infestation in this analysis, it is evident from the standard errors in 
these results that there was large between animal variation and therefore these 
recorded measurements may be due to other underlying conditions. Analysis of 
additional sera samples from sheep infected with these diseases would be required to 
confirm serum levels of Hp and SAA during these infections. In addition, when one 
of these APPs was high in a particular infection, the other was low. This illustrates 
the potential for using a signature of BMs rather than an individual BM as a method 
of combating lack of specificity of the APPs and will be further discussed in the 
general discussion in Chapter 5.  
Hp and SAA, although showing potential in validation using sera from animals 
infested experimentally with P. ovis, require further validation using field samples 
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from sheep scab positive and negative animals. The 12 clinically positive sheep from 
the natural sheep scab outbreak analysed herein, showed much lower mean Hp and 
SAA levels at the point of diagnosis (see Figures 4.11 and 4.12) and greater between 
animal variation than those from the experimentally infested sheep. This may be 
explained as the field outbreak at the point of clinical diagnosis was in its early 
stages with most of the diagnosed clinically positive animals having low clinical 
scores and small lesions (Burgess et al., 2012b). Further validation of Hp and SAA as 
potential BMs for current disease status in sheep will therefore be required using sera 
from sheep confirmed positive and negative in natural outbreaks. 
Compared to Hp and SAA levels, the development of ovine IgG to the mite antigen 
Pso o 2 provided earlier diagnosis of P. ovis infestation as shown in Table 4.6, where 
the majority of animals showed an elevated serum IgG response to Pso o 2 in the 
primary infestation by week 2 post-infestation. This agreed with previously reported 
results using this assay (Nunn et al., 2011).  As previously discussed, the problem 
with the existing assay in diagnosing current disease status after treatment or on 
disease resolution is due to the persistence of the antibody. When the decreases in Hp 
and SAA levels post-treatment were compared to those of the Pso o 2 specific IgG 
levels, it was evident that Hp and SAA levels gave a rapid indication of current 
disease status post-treatment, whereas the antibody response was still measurable 20 
weeks post-treatment. The differences in half life also illustrated the differing 
responses to treatment i.e. 56 days for the antibody response, compared to 2.3 days 
for Hp and 0.84 days for SAA. However, as serum Hp and SAA levels increase in 
many inflammatory diseases in ruminants, these APPs could not be used alone as 
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BMs for the diagnosis of sheep scab. The relative merits of the tests measuring IgG 
response compared with Hp/SAA levels indicate that a combined diagnostic test 
incorporating the IgG response to Pso o 2 along with Hp and/or SAA would result in 
a highly specific test which would indicate early infestation and current disease 
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4.5 Conclusions 
 Hp and SAA, two major APPs of ruminants, were evaluated as potential BMs 
for use in the diagnosis of active sheep scab infestation.  
 Immunoblotting indicated a positive relationship between Hp and SAA sera 
concentration and disease progression, as indicated by lesion size 
development.  
 Quantitative analysis showed that Hp and SAA levels in sheep sera increased 
following infestation with P. ovis but were not statistically significantly until 
4 weeks post-infestation. 
 SAA was the more discriminatory marker, with lower pre-infestation levels 
and higher sensitivity at the optimum cut-off values than Hp. 
 After treatment of infested sheep with an acaricide, Hp and SAA levels in 
sheep sera declined rapidly, with a half-life of less than 3 days.  
 In comparison, the half life of Pso o 2-specific IgG in sheep sera following 
acaricidal treatment was estimated as being 56 days.  
 Further evaluation of Hp and SAA as BMs indicating current disease status 
during sheep scab outbreaks is required using extensive field positive and 
negative samples to optimise the assays.  
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Chapter 5: General Discussion 
Sheep scab, a disease caused by the ectoparasitic mite P. ovis, is endemic in the 
national flock and is a major welfare and production issue for UK sheep farmers 
(Van den Broek and Huntley, 2003a) and worldwide. The problems associated with 
disease control have recently been tackled in Scotland through the Sheep Scab 
(Scotland) Order 2010 in which the disease was made notifiable, and therefore 
accurate diagnosis of active infestation is crucial. As existing methods of diagnosis 
are unreliable, particularly in early infestation where the disease can be sub-clinical 
(Bates, 1999c), a new diagnostic assay based on the host antibody response to a mite 
antigen, Pso o 2, has been developed. This assay is highly sensitive and specific and 
can detect disease from two weeks post-infestation (Nunn et al., 2011). However, as 
the Pso o 2-specific antibody is detectable in serum for several months after 
successful treatment (Burgess et al., 2012b), this test does not indicate current 
disease status post-treatment or following active disease resolution.  
This thesis aimed to address this issue by identifying and evaluating potential BMs 
for sheep scab which indicate current disease status by increasing in serum 
concentration during early infestation, from low pre-infestation levels, and returning 
to low levels rapidly following successful treatment. Overall, 178 potential BMs 
were identified, 13 preliminarily evaluated and three selected for further quantitative 
evaluation.  
To enable selection of the most suitable BMs, a bioinformatic analysis was initially 
performed which resulted in the identification of a list of 178 genes differentially 
expressed in circulating leukocytes across a time course of P. ovis infestation 
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(Burgess et al., 2012a) ranked according to set criteria. It is widely recognised that 
the approach used in this study, using transcriptomics to anticipate changes in plasma 
proteins levels between health and disease states has limitations, but as ruminant - 
specific protein arrays and the technology to accurately analyse low abundance 
proteins in sera are not yet available, genomic approaches are currently commonly 
adopted (Kulasingam et al., 2010).  
A recent study has approached the search for potential diagnostic BMs for bovine 
tuberculosis (bTb) using similar methods i.e. transcriptional gene profiling and 
bioinformatic analysis of microarray results (Aranday-Cortes et al., 2012). This bTb 
study initially used a murine bTb model to identify promising candidates post-
infection from microarray analysis of RNA from in vitro-stimulated splenocytes and 
lung cells, to identify possible BM candidates and guide the selection of such 
markers in cattle. Genes with the largest fold-change increase between healthy and 
Mycobacterium bovis- infected mice were selected and their bovine orthologues were 
evaluated by real-time PCR (qPCR) using RNA extracted from peripheral blood 
mononuclear cells (PBMCs) from uninfected and naturally infected cattle. Five out 
of the 14 up-regulated genes based on the murine transcriptomic analysis were also 
significantly up-regulated in bovine PBMCs during bTb infection and included 
interferon gamma, interleukin-22, interleukin-17A and chemokine ligand 9 and 10 
(Aranday-Cortes et al., 2012). BMs for bTb, defined in the murine system, have 
therefore been shown to guide selection of BMs in cattle, providing a more cost 
effective model with a wider variety of available immunological reagents available 
compared with a ruminant model. Unfortunately, there is no such available model for 
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sheep scab as, although the rabbit mite, P. cuniculi, is thought to be a rabbit-adapted 
con-specific variant of P. ovis (Pegler et al., 2005), the differences in pathology 
between P. ovis / P. cuniculi in rabbits compared with sheep (Rafferty and Gray, 
1987) indicate the rabbit would not be a suitable model for sheep scab. Following the 
genomic analysis in the bTb study, confirmation will be required that there is 
increased production of the identified potential BMs at the protein level to enable 
developing this research into a practical antibody-based diagnostic test for bTb 
(Aranday-Cortes et al., 2012). 
In applied BM research, the lack of analyte-specific reagents, essential for BM 
validation using techniques such as ELISA, was the major reason suggested for the 
bottleneck from BM discovery to clinical translation (Pepe et al., 2008). This was 
also an issue for the preliminary evaluation of the ranked list of potential BMs for 
sheep scab after the bioinformatic analysis, as there were no commercially-available 
antibodies specific to the ovine proteins for any of the highly ranked BMs at the time 
of testing. As noted previously, this is a recognised problem in veterinary 
immunology research which is now being addressed (Entrican et al., 2009) and 
because of work such as the Veterinary Immunology Committee Toolkit (Entrican 
and Lunney, 2012) recent increases in veterinary species specific assays, such as 
diagnostic applications of major APP testing in companion animals, are being 
developed (Kjelgaard-Hansen and Jacobsen, 2011). In the future this work should 
also lead to further assays being commercialised for routine health and welfare tests 
in ruminant veterinary medicine and, as such, the list of potential BMs for sheep scab 
produced in Chapter 2 is a useful resource for future BM evaluation.  
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The problem of a lack of species specific analytes in ruminant immunology was 
illustrated by the absence of, or weak, antibody/antigen recognition obtained in many 
of the Western blot analysis results (Chapter 2), even when relatively high homology 
was found between the ovine/bovine and human amino acid sequences for the 
protein under investigation, such as that seen with collectin 11 and oxytocin (Chapter 
2, Table 2.5). Despite these problems, the results obtained in the preliminary 
evaluation of C4BPB suggested that it was a potential BM for P. ovis infestation in 
sheep and as such warranted further investigation.  
The ovine C4BPB gene was sequenced (Chapter 3) and a recombinant protein was 
expressed successfully in a bacterial system. The recombinant protein obtained was 
insoluble in an aqueous solution suggesting it would be advantageous to use a 
mammalian system for future expression of ovine C4BPB, as the method of choice 
for expressing sheep proteins, e.g. see Demain and Vaishnav, 2009. Optimisation of 
the ELISA developed in Chapter 3 to quantify C4BPB in sheep serum resulted in a 
sandwich ELISA which, when used to analyse C4BPB concentrations in ovine sera 
showed promising preliminary results. C4BPB levels in the sera of sheep prior to 
infestation with P. ovis were low with statistically significant increases in mean 
OD₄₅₀ by three weeks post-infestation. Although this was one week later than the 
measurable increase in host antibody response to Pso o 2 (Nunn et al., 2011), the 
decrease in C4BPB level in response to acaricide treatment was rapid, with 
significantly decreased OD₄₅₀ values by day three post-treatment and serum C4BPB 
levels halved by one week post-treatment, illustrating the potential of C4BPB to 
indicate current disease status. In comparison, the decrease in host antibody levels to 
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Pso o 2, as measured by half-life, was 56 days. It was concluded that further 
validation of C4BPB as a BM would be required, particularly using samples obtained 
from natural outbreaks.  
One issue with the sandwich ELISA developed in Chapter 3 was that it included an 
expensive, anti-human mC4BPB capture antibody, which, if used for the high 
numbers of samples required to validate a diagnostic test, would be cost prohibitive. 
Further work would therefore be required to develop an alternative capture antibody, 
possibly by production of a mouse anti-ovine C4BPB monoclonal antibody. This 
may also improve the assay as the capture antibody would be a species specific one, 
potentially leading to a stronger signal. 
 
An alternative or additional approach is to use existing BM assays, and, in Chapter 4 
evaluation of the major ruminant APPs, SAA and Hp was performed using 
commercially available diagnostic assays which confirmed the potential of SAA and 
Hp as BMs for current disease status in sheep scab diagnosis. SAA serum 
concentration increased marginally earlier, by a higher magnitude and from lower 
pre-infestation levels than Hp and was the more accurate, discriminatory indicator of 
current disease status in the experimental trial studied. The serum samples from 
clinically positive sheep in a natural outbreak of sheep scab, which were analysed for 
Hp and SAA concentration, produced lower levels of these APPs compared to the 
experimental trial samples tested, which may have been a result of the natural 
outbreak being in early stages (as most of the sheep diagnosed as clinically positive 
had small lesions).  
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It is an important consideration that because of differences in the epidemiology of 
natural sheep scab outbreaks compared to experimental trials that the size and timing 
of the APP response will vary between them, mainly due to the lower mite numbers 
initiating the infestation in a natural outbreak and the longer time for the infestation 
to spread through a flock in the field.  
The infestation of sheep by P. ovis has been described as following a characteristic 
cycle of ‘lag’, ‘growth’ and ‘recovery’ stages reflecting mite numbers and lesion size 
development (Bates, 1997) but a simulation model analysing the population 
dynamics of P. ovis infestation in naturally infested and one experimentally infested 
sheep suggested that the observed pattern of mite numbers and lesion growth was a 
result of an exponential increase in numbers with the initial 20 days of the 
exponential growth period equating to the previously described ‘lag’ phase (Wall et 
al., 1999). As the number of mites present at any time point during the infestation in 
its exponential growth phase depended on the number of mites starting the 
infestation (Wall et al., 1999), infestation dynamics are likely to vary between natural 
outbreaks and experimental trials and it is therefore crucial that further field-derived 
serum samples are analysed to optimise Hp and SAA cut-off values if they are to be 
used to assess current disease status in natural outbreaks of sheep scab.  
This can be illustrated if the cut-off values, to differentiate between ‘normal’ and 
‘elevated’ animals for APPs estimated on the experimental trial data are used on the 
results from the natural outbreak. For example, the cut-off value for Hp was 1.260 
mg/ml and for SAA was 29.5 µg/ml, whereas the mean Hp level in the field positives 
was 0.776 mg/ml and for SAA was 10.686 µg/ml. The cut-off values used in the 
statistical analysis of the TCT1 trial results were set at a high level to minimise false 
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positive (FP) results. Previously it has been suggested that for an accurate diagnostic 
test for sheep scab high specificity is required as it is essential to minimise FP results 
and thereby eliminate unnecessary treatments as, for example, has been obtained in 
the current diagnostic ELISA (Burgess et al., 2012b). Reducing the cut-off values in 
the APP analysis to take the expected lower Hp and SAA levels in the serum of 
sheep naturally infested into account, will therefore reduce the accuracy of the test 
(Obuchowski, 2003).  
It is evident that many more clinically positive and negative samples from natural 
outbreaks will need to be analysed so that optimal cut-off values for Hp and SAA can 
be set using ROC curves. These are plots of test sensitivity versus 1- specificity for 
all possible cut-off points, where the area under the ROC curve (AUC) is recognised 
as being a reliable measure of test accuracy as it does not depend on disease 
prevalence (Obuchowski, 2003). This is an important point when considering sheep 
scab diagnosis, as disease prevalence has previously been shown to be highly 
variable depending on factors such as sheep density, elevation, temperature and 
access to common grazing (Bisdorff et al., 2006) and has been observed to be 
persistent on particular farms or geographic areas suggesting likely management or 
environmental risk factors associated with these farms, allowing the development of 
risk models directing effective management towards sheep scab control (Rose et al., 
2009). This model has been further refined as results have suggested upland and 
lowland sheep farms should be approached as two distinct epidemiological systems 
due to access to common grazing, and therefore direct contact with neighbouring 
sheep, in the former (Rose and Wall, 2012). With the evident differences in sheep 
scab epidemiology and disease prevalence depending on geographical area and sheep 
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farming systems, it will be important to incorporate ROC curve analysis into further 
BM test validation, and this should be carried out with C4BPB validation as well as 
for Hp and SAA. A solution to estimating cut-off values for use in the many different 
scenarios the BM test could be applied in, may be to have different cut-off values 
calculated depending on the situation for which the test is to be used in. For example, 
where some sheep are obviously pruritic in a flock the cut-off value could be 
decreased to increase the chance of getting all positives included (even sub-clinical 
animals). This would also be the case in a quarantine or eradication campaign, 
whereas in contrast to this, for random testing in a livestock market the cut-off value 
could be increased to increase the accuracy of the test as false positives would be 
highly undesirable in this situation.  
 
Another method of increasing test accuracy may be to use a signature of BMs in the 
assay, rather than a single protein assay. This has previously been suggested due to 
the variation in response obtained from different APPs, particularly with reference to 
acute and chronic phases of inflammatory disease, as the use of a panel or signature 
of BMs may provide more powerful diagnostic information and increase assay 
specificity, compared to a single APP assay (Eckersall et al., 2007). Future work 
validating the use of a BM assay for P. ovis infestation should include AGP, if it was 
quantitatively evaluated as a potential BM, as it has a previously suggested role as a 
potential BM of chronic inflammatory conditions in sheep (Eckersall et al., 2007) 
The idea of using a signature of APPs as BMs for disease diagnosis has been 
practiced in human medicine by their inclusion as indices in general health profiles 
for several decades (Eckersall and Bell, 2010, Gruys et al., 2006).  As these indices 
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have previously been shown to increase the sensitivity and specificity of APPs as 
clinical markers, a signature of positive APPs, such as Hp and SAA, could be 
incorporated with a negative APP, e.g. albumin, if validated successfully, with the 
aim of combining them into a multiplex BM test to assess if the diagnostic capability 
of the test in indicating current disease status in sheep scab outbreaks was improved.  
The promising results obtained using C4BPB as a potential BM for sheep scab 
indicates that, if a signature of BMs increased the sensitivity and specificity of the 
diagnostic test, a combination of C4BPB, SAA and/or Hp should be investigated. 
Preliminary results, using the ELISA developed to detect C4BPB in sheep sera, 
demonstrated that serum C4BPB levels are elevated earlier than SAA or Hp during 
P. ovis infestation and decrease as rapidly as SAA following treatment. Using all 
three evaluated BMs would increase the specificity of the assay as, for example, Hp 
and SAA reacted to different field infections in sheep but did not react to the same 
infections; C4BPB increased in serum concentration earlier post-infestation than 
either Hp or SAA and all three decreased quickly enough post-treatment to be useful 
in the context of the Sheep Scab (Scotland) Order 2010. Positive diagnosis of sheep 
scab on Scottish farms results in movement restrictions for 16 days post-treatment 
until the sheep can be confirmed as having been successfully treated. If the BM assay 
was used in this situation, movement restrictions could potentially be shortened as 
sheep may be confirmed as successfully treated three days post-treatment.  
 
Finally, the potential of the above signature of BMs should be assessed in 
combination with the existing Pso o 2 ELISA. As previously discussed, this ELISA 
provides a highly sensitive and specific diagnosis of early P. ovis infestation [prior to 
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obvious clinical symptoms (Burgess et al., 2012b)] and is currently being 
commercialised as a diagnostic ELISA, with further development ongoing to 
investigate possible production of a lateral flow assay (LFA) for pen-side diagnosis. 
To solve the problem of the existing assay in its inability to diagnose current disease 
status post-treatment, the BMs evaluated in this study could be multiplexed with the 
Pso o 2 ELISA, providing an improved diagnostic test which would provide a very 
useful tool for the eradication or control of sheep scab.  
A pen-side test for the early diagnosis of sheep scab would be of particular benefit to 
the sheep industry; as such a test is likely to be useful on farm to confirm active 
infestation or successful treatment, or at livestock markets and agricultural shows. 
ELISAs enable highly sensitive, quantitative and multiplexed measurements but may 
require multiple steps (Lequin, 2005) and costly laboratory equipment so are 
therefore unsuitable for use in the field. In contrast, LFAs are ideal for pen-side 
testing as they are relatively inexpensive, portable and give rapid results without the 
need for a laboratory. To date however, they are less sensitive than ELISA and are 
unable to provide quantitative measurements and are therefore used in situations 
requiring a single YES/NO result such as human pregnancy tests (Posthuma-Trumpie 
et al., 2009). Recent advances in microfluidics technology have potential to offer 
rapid, reliable detection of multiple analytes from a single biological sample using 
portable, low-cost devices (Yager et al., 2006, Whitesides, 2006). The main 
advantage of the microfluidic chip is its ability to perform diagnostic processes 
without the need for skilled operators or a well equipped laboratory and, as such, 
devices have now been developed to perform multiplexed bioassays using low-cost 
paper materials for inexpensive point of care analysis in human medicine (Martinez 
 
Chapter 5: General discussion  
191 
et al., 2007). This development may have potential for use in developing countries 
where ease of storage (no refrigeration required), ease of use and low cost are highly 
advantageous. Parallels may be drawn here to the UK sheep industry where cost 
margins are tight, particularly in the upland sector, therefore lower costs are 
beneficial, as are ease of use and storage for tests which are aimed to be carried out 
pen-side, in a variety of difficult conditions. 
As current methods for testing APP levels are limited to laboratory-based tests which 
are costly and require separate tests for each factor, the development of a paper-
based microfluidics platform for pen-side testing would be highly beneficial. The 
simultaneous assessment of  BMs combined with the measurement of antibody levels 
specific for mite Pso o 2 on a microfluidics platform would provide an accurate, 
rapid, cost-effective and early diagnostic test indicating current disease status, which 
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A2.1 Buffer Preparation  
A2.1.1 MES buffer for electrophoresis 
A litre of running buffer was made up by mixing 50ml NuPage MES SDS Running 
Buffer (20X) (Invitrogen) with 950ml ultrapure (UP) water. 
A2.1.2 Wash buffer and antibody diluent  
A litre of wash buffer/antibody diluent was obtained by mixing 100ml 10xPBS with 















Table A2.1: Secondary antibodies used for the evaluation of potential BMs by 
Western blot analysis, including optimal concentrations used as determined by 
titration blots. All secondary antibodies were HRP conjugated except *where no 
secondary antibody was required as the primary antibody was HRP conjugated. 




Pig anti-rabbit Dako P0399 1:2000 
Calgranulin (SA100A9) 
Pig anti-rabbit Dako P0399 1:2000 
Calgranulin (SA100A8) 
Rabbit anti-mouse Dako P0260 1:1000 
Complement 4 binding 
protein (C4BPB) 
Rabbit anti-mouse Dako P0260 1:1000 
Tumour necrosis factor 
(TNF-α) 
Streptavidin Dako P0397 1:2000 
Oxytocin (OXT) 
Goat anti-guinea pig Abcam ab6908 1:2000 
Potassium voltage gated 
channel (KNCQ1) 
Chicken anti-rabbit Abcam ab6829 1:3000 
Solute carrier family 7 
(SCL7A11) 
No secondary required*   
Collectin11  (COLEC11) 
Pig anti-rabbit Dako P0399 1:2000 
Tenascin C (TNC) 













1. SPP: Human (accession no P10451) and ovine (Q9XSY9) 
 
MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQNA  Human   
MRIAVICFCLLGIASALPVKPTSSGSSEEKQLNNKYPDAVATWLKPDPSQKQTFLEPQNS  Ovine            
*************:.*:*** :.********* ***********:*******.:* ***: 
 
VSSEETNDFKQETLPSKSNESHDHMDDMDDEDDDDHVDSQDSIDSNDSDDVDDTDDSHQS 
VSSEETDDNKQNTLPSKSNESPEQTDDLDDDDENS-----QEVNSDDSDDAETPDDSDHS                     




NESHHSDESDE--ADFPTDIPTIAVFTPPFPTESTNDGRGDSVAYGLKSKSKKFRRSNVE                     
:**********  :*****:*:  **** .** .* *******.***:******** ::: 
 
YPDATDEDITSHMESEELNGAYKAIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSH 
SPDATEEDFTSHIESEEMHDAPKKTSQ----------------------LTDHSEETNSD                     
****:**:***:****:. * *                          * *:* **.*. 
 
KQSRLYKRKANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKF 
ELPKELTPKA-KEESKHSNRIESQENSKLSQEFH-----SLEDKLDLDHK-SEEDKRLKI                     















* **.:**:***:****:*: **:: *:*     
 
 




*  ****:* .****** ******:*** *** * ***:**:*:* *****::*** .*: 
 
HIMEDLDTNADKQLSFEEFIMLMARLTWASHEKMHEG-DEGPGHHHKPGLGEGTP----- 
EIMEDLDTNVDKQLSFEEFIMLVARLTVASHEEMHNTAPPGQGHRHGPGYGKGGSGSCSG                      


























                 :******:**. ****  ****.*.: * **:* *:**** **                                  
 
CLEDHTWAPPFPICKSRDCDPPGNPVHGYFEGNNFTLGSTISYYCEDRYYLVGVQEQQCV 
CRENHTRVTHSPVSKSRDCGPPETPTHGYFEGRDFKSGSTITYYCEARYRLVGTQHQQCI                      
* *:** .   *:.***** ** .*.******.:*. ****:**** ** ***.*.***: 
 
DGEWSSALPVCKLIQEAPKPE---CEKALLAFQESKNLCEAMENFMQQLKESGMTMEELK 
DGEWTSAPPICELIQEAPKPAELELEKAFLAFQESKELCKAIKKFTQRLKKSDLTMEKVK                      




**** ***:****:*  
 
 







EEQSPAGPSFNRPLVQTLRSSSQASNNKPVAHVVANISAPGQLRWGDSYANALMANGVEL                     
















*** ****************************. *****.***************.***. 
 
EELGCFVGTAEALRCQEENYLPSPCQSGQKACGSGGRCAVLGLCCSPDGCHADPACDAEA 
DELGCFVGTAEALRCREENYLPSPCQSGQKPCGSGGRCAAAGICCSPDGCHADPACDPEA                     
















                                                                                    
 
PAPPASPAAPAAPPVASDLGPRPPVSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGW  




                                       *********************                       
 
RSKYVGLWGRLRFARKPISIIDLIVVVASMVVLCVGSKGQVFATSAIRGIRFLQILRMLH 












QKHFNRQIPAAASLIQTAWRCYAAENPDSSTWKIYVRKPSRNHALLSPSPKPKKSAMVKK                       
***********************************:**  *.*:***********.:*** 
 
KKFKLDKDNGVTPGEKMLTVPHITCDPPE-ERRLDHFSVDGYDSSVRKSPTLLEVSMPHF 
KKFKLDKDNGVSPGEKALVVPHITCDPVAEDRRPEPFSVDGYDSTGEEPPLTVGVGVGVG                       
***********:**** *.********   :** : ********: .: *  : *.:    
 
MRTNSFAEDLDLEGETLLTPITHISQLREHHRATIKVIRRMQYFVAKKKFQQARKPYDVR  




                                                                                    
TQLDQRLALITDMLHQLLSLHGGSTPGSGGPPREGGAHITQPCGSGGSVDPELFLPSNTL  
------------------------------------------------------------ 





















8. SLC7A11: Human (Q9UPY5) and bovine fragment (B6D7N9) 
                                         
MVRKPVVSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIIIGTIIGA Human 




                                                                                    
 
LPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLITAVGITVVMVLN  




                                                                                    
YGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTTINAEELLLS  
------------------------------------------------------------ 




---------------------FVALSCFGSMNGGVFAVSRLFYVASREGHLPEILSMIHI                      
**************************************:********************. 
                        
RKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYLRYKCPDMHRP  
------------------------------------------------------------  
                                                                               
FKVPLFIPALFSFTCLFMVALSLYSDPFSTGIGFVITLTGVPAYYLFIIWDKKPRWFRIM  




                         
 
 
9. Colec11: Human (Q9BWP8) and bovine (Q17QH6) 
                  
MRGNLALVGVLISLAFLSLLPSGHPQPAGDDACSVQILVPGLKGDAGEKGDKGAPGRPGR Human 
MKR----ALALMGLAFLCVLRAGAAQQTVDDACSVQILVPGLKGDAGEKGDKGAPGRPGR Bovine 

























10. TNC: Human (P24821) and bovine (A0JN60) 
 
MGAMTQLLAGVFLAFLALATEGGVLKKVIRHKRQSGVNATLPEENQPVVFNHVYNIKLPV Human 
MGVMTRLWAGLFLALLALPAEGGVLKKVIRHKQQSGMNVTLPEENQPVVFNHVYNIKLPV Bovine  
**.**:* **:***:*** :************:***:*.********************* 
 
GSQCSVDLESASGEKDLAPPSEPSESFQEHTVDGENQIVFTHRINIPRRACGCAAAPDVK  
GSQCSVDLESASGEKDLAAPSEPRESFQEHTVDGENQIVFTHRINIPRRACGCAAAPDVK                       
****************** **** ************************************ 
 
ELLSRLEELENLVSSLREQCTAGAGCCLQPATGRLDTRPFCSGRGNFSTEGCGCVCEPGW  
ELLSRLEELENLVSSLREQCTSGAGCCLQSAEGRVDTRPFCSGRGNFSTEGCGCVCEPGW                       







GYSGLDCSQETCPVPCSEEHGRCVDGRCVCQEGFAGEDCREPLCLHNCHGRGRCVENECV                       
**:* ***:* ********** **** ***::****:**.:****.**: ********** 
 
CDEGFTGEDCSELICPNDCFDRGRCINGTCYCEEGFTGEDCGKPTCPHACHTQGRCEEGQ  
CDEGFTGDDCGELVCPNDCFDRGRCLNGTCSCDEGFTGEDCGQLACPHACHGHGRCDEGQ                     
*******:**.**:***********:**** *:*********: :****** :***:*** 
 
CVCDEGFAGVDCSEKRCPADCHNRGRCVDGRCECDDGFTGADCGELKCPNGCSGHGRCVN  
CVCDEGFAGPDCSERRCPSDCHERGRCVDGRCECNDGFTGADCGELQCPRDCSGHGRCVN                       
********* ****:***:***:***********:***********:**. ********* 
 
GQCVCDEGYTGEDCSQLRCPNDCHSRGRCVEGKCVCEQGFKGYDCSDMSCPNDCHQHGRC  
GQCVCDEGYTGEDCGQRQCPSDCHGRGRCVDGLCECQPGFQGDDCGEMSCPHDCHQHGRC                       
**************.* :**.***.*****:* * *: **:* **.:****.******** 
 
VNGMCVCDDGYTGEDCRDRQCPRDCSNRGLCVDGQCVCEDGFTGPDCAELSCPNDCHGQG  
VNGMCVCDDAYTGEDCRELRCPGDCSQRGRCVDGRCVCEDGFAGPDCADLACPGNCHGRG                       
*********.*******: :** ***:** ****:*******:*****:*:** :***:* 
 
RCVNGQCVCHEGFMGKDCKEQRCPSDCHGQGRCVDGQCICHEGFTGLDCGQHSCPSDCNN  
RCVDGQCVCLEGFTGPDCAQRRCPGDCHGQGRCVDGQCVCHEGFTGPDCAQRSCPNDCSN                       







EDGLEMQFRVPGDQTSATIRELEPGVEYFIRVFAILENKKSIPVSARVATYLPTPEGLKF                       
* **************: *:*********************************:****** 
 
KSIKETSVEVEWDPLDIAFETWEIIFRNMNKEDEGEITKSLRRPETSYRQTGLAPGQEYE  




ISLHIVKNNTRGPGLKRVTTTRLDAPSQIEVKDVTDTTALITWSKPLAEIDSIELMYGIK                       











RISQTDNSITLEWRNVKAAADSYRIKYAPISGGDHAEVEVPRSQQTTTRTTLTGLRPGTE                       
*:************* *** ******************:**:***:**:*********** 
 
YGIGVSAVKEDKESNPATINAATELDTPKDLQVSETAETSLTLLWKTPLAKFDRYRLNYS  
YGIGVSAVKGDKESDPATINAATELDTPKDLRISDPTETSLTLVWQTPVAKFDRYRLNYS                       
********* ****:****************::*: :******:*:**:*********** 
 
LPTGQWVGVQLPRNTTSYVLRGLEPGQEYNVLLTAEKGRHKSKPARVKASTEQAPELENL  
LPSGQPKEVQLTRDTTSFVLRGLEPGQEYSILLTAEKGRHKSKPARVQASTDHTPELGNL                       
**:**   *** *:***:***********.:****************:***:::*** ** 
 
TVTEVGWDGLRLNWTAADQAYEHFIIQVQEANKVEAARNLTVPGSLRAVDIPGLKAATPY  





 *:*:***:**************:**.****.*:****:***********.** *:**** 
 
EADTVEAAQNLTVPGGLRSTDLPGLKAATHYTITIRGVTQDFSTTPLSVEVLTEEVPDMG  
EPGKEEAAQNLTVPGGLRSVDLPGLKAATHYSITIRGVTRDFSTAPHSVE----------                       




                                                                                    
PYTVTLHGEVRGHSTRPLAVEVVTEDLPQLGDLAVSEVGWDGLRLNWTAADNAYEHFVIQ  
------------------------------------------------------------ 
                                                                                  
VQEVNKVEAAQNLTLPGSLRAVDIPGLEAATPYRVSIYGVIRGYRTPVLSAEASTAKEPE  
------------------------------------------------------------ 
                                                                                    
IGNLNVSDITPESFNLSWMATDGIFETFTIEIIDSNRLLETVEYNISGAERTAHISGLPP  
------------------------------------------------------------ 
                                                                                    
STDFIVYLSGLAPSIRTKTISATATTEALPLLENLTISDINPYGFTVSWMASENAFDSFL  
------------------------------------------------------------ 
                                                                                    
VTVVDSGKLLDPQEFTLSGTQRKLELRGLITGIGYEVMVSGFTQGHQTKPLRAEIVTEAE  
------------------------------------------------------------ 
                                                                                     
PEVDNLLVSDATPDGFRLSWTADEGVFDNFVLKIRDTKKQSEPLEITLLAPERTRDITGL  
------------------------------------------------------------ 
                                                                                    
REATEYEIELYGISKGRRSQTVSAIATTAMGSPKEVIFSDITENSATVSWRAPTAQVESF  
-------------------------ALTAMGSPKEIIFSDITENAASVSWMAPTTQVESF  
                         * ********:********:*:*** ***:***** 
 
RITYVPITGGTPSMVTVDGTKTQTRLVKLIPGVEYLVSIIAMKGFEESEPVSGSFTTALD  




GPSSLVTANITDSEALAMWQPAIAPVDNYVISYTGERVPEITRTVSGNTVEYALTNLEPA                       







YESVDGTIKEVVLDPDTTSYSLTDLSPSTYYTARIQALNGTLRSKTVKTIFTTSGVLYRF                       





PRDCSQAMLNGDTTSGVYTIYLNNDKTQKQEVFCDMTSDGGGWIVFLRRKNGREDFYRNW                       
*:**************:****** **::  ************************:**:** 
 
KAYAAGFGDRREEFWLGLDNLNKITAQGQYELRVDLRDHGETAFAVYDKFSVGDAKTRYK  














Figure A2.1: Amino acid sequence alignments of ovine (or if not available, bovine) 
with human sequences. Sequences obtained from UniProt (EMBL-EBI) and aligned 
using Clustal O (1.1.0). Asterisks represent identity, colons represent high similarity, 





Figure A2.2: The complement cascade illustrating the role of C4BP in the classical 





Table A3.1: Primer names and sequences used in the sequencing and cloning of 
C4BPB. InFusion primers: red sequence is from the pET22b(+) vector and black 
from ovine C4BPB sequence. 
 







Gene specific primer 
5’ RACE 
GAAAGGCAAGAAGGGCCTTCTCCAACG 
Nested forward RACE 
primer 
TGTCTGCAAAAGCAGAGACTGT 
Nested reverse RACE 
primer 
TCTTGGATCAACTCACAGATGG 









pET SUMO forward 
primer 
TCAGATGTGGGCCACTGTCCT 













Table A3.2: Optimal assay component concentrations as determined by 
checkerboard ELISA 
Assay component Function Optimal conc./dilution 
mC4BPB antibody Coating antibody 1:100 
Soya milk Blocking buffer 1% 
Sheep sera infested and 
control 
Antigen Undiluted 
Rabbit anti-sheep C4BPB Detection antibody 1:100 
Mouse anti-rabbit 
biotinylated 
Secondary antibody 1:100 
Streptavidin HRP Conjugate 1:1000 
 
A3.1 General procedures and solutions 
Included in this section are all the general procedures and solutions used in chapter 3 
A3.1.1 Tris Acetic Acid and EDTA buffer (TAE) 
TAE (pH7.4) made up as 50X by dissolving 242g Tris (Sigma) in 500ml H₂O, 100ml 
0.5M Na₂EDTA (pH 8.0) and 57.1ml glacial acetic acid. Volume was adjusted to 1L 
with UP H₂O and stored at room temperature. 1x TAE was made by adding 20ml of 
the 50X TAE stock solution to 1L UP H₂O 
A3.1.2 1% agarose gel 
Agarose (Promega) (1g) was added to 100ml 1xTAE (diluted from 50x TAE stock 
buffers with UP H₂O) and melted in a microwave for 1minute. 10µl Gel Red Nucleic 
Acid Stain (Biotium) was added.  
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The gel was loaded using 5µl DNA MW Marker X (Roche) in lane 1 and 3µl of each 
sample mixed with 1µl Gel Pilot 5x loading dye (Qiagen). Gels were run in a 
Horizon58 cell (Thistle Scientific) on a ThermoEC (EC105) at 70V for 45 minutes 
and visualised in a AlphaImager™ 2200 (Alpha Innotech) under UV light. 
A3.1.3 LB Agar Plates for JM109 transformed cells 
LB agar plates were prepared using a solution of 50ml LB agar (MRI stock), 200µl 
ampicillin (25mg/ml) (Agilent Technologies), 80µl XGal (5-bromo-4-chloro-indolyl-
β-D-galactopyranoside) (50mg/ml) (Promega) and 25µl IPTG (Isopropyl β-D-1-
thiogalactopyranoside) (1M) (Promega). 
A3.1.4 Binding buffer (20mM sodium phosphate, 0.5M NaCl, 20mM imidazole, 
pH 7.4) 
20ml 0.1M sodium phosphate monobasic was diluted with 80ml UP H₂O. 20ml 0.1M 
sodium phosphate dibasic was diluted with 80ml UP H₂O. 19ml sodium phosphate 
monobasic was mixed with 81ml sodium phosphate dibasic and the pH checked and 
altered if necessary to 7.4. Finally, 2.9g NaCl and 0.136g imidazole (Sigma Aldrich) 
was added and the buffer was stored at 4ºC. 
A3.1.5 Binding buffer with 8M urea (for insoluble proteins) 
8M urea was added to a stock of binding buffer (as described in section A3.1.4) 
A3.1.6 Elution buffers for protein purification column 
Elution buffers were based on 20mM sodium phosphate, 0.5M NaCl pH 7.4, 
therefore the recipe for binding buffer (A3.1.4) was followed until this point. Elution 
buffer 1 (50mM): 0.34g imidazole (Sigma Aldrich) was added to 100ml 20mM 
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sodium phosphate, 0.5M NaCl. Elution buffer 2 (200mM):1.36g imidazole was 
added to 100ml 20mM sodium phosphate, 0.5M NaCl. Elution buffer 3 (350mM): 
2.38g imidazole was added to 100ml 20mM sodium phosphate, 0.5M NaCl. Elution 
buffer 4 (500mM): 3.4g imidazole was added to 100ml 20mM sodium phosphate, 
0.5M NaCl. 
A3.1.7 Dialysis buffer 
200ml 0.1M sodium phosphate monobasic was diluted with 800ml H₂O to make 
20mM solution A and 200ml 0.1M sodium phosphate dibasic was diluted with 800ml 
H₂O to make 20mM solution B. 190ml solution A was added to 810ml solution B 
and pH adjusted to 7.4. 29g NaCl and 120g urea was added and pH checked and 
adjusted if necessary. 
A3.1.8 Buffers for Protein G column immuno-purification  
1. Elution buffer = 0.1M Glycine-HCl (pH 2.7): 7.51g glycine (Fisher Scientific) 
was dissolved in 800ml UP H₂O and pH adjusted to 2.7 by addition of 1M HCl and 
solution topped up to 1L by addition of  UP H₂O. 
2. 1M Tris-HCl pH 9: 121.14g Trizma Base (Sigma Aldrich) was added to 800ml 
UP H₂O and the pH adjusted to 9 by addition of 1M HCl and solution topped up to 






A3.1.9 HiTrap Affinity Column Wash Buffers 
1. Wash buffer A: 0.5M Ethanolamine, 0.5M NaCl pH 8.3: 3ml ethanolamine was 
added to 80ml UP H₂O and 4.87g NaCl. The pH was adjusted to 8.3 and the solution 
topped up to 1L with UP H₂O. 
2. Wash buffer B: 0.1M acetate, 0.5M NaCl pH 4: 2.86ml 100% acetic acid was 
added to 400ml UP H₂O and 14.61g NaCl. The pH was adjusted to 4 and the solution 
topped up to 500ml with UP H₂O. 
A3.1.10 Optimised sandwich ELISA 
Buffers: Washing solution = phosphate buffered saline (PBS) (MRI stock) pH7.4 + 
0.05% Tween 20 (PBST20); Carbonate coating buffer (100 mM) 3.03 g Na2CO3; 
6.0 g NaHCO3; 1000 ml distilled water adjusted to pH 9.6; Blocking buffer and 
primary (detection) antibody diluent: 1% soya milk (Infasoy, Cow n Gate) in PBS 
0.05% Tween 80 (PBST80). 
Antigen = Pooled sera from sheep (n = 12) infested with P. ovis in an experimental 
primary infestation/treatment trial (as described in the Appendix A3.1.11). Pooled 
week 6 post-infestation sera from 12 animals were used as “infested” sera and pre-
bleeds for negative sera controls. A full dilution set of negative sera controls, using 
the pre-bleed sera from the same trial as the infested sera, were included in each 
ELISA. Sera concentration used, as determined by checkerboard ELISA, was 
undiluted. 
Sample wells in flat bottomed, high binding 96 well plates (Greiner) were coated in 
triplicate with 50µl mC4BPB antibody (Novus Biologicals) diluted 1:100 in 
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carbonate coating buffer, except positive control wells which were coated with 
0.12µg rC4BPB diluted in carbonate coating buffer. The plate was covered with a 
plate sealer and incubated overnight at room temperature, then emptied and washed x 
6 by adding 300µl PBS/Tween 20 to each well. This washing was carried out after 
each of the incubation steps listed below, ensuring the wash buffer was left in the 
wells for at least 30s at each wash. Following washing, 100µl blocking buffer was 
added to each well, the plate covered and the ELISA incubated for 1 hr at 37ºC. After 
washing, 50μl of the undiluted antigen (as described above) was added to each well 
except the positive controls where PBST80 buffer only was added and the plate 
incubated for 1 hr at 37⁰C. Following washing, 50µl of diluted rabbit anti-ovine 
C4BPB, diluted 1:100 with 1% soya milk, was added to each well except any 
negative (no primary) controls, where blocking buffer only was added and the plate 
incubated for 1 hr at 37⁰C. Finally, 50µl biotinylated secondary antibody raised in 
mice against rabbit (Abcam) diluted 1:100 with PBST80) was added to each well and 
the plate incubated for 1 hr at 37⁰C. Streptavidin HRP Ultrasensitive (Sigma) (50µl) 
diluted 1:1000 with PBST80, was added to all wells and the plate incubated for 1 hr 
at 37⁰C, after which 50μl 3, 3’, 5, 5’-Tetramethylbenzidine substrate solution (TMB) 
(KPL) substrate was added to all wells and incubated at room temperature for 10 
mins. The reaction was stopped by adding 50μl of TMB Stop solution (100% 
diethylene glycol, KPL) to each well and the optical density at wavelength 450nm 





A3.1.11 Primary and secondary infestation and treatment trial  
Twelve sheep scab naïve sheep were pre-bled then infested with 25-50 P. ovis mites 
on the withers area. They were blood sampled weekly for 6 weeks then treated with 
Dectomax (Pfizer Animal Health) by intra-muscular injection at the recommended 
dosage rate of 1ml / 33kg bodyweight. Post-treatment, they were blood sampled 
twice weekly for a month then weekly for further 10 weeks. Lesion size 
measurements were taken weekly in the primary post-infestation period and for 2 
weeks post-treatment. A secondary infestation and treatment trial was started at week 














Table A4.1: Mean Hp concentration in sheep serum across a time course of 
infestation with P. ovis. Sera from the TC1 (n = 6) and TC2 (n = 8) trials tested for 
individual animals in duplicate using a commercial colorimetric assay (ReactivLab). 
 TC1  TC2  








0 0.550 0.191 - - 
1 0.456 0.116 0.077 0.015 
2 0.439 0.132 0.120 0.008 
3 0.569 0.125 0.173 0.043 
4 2.247 0.575 0.090 0.019 
5 3.220 0.819 1.122 0.642 

















Table A4.2: Mean serum Hp concentration in sheep infested with P. ovis across a 
time course of infestation and following successful treatment with an injectable 
endectocide. Sera from the primary and secondary infestation and treatment trial 
(TCT1) (n = 12) described in A3.1.11 and tested for individual animals in duplicate 
by colorimetric assay (ReactivLab). P.i = post-infestation; p.t = post-treatment. 
*treatment at 6 weeks p.i. 
Week p.i/p.t Mean Hp 
(mg/ml) 
SE ± 
0 0.295 0.060 
1 0.316 0.099 
2 0.673 0.442 
3 0.177 0.006 
4 0.828 0.414 
5 3.327 0.890 
*6 3.533 0.638 
6.5 2.986 0.574 
7 1.566 0.351 
7.5 0.491 0.143 
8 0.219 0.042 
8.5 0.040 0.042 
10 0.000 0.000 
15 0.000 0.000 
20 0.000 0.000 
21 0.435 0.063 
21.25 0.978 0.116 
22 1.246 0.270 
23 0.462 0.078 
24 0.577 0.170 
25 0.430 0.056 
26 0.675 0.164 
26.5 0.638 0.198 
27 0.433 0.064 
27.5 0.342 0.008 
28 0.383 0.046 





Table A4.3: Mean serum SAA concentration across three time course studies 
following infestation with P. ovis. Sera from the TC1 (n = 6); TC2 (n = 8) and TC3 
(n = 6) trials tested for individual animals in duplicate by SAA ELISA (Tridelta 
Development Ltd). No sample available for TC2 week 0. 
 TC1  TC2  TC3  










0 0 0 - - 0.000 0.000 
1 7.340 3.662 0.000 0.000 0.000 0.000 
2 9.312 5.071 0.000 0.000 0.000 0.000 
3 27.622 7.606 16.354 0.282 24.524 0.394 
4 109.034 6.197 40.158 2.817 42.411 0.451 
5 185.093 19.156 74.666 3.944 111.569 1.606 















Table A4.4: Mean serum SAA concentration in sheep infested with P. ovis across a 
time course of infestation and following successful treatment with an injectable 
endectocide. Sera from the primary and secondary infestation and treatment trial 
(TCT1) (n = 12) described in A3.1.11 and tested for individual animals in duplicate 
by SAA ELISA (Tridelta Development Ltd). *treated at week 6 p.i. 
Week Mean SAA 
(µg/ml) 
SE ± 
0 0.822 0.528 
1 5.166 2.567 
2 6.459 5.058 
3 3.770 3.312 
4 95.244 54.398 
5 284.750 71.144 
*6 217.002 46.358 
6.5 57.282 34.750 
7 19.762 19.762 
7.5 0.103 0.092 
8 0.000 0.000 
9 0.578 0.587 
10 0.000 0.000 
15 0.000 0.000 
20 2.457 2.226 
20.2 298.548 79.708 
21 49.564 23.954 
22 4.512 2.464 
23 5.517 2.586 
24 52.793 29.336 
26 7.311 3.714 
26.5 14.214 2.130 
27 10.475 1.042 






Table A4.5: Mean serum Hp in sheep (n = 12) pre-infestation, at clinical diagnosis 
as positive for sheep scab and 2 months post-treatment in a field outbreak of sheep 
scab. Hp measurement by colorimetric assay (ReactivLab); sera tested for individual 
animals in duplicate. 
Time Hp concentration 
(mg/ml) 
SE ± 
Pre-infestation 0.228 0.219 
Mid-infestation 0.776 0.382 




Table A4.6: Mean serum SAA in sheep (n = 12) pre-infestation, at clinical diagnosis 
as positive for sheep scab and 2 months post-treatment in a field outbreak of sheep 
scab. SAA measurement by commercial ELISA (Tridelta Development Ltd); sera 
assayed for individual animals in duplicate and diluted 1:50. 
Time SAA concentration (µg/ml) SE ± 
Pre-infestation 1.068 0.237 
Mid-infestation 10.686 2.659 







Table A4.7: Mean normalised OD450 ± SE results measuring the ovine serum IgG 
response to the mite antigen Pso o 2 following infestation with P. ovis across a 6-
week time course and after treatment with an injectable endectocide (TCT1 trial, n = 
12). Sera tested for individual animals in duplicate by Pso o 2 ELISA (MRI) as 




0 0.573 0.019 
1 0.674 0.044 
2 1.081 0.126 
3 1.197 0.115 
4 1.438 0.141 
5 1.577 0.138 
*6 2.793 0.062 
7 2.760 0.058 
8 2.663 0.066 
9 1.727 0.098 
10 1.580 0.101 
11 1.589 0.101 
12 1.682 0.175 
13 1.542 0.155 
15 1.302 0.129 
16 0.965 0.095 
18 0.853 0.075 
20 0.760 0.064 
21 1.012 0.060 
22 2.378 0.066 
23 2.384 0.054 
24 2.372 0.076 
25 2.403 0.032 
27 2.322 0.041 
28 2.343 0.064 
29 2.293 0.073 
 
 
